EP3233849A1 - HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS - Google Patents

HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS

Info

Publication number
EP3233849A1
EP3233849A1 EP15819803.6A EP15819803A EP3233849A1 EP 3233849 A1 EP3233849 A1 EP 3233849A1 EP 15819803 A EP15819803 A EP 15819803A EP 3233849 A1 EP3233849 A1 EP 3233849A1
Authority
EP
European Patent Office
Prior art keywords
methyl
phenyl
difluoro
dioxo
thiazinan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15819803.6A
Other languages
German (de)
French (fr)
Inventor
Benjamin Fauber
Tammy LADDUWAHETTY
Olivier RENE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP3233849A1 publication Critical patent/EP3233849A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the invention pertains to compounds that modulate the function of retinoid-receptor related orphan receptor RORc (RQRy) and use of such compounds for treatment of autoimmune diseases
  • T helper 17 cells are interleukin (IL)-17 secreting CD4+ T cells involved in pathogenesis of autoimmune diseases such as rheumatoid arthritis, irritable bowel disease, psoriasis, psoriatic arthritis and spondyloarthridities.
  • the retinoic acid-related orphan receptor ⁇ (RORy or RORc) is recognized as a transcription factor necessary for Thl7 cell differentiation.
  • RORc is an orphan member of the nuclear hormone receptor subfamily that includes RORa (RORa) and RORp (RORb). RORc controls gene transcription by binding to DNA as a monomer. Selective modulation of RORc has been proposed as a route to discovery and development of Thl7 cell-associated autoimmune diseases.
  • n 0 or 1 ;
  • n 0 or 1 ;
  • p is from 0 to 3;
  • q is from 0 to 3;
  • a five membered heterocyclyl selected from:
  • A is:
  • W is: -CR b R c -; -0-; -S-; -S0 2 -; or -NR d -;
  • one of X 1 , X 2 , X 3 and X 4 is N and the others are CR e ; or two of X 1 , X 2 , X 3 and X 4 are N and the others are CR e ; or three of X 1 , X 2 , X 3 and X 4 are N and the other is CR e ; or each of X 1 , X 2 , X 3 and X 4 is CR e ;
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently is: hydro gen; or Ci_ 6 aikyl which may be unsubstituted or substituted one or more times with halo;
  • R 7 and R 8 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 3 and R 4 together with one of R 5 and R 6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 5 and R 6 together with one of R 7 and R 8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • each R 9 is independently:
  • each R 10 is independently:
  • R a is:
  • Ci_ 6 aikoxy Ci. 6 alkoxy-Ci. 6 alkyl
  • heterocyclyl moieties are each independently selected from oxetanyl
  • tetrahydrofuranyl tetrahydropyranyl
  • azetidinyl pyrrolidinyl and piperidinyl
  • heterocycyl moieties and C 3 . 6 cycloalkyl moieties each may be unsubstituted or substituted one or more times with R f ;
  • R b , R c , and R d each independent is:
  • R b and R c together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R b and R c together with one of R 7 and R 8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R b and R c together with one of R 5 and R 6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • each R e is independently:
  • Ci_ 6 alkyl moieties may be unsubstituted or substituted one or more times with halo
  • R f is: Ci_ 6 alkyl; halo; oxo; hydroxy; or
  • the invention also provides and pharmaceutical compositions comprising the compounds, methods of using the compounds, and methods of preparing the compounds.
  • Alkyl means the monovalent linear or branched saturated hydrocarbon moiety, consisting solely of carbon and hydrogen atoms, having from one to twelve carbon atoms.
  • “Lower alkyl” refers to an alkyl group of one to six carbon atoms, i.e. Ci-C 6 alkyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec -butyl, tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like.
  • Alkenyl means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms, containing at least one double bond, e.g. , ethenyl, propenyl, and the like.
  • Alkynyl means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms, containing at least one triple bond, e.g. , ethynyl, propynyl, and the like.
  • Alkylene means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g., methylene, ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene, butylene, pentylene, and the like.
  • alkoxy moieties include, but are not limited to, methoxy, ethoxy, isopropoxy, and the like.
  • Alkoxyalkyl means a moiety of the formula R a -0-R b -, where R a is alkyl and R b is alkylene as defined herein.
  • exemplary alkoxyalkyl groups include, by way of example, 2-methoxy ethyl, 3-methoxypropyl, 1 -methyl -2 -methoxyethyl, l-(2-methoxyethyl)-3-methoxypropyl, and l-(2- methoxyethyl)-3 -methoxypropyl.
  • Alkoxyalkoxy' means a group of the formula -O-R-R' wherein R is alkylene and R' is alkoxy as defined herein.
  • Alkylcarbonyl means a moiety of the formula -C(0)-R, wherein R is alkyl as defined herein.
  • Alkoxycarbonyl means a group of the formula -C(0)-R wherein R is alkoxy as defined herein.
  • Alkylcarbonylamino means a group of the formula -R-C(0)-NR'- wherein R is alkyl and R' is hydrogen or alkyl.
  • Alkylcarbonylalkyl means a group of the formula -R-C(0)-R' wherein R is alkylene and R' is alkyl as defined herein.
  • Alkoxyalkylcarbonyl means a moiety of the formula -C(0)-R-R', wherein R is alkylene and R' is alkoxy as defined herein.
  • Alkoxycarbonylalkyl means a group of the formula -R-C(0)-R wherein R is alkylene and R' is alkoxy as defined herein.
  • Alkoxycarbonylamino means a moiety of the formula R-C(0)-NR'-, wherein R is alkoxy and
  • R' is hydrogen or alkyl as defined herein.
  • Alkoxycarbonylaminoalkyl means a moiety of the formula R-C(0)-NR'-R"-, wherein R is alkoxy, R' is hydrogen or alkyl, and R" is alkylene as defined herein.
  • Alkoxycarbonylalkoxy means a group of the formula -0-R-C(0)-R' wherein R is alkylene and R' is alkoxy as defined herein.
  • Haldroxycarbonylalkoxy means a group of the formula -0-R-C(0)-OH wherein R is alkylene as defined herein.
  • Alkylaminocarbonylalkoxy means a group of the formula -0-R-C(0)-NHR' wherein R is alkylene and R' is alkyl as defined herein.
  • Dialkylaminocarbonylalkoxy means a group of the formula -0-R-C(0)-NR'R" wherein R is alkylene and R' and R" are alkyl as defined herein.
  • Alkylaminoalkoxy means a group of the formula -O-R-NHR' wherein R is alkylene and R' is alkyl as defined herein.
  • Dialkylaminoalkoxy means a group of the formula -O-R-NR'R' wherein R is alkylene and R' and R" are alkyl as defined herein.
  • Alkylsulfonyl means a moiety of the formula - S0 2 -R, wherein R is alkyl as defined herein.
  • Alkylsulfonylalkyl means a moiety of the formula -R'-S0 2 -R" where where R' is alkylene and R" is alkyl as defined herein.
  • Alkylsulfonylalkoxy means a group of the formula -0-R-S0 2 -R' wherein R is alkylene and R' is alkyl as defined herein.
  • Amino means a moiety of the formula -NRR' wherein R and R' each independently is hyrdogen or alkyl as defined herein. "Amino thus includes “alkylamino (where one of R and R' is alkyl and the other is hydrogen) and “dialkylamino (where R and R' are both alkyl.
  • Aminocarbonyl means a group of the formula -C(0)-R wherein R is amino as defined herein.
  • N-hydroxy-aminocarbonyl means a group of the formula -C(0)-NR-OH wherein R is hydrogen or alkyl as defined herein.
  • N-alkoxy-aminocarbonyl means a group of the formula -C(0)-NR-R' wherein R is hydrogen or alkyl and R' is alkoxy as defined herein.
  • “Ammocarbonylaminoalkyl” means a group of the formula R 2 N-C(0)-NR'-R"- wherein each R is independently hydrogen or alkyl, R' is hydrogen or alkyl, and R" is alkylene as defined herein.
  • N-alkyl-aminocarbonyl means a group of the formula -C(0)-NH-R wherein R is alkyl as defined herein.
  • N-hydroxy-N-alkylaminocarbonyl means a group of the formula -C(0)-NRR' wherein R is alkyl as defined herein and R' is hydroxy.
  • N-alkoxy-N-alkylaminocarbonyl means a group of the formula -C(0)-NRR' wherein R is alkyl and R' is alkoxy as defined herein.
  • N,N-di-Ci. 6 alkyl-aminocarbonyl means a group of the formula -C(0)-NRR' wherein R and R' are alkyl as defined herein.
  • Aminosulfonyl means a group of the formula -S0 2 -NH 2 .
  • N-alkylaminosulfonyl means a group of the formula -S0 2 -NHR wherein R is alkyl as defined herein.
  • ⁇ , ⁇ -dialkylaminosulfonyl means a group of the formula -S0 2 -NRR' wherein R and R' are alkyl as defined herein.
  • Alkylsulfonylamino means a group of the formula -NR'-S0 2 -R wherein R id alkyl and R' is hydrogen or alkyl as defined herein.
  • N-(alkylsulfonyl)-aminoalkyl means a group of the formula -R-NH-S0 2 -R' wherein R is alkylene and R' is alkyl as defined herein.
  • N-(Alkylsulfonyl)aminocarbonyl means a group of the formula -C(0)-NH-S0 2 -R wherein wherein R is alkyl as defined herein.
  • N-(Alkylsulfonyl)-N-alkylaminocarbonyl means a group of the formula -C(0)-NR-S0 2 -R' wherein wherein R and R' are alkyl as defined herein.
  • N-Alkoxyalkyl-aniinocarbonyl means a group of the formula -C(0)-NR-R'-OR” wherein R is hydrogen or alkyl, R' is alkylene, and R" is alkyl as defined herein.
  • N-Hydroxyalkyl-aminocarbonyl means a group of the formula -C(0)-NR-R'-OH" wherein R is hydrogen or alkyl and R' is alkylene as defined herein.
  • Alkoxyamino means a moiety of the formula -NR-OR' wherein R is hydrogen or alkyl and R' is alkyl as defined herein.
  • Alkylsulfanyl means a moiety of the formula -SR wherein R is alkyl as defined herein.
  • Aminoalkyl means a group -R-R' wherein R' is amino and R is alkylene as defined herein.
  • aminoalkyl includes aminomethyl, aminoethyl, 1-aminopropyl, 2-aminopropyl, and the like.
  • the amino moiety of “aminoalkyl” may be substituted once or twice with alkyl to provide
  • alkylaminoalkyl and “dialkylaminoalkyl” respectively.
  • alkylaminoalkyl includes
  • methylaminomethyl methylaminoethyl, methylaminopropyl, ethylaminoethyl and the like.
  • Dialkylaminoalkyl includes dimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl, N- methyl-N-ethylaminoethyl, and the like.
  • Aminoalkoxy means a group -OR-R' wherein R' is amino and R is alkylene as defined herein.
  • Alkylsulfonylamido means a moiety of the formula -NR'S0 2 -R wherein R is alkyl and R' is hydrogen or alkyl.
  • Aminocarbonyloxyalkyl or “carbamylalkyl” means a group of the formula -R-0-C(0)-NR'R" wherein R is alkylene and R', R" each independently is hydrogen or alkyl as defined herein.
  • Alkynylalkoxy means a group of the formula -O-R-R' wherein R is alkylene and R' is alkynyl as defined herein.
  • Aryl means a monovalent cyclic aromatic hydrocarbon moiety consisting of a mono-, bi- or tricyclic aromatic ring.
  • the aryl group can be optionally substituted as defined herein.
  • aryl moieties include, but are not limited to, phenyl, naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl, benzomorpholinyl, methylenedioxy
  • Arylsulfonyl means a group of the formula -S0 2 -R wherein R is aryl as defined herein.
  • Aryloxy means a group of the formula -O-R wherein R is aryl as defined herein.
  • Aralkyloxy means a group of the formula -O-R-R" wherein R is alkylene and R' is aryl as defined herein.
  • Carboxy or “hydroxycarbonyl”, which may be used interchangeably, means a group of the formula -C(0)-OH.
  • Cyanoalkyl means a moiety of the formula -R'-R", where R' is alkylene as defined herein and R" is cyano or nitrile.
  • Cycloalkyl means a monovalent saturated carbocyclic moiety consisting of mono- or bicyclic rings. Particular cycloalkyl are unsubstituted or substituted with alkyl. Cycloalkyl can optionally be substituted as defined herein. Unless defined otherwise, cycloalkyl may be optionally substitued with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino.
  • cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, including partially unsaturated (cycloalkenyl) derivatives thereof.
  • Cycloalkenyl means a cycloalkyl as defined herein that includes at least one double bond or unsaturation.
  • exemplary cycloalkenyl include cyclohexenyl, cyclopentenyl, cyclobutenyl and the like.
  • Cycloalkylalkyl means a moiety of the formula -R'-R", where R' is alkylene and R" is cycloalkyl as defined herein.
  • Cycloalkylalkoxy means a group of the formula -O-R-R' wherein R is alkylene and R' is cycloalkyl as defined herein.
  • Cycloalkylcarbonyl means a moiety of the formula -C(0)-R, wherein R is cycloalkyl as defined herein.
  • C3_ 6 cycloalkyl-Ci_ 6 alkyl-carbonyl means a moiety of the formula -C(0)-R, wherein R is cycloalkylalkyl as defined herein.
  • Cyanoalkylcarbonyl means a moiety of the formula -C(0)-R-R' , wherein R is alkylene as defined herein and R' is cyano or nitrile.
  • N-Cyano-aminocarbonyl means a moiety of the formula -C(0)-NHR, wherein R is cyano or nitrile.
  • N-Cyano-N-alkyl-aminocarbonyl means a moiety of the formula -C(0)-NRR' -R, wherein R' is alkyl as defined herein and R is cyano or nitrile.
  • Cycloalkylsulfonyl means a group of the formula -S0 2 -R wherein R is cycloalkyl as defined herein.
  • Cycloalkylalkylsulfonyl means a group of the formula -S0 2 -R wherein R is cycloalkylalkyl as defined herein.
  • Forml means a moiety of the formula -C(0)-H.
  • Heteroaryl means a monocyclic or bicyclic radical of 5 to 12 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, with the understanding that the attachment point of the heteroaryl radical will be on an aromatic ring.
  • the heteroaryl ring may be optionally substituted as defined herein.
  • heteroaryl moieties include, but are not limited to, optionally substituted imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, thienyl, benzothienyl, thiophenyl, furanyl, pyranyl, pyridyl, pyrrolyl, pyrazolyl, pyrimidyl, quinolinyl, isoquinolinyl, benzofuryl, benzo thiophenyl, benzothiopyranyl, benzimidazolyl, benzooxazolyl, benzooxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzopyranyl, indolyl, isoindolyl, triazolyl, triazinyl, quinoxalinyl, purinyl, quinazolin
  • Heteroarylalkyl or “heteroaralkyl” means a group of the formula -R-R' wherein R is alkylene and R' is heteroaryl as defined herein.
  • Heteroarylsulfonyl means a group of the formula -S0 2 -R wherein R is heteroaryl as defined herein.
  • Heteroaryloxy means a group of the formula -O-R wherein R is heteroaryl as defined herein.
  • Heteroaralkyloxy means a group of the formula -O-R-R" wherein R is alkylene and R' is heteroaryl as defined herein.
  • halo refers to a substituent fluoro, chloro, bromo, or iodo.
  • Haloalkyl means alkyl as defined herein in which one or more hydrogen has been replaced with same or different halogen.
  • exemplary haloalkyls include -CH 2 C1,
  • Haloalkoxy means a moiety of the formula -OR, wherein R is a haloalkyl moiety as defined herein.
  • An exemplary haloalkoxy is difluoromethoxy.
  • Heterocycloamino means a saturated ring wherein at least one ring atom is N, NH or N-alkyl and the remaining ring atoms form an alkylene group.
  • Heterocyclyl means a monovalent saturated moiety, consisting of one to three rings, incorporating one, two, or three or four heteroatoms (chosen from nitrogen, oxygen or sulfur).
  • the heterocyclyl ring may be optionally substituted as defined herein.
  • Examples of heterocyclyl moieties include, but are not limited to, optionally substituted piperidinyl, piperazinyl, morpholinyl,
  • Heterocyclylalkyl means a moiety of the formula -R-R' wherein R is alkylene and R' is heterocyclyl as defined herein.
  • Heterocyclyloxy means a moiety of the formula -OR wherein R is heterocyclyl as defined herein.
  • Heterocyclylalkoxy means a moiety of the formula -OR-R' wherein R is alkylene and R' is heterocyclyl as defined herein.
  • Hydroalkoxy means a moiety of the formula -OR wherein R is hydroxyalkyl as defined herein.
  • Haldroxyalkylamino means a moiety of the formula -NR-R' wherein R is hydrogen or alkyl and R' is hydroxyalkyl as defined herein.
  • Haldroxyalkylaminoalkyl means a moiety of the formula -R-NR'-R" wherein R is alkylene, R' is hydrogen or alkyl, and R" is hydroxyalkyl as defined herein.
  • Haldroxycarbonylalkyl or “carboxyalkyl” means a group of the formula -R-(CO)-OH where R is alkylene as defined herein.
  • Haldroxycarbonylalkoxy means a group of the formula -0-R-C(0)-OH wherein R is alkylene as defined herein.
  • Haldroxyalkylcarbonyl means a moiety of the formula -C(0)-R-R' , wherein R is alkylene as defined herein and R' is hydroxy.
  • Haldroxyalkyloxycarbonylalkyl or “hydroxyalkoxycarbonylalkyl” means a group of the formula -R-C(0)-0-R-OH wherein each R is alkylene and may be the same or different.
  • Hydroalkyl means an alkyl moiety as defined herein, substituted with one or more, for example, one, two or three hydroxy groups, provided that the same carbon atom does not carry more than one hydroxy group.
  • Representative examples include, but are not limited to, hydroxymethyl,
  • Hydrocycloalkyl means a cycloalkyl moiety as defined herein wherein one, two or three hydrogen atoms in the cycloalkyl radical have been replaced with a hydroxy substituent. Representative examples include, but are not limited to, 2-, 3-, or 4-hydroxycyclohexyl, and the like.
  • a 1-oxo-ethyl group is an acetyl group.
  • Alkoxy hydroxyalkyl and "hydroxy alkoxyalkyl”, which may be used interchangeably, means an alkyl as defined herein that is substituted at least once with hydroxy and at least once with alkoxy.
  • Alkoxy hydroxyalkyl and “hydroxy alkoxyalkyl” thus encompass, for example, 2-hydroxy-3- methoxy-propan-l-yl and the like.
  • Rea'Or “ureido” means a group of the formula -NR'-C(0)-NR"R"' wherein R', R" and R'" each independently is hydrogen or alkyl.
  • “Carbamate” means a group of the formula -0-C(0)-NR'R" wherein R' and R" each
  • Carboxy means a group of the formula -0-C(0)-OH.
  • Sulfonamido means a group of the formula -S0 2 -NR'R" wherein R', R" and R'" each independently is hydrogen or alkyl.
  • cycloalkyl or heterocyclyl moiety means that such moiety may be unsubstituted (i.e., all open valencies are occupied by a hydrogen atom) or substituted with specific groups as related herein.
  • leaving group means the group with the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or group displaceable under substitution reaction conditions.
  • Examples of leaving groups include, but are not limited to, halogen, alkane- or arylenesulfonyloxy, such as methanesulfonyloxy, ethanesulfonyloxy, thiomethyl, benzenesulfonyloxy, tosyloxy, and thienyloxy, dihalophosphinoyloxy, optionally substituted benzyloxy, isopropyloxy, acyloxy, and the like.
  • Module means a molecule that interacts with a target. The interactions include, but are not limited to, agonist, antagonist, and the like, as defined herein.
  • “Disease” and “Disease state” means any disease, condition, symptom, disorder or indication.
  • “Inert organic solvent” or “inert solvent” means the solvent is inert under the conditions of the reaction being described in conjunction therewith, including for example, benzene, toluene, acetonitrile, tetrahydrofuran, ⁇ , ⁇ -dimethylformamide, chloroform, methylene chloride or dichloromethane, dichloroethane, diethyl ether, ethyl acetate, acetone, methyl ethyl ketone, methanol, ethanol, propanol, isopropanol, ieri-butanol, dioxane, pyridine, and the like.
  • the solvents used in the reactions of the present invention are inert solvents.
  • “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salts” of a compound means salts that are pharmaceutically acceptable, as defined herein, and that possess the desired pharmacological activity of the parent compound.
  • Protecting group means the group which selectively blocks one reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry. Certain processes of this invention rely upon the protective groups to block reactive nitrogen and/or oxygen atoms present in the reactants.
  • the terms "amino-protecting group” and “nitrogen protecting group” are used interchangeably herein and refer to those organic groups intended to protect the nitrogen atom against undesirable reactions during synthetic procedures.
  • Exemplary nitrogen protecting groups include, but are not limited to, trifluoroacetyl, acetamido, benzyl (Bn), benzyloxycarbonyl
  • Solidvates means solvent additions forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one of the substances in which the water retains its molecular state as H 2 0, such combination being able to form one or more hydrate.
  • Arthritis means a disease or condition that causes damage to joints of the body and pain associated with such joint damage. Arthritis includes rheumatoid arthritis, osteoarthritis, psoriatic arthritis, septic arthritis, spondyloarthropathies, gouty arthritis, systemic lupus erythematosus and juvenile arthritis, osteoarthritis, and other arthritic conditions.
  • Respiratory disorder refers to, without limitation, chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, and the like.
  • COPD chronic obstructive pulmonary disease
  • Subject means mammals and non-mammals. Mammals means any member of the mammalia class including, but not limited to, humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but are not limited to, birds, and the like. The term "subject” does not denote a particular age or sex.
  • “Therapeutically effective amount” means an amount of a compound that, when administered to a subject for treating a disease state, is sufficient to effect such treatment for the disease state.
  • the “therapeutically effective amount” will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
  • Treating" or “treatment” of a disease state includes, inter alia, inhibiting the disease state, i.e. , arresting the development of the disease state or its clinical symptoms, and/or relieving the disease state , i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.
  • treating when referring to a chemical reaction means adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
  • the atoms represented in the structures herein are intended to encompass all naturally occurring isotopes of such atoms.
  • the hydrogen atoms represented herein are meant to include deuterium and tritium
  • the carbon atoms are meant to include C 13 and C 14 isotopes.
  • One or more carbon atom(s) of a compound of the invention may be replaced by a silicon atom(s), and it is contemplated that one or more oxygen atom(s) of a compound of the invention may be replaced by a sulfur or selenium atom(s).
  • the invention provides compounds of formula I:
  • n 0 or 1 ;
  • n 0 or 1 ;
  • p is from 0 to 3;
  • q is from 0 to 3;
  • a five or six membered heteroaryl selected from: pyrrolyl;
  • a five membered heterocyclyl selected from: pyrrolidinyl; oxazolidinyl;
  • A is:
  • W is: -CR b R c -; -0-; -S-; -S0 2 -; or -NR d -;
  • one of X 1 , X 2 , X 3 and X 4 is N and the others are CR e ; or two of X 1 , X 2 , X 3 and X 4 are N and the others are CR e ; or three of X 1 , X 2 , X 3 and X 4 are N and the other is CR e ; or each of X 1 , X 2 , X 3 and X 4 is CR e ;
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 each independently is: hydro gen; or Ci_ 6 alkyl which may be unsubstituted or substituted one or more times with halo;
  • R 3 and R 4 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 5 and R 6 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 7 and R 8 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 3 and R 4 together with one of R 5 and R 6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R 5 and R 6 together with one of R 7 and R 8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR d - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • each R 9 is independently: d_ 6 alkyl
  • each R 10 is independently:
  • R a is:
  • heterocyclyl moieties are each independently selected from oxetanyl
  • tetrahydrofuranyl tetrahydropyranyl
  • azetidinyl pyrrolidinyl and piperidinyl
  • heterocycyl moieties and C 3 . 6 cycloalkyl moieties each may be unsubstituted or substituted one or more times with R f ;
  • R b , R c , and R d each independent is:
  • R b and R c together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R b and R c together with one of R 7 and R 8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • R b and R c together with one of R 5 and R 6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be unsubstituted or substituted one or more times with R f ;
  • each R e is independently:
  • Ci_ 6 aikyl moieties may be unsubstituted or substituted one or more times with halo
  • R f is: Ci_ 6 aikyl; halo-Ci_ 6 aikyl; halo; oxo; hydroxy; or Ci_ 6 alkoxy.
  • m is 0.
  • m is 1.
  • n 0.
  • n is 1.
  • p is from 0 to 2
  • p is O or 1.
  • p is 0.
  • p is 1.
  • p is 2.
  • p is 3.
  • q is 1.
  • q is 2. In certain embodiments of formula I, q is 0 or 1.
  • q is 0, 1 or 2.
  • Het is a five or six membered heteroaryl selected from:
  • Het is : oxadiazolyl
  • Het is imidazolyl .
  • Het is pyrazolyl .
  • Het is isoxazolyl .
  • Het is oxazolyl .
  • Het is thiazolyl .
  • Het is oxadiazolyl .
  • Het is triazolyl
  • Het is tetrazolyl .
  • Het is thiophenyl .
  • Het is furanyl .
  • Het is pyridinyl .
  • Het is pyrimidinyl . In certain embodiments of formula I, Het is pyridazinyl .
  • Het is pyrazinyl .
  • Het is 3H-l,3,4-oxadiazol-2-one-5-yl.
  • Het is 2-hydroxymethyl-l,3,4-oxadiazol-5-yl. In certain embodiments of formula I, Het is a five membered heterocyclyl selected from:
  • Het is pyrrolidinyl
  • Het is oxazolidinyl.
  • Het is dioxolanyl
  • Het is imidazolidinyl.
  • A is:Ci_ 6 alkylene which may be unsubstituted or substituted once or twice with R a .
  • A is:Ci_ 6 alkenylene which may be unsubstituted or substituted once or twice with R a .
  • A is: methylene; or ethylene; each of which may be unsubstituted or substituted with R a .
  • A is: -CH 2 -; -C(CH 3 ) 2 -; -CHCH 3 -; or -CHR a -.
  • A is methylene which may be unsubstituted or substituted with R a .
  • A is ethylene which may be unsubstituted or substituted with R a .
  • A is methylene
  • A is ethylene
  • A is -CH 2 - -.
  • A is -CHCH 3 -.
  • A is -C(CH 3 ) 2 -.
  • A is -CHR a -.
  • W is -CR b R c - or -0-.
  • W is -CR b R c -.
  • W is -0-.
  • W is -NR d -. n certain embodiments of formula W is -S-.
  • n certain embodiments of formula W is -SO2-.
  • n certain embodiments of formula W is -CH 2 -.
  • n certain embodiments of formula X ⁇ X 2 , X 3 and X 4 are CR e .
  • n certain embodiments of formula X 1 is N and X 2 , X 3 and X 4 are CR e .
  • n certain embodiments of formula X 2 is N and X 1 , X 3 and X 4 are CR e .
  • n certain embodiments of formula X 1 and X 4 are N, and X 2 and X 3 are CR a .
  • n certain embodiments of formula X 2 and X 3 are N, and X 1 and X 4 are CR e .
  • n certain embodiments of formula X 1 and X 2 are N, and X 3 and X 4 are CR e .
  • R 1 is Ci_ 6 aikyl.
  • R 2 is Ci_ 6 aikyl.
  • R 3 is Ci_ 6 aikyl.
  • n certain embodiments of formula R 4 is Ci_ 6 aikyl.
  • R 5 is Ci_ 6 alkyl.
  • R 6 is Ci_ 6 aikyl.
  • n certain embodiments of formula R 7 is Ci_ 6 alkyl.
  • n certain embodiments of formula R 8 is Ci_ 6 aikyl.
  • R 3 and R 4 together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • R 3 and R 4 together with the atoms to which they are attached form a three, four or five membered saturated ring.
  • R 5 and R 6 together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • R 5 and R 6 together with the atoms to which they are attached form a three, four or five membered saturated ring.
  • R 7 and R 8 together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • R 7 and R 8 together with the atoms to which they are attached form a three, four or five membered saturated ring.
  • one of R 3 and R 4 together with one of R 5 and R 6 and the atoms to which they are attached form a three, four, five, six or seven membered ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • one of R 5 and R 6 together with one of R 7 and R 8 and the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • each R 9 is independently: C h alky!; halo; or halo-
  • R 9 is Ci_ 6 alkyl.
  • R 9 is halo
  • R 9 is
  • R 9 is cyano
  • R 9 is halo-Ci_ 6 alkyl.
  • each R 9 is independently: fluoro; chloro; or trifluoromethyl.
  • R is: Ci_ 6 alkyl; hydroxy; oxo; or hydroxy-Ci.
  • R is hydroxy. In certain embodiments of formula I, R is oxo.
  • R 10 is cyano
  • R 10 is halo
  • R 10 is
  • R 10 is
  • R 10 is Ci_ 6 alkyl.
  • R 10 is halo-Ci_ 6 alkyl.
  • R 10 is cyano-Ci_ 6 alkyl.
  • R a is: C 3 . 6 cycloalkyloxy; C ⁇ ecycloalkyl-C ! ⁇ alkoxy; heterocylyl-C ! ⁇ alkyl; or heterocylyl-C ! ⁇ alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl,
  • heterocycyl moieties and C 3 _ 6 cycloalkyl each may be unsubstituted or substituted one or more times with R f .
  • R a is: Ci_ 6 alkoxy; heterocylyl-Ci_ 6 alkyl; or heterocylyl-Ci_ 6 alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, and wherein the heterocycyl moieties each may be unsubstituted or substituted one or more times with R f .
  • R a is: Ci_ 6 alkoxy; heterocylyl-Ci_ 6 alkyl; or heterocylyl-Ci_ 6 alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and azetidinyl.
  • R a is Ci_ 6 alkoxy.
  • R a isC ⁇ alkoxy-C ealkyl.
  • R a is
  • R a is C 3 . 6 cycloalkyl which may be unsubstituted or substituted one or more times with R f .
  • R a is C ⁇ cycloalkyl-CVealkyl wherein the C 3 _ 6 cycloalkyl moiety may be unsubstituted or substituted one or more times with R f .
  • R a is C 3 . 6 cycloalkyloxy; C ecycloalkyl-C ealkoxy; heterocyclyl; heterocylyl-Ci_ 6 alkyl; or heterocylyl-Ci_ 6 alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, and wherein the heterocycyl moieties and C 3 . 6 cycloalkyl each may be unsubstituted or substituted one or more times with R f .
  • R a is C ⁇ cycloalkyl-CVealkoxy wherein the C 3 _ 6 cycloalkyl moiety may be unsubstituted or substituted one or more times with R f .
  • R a is heterocyclyl selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, each of which may be unsubstituted or substituted one or more times with R f .
  • R a is heterocylyl-C ⁇ alkyl wherein the heterocyclyl moiety is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, each of which may be unsubstituted or substituted one or more times with R f .
  • R a is heterocylyl-Ci_ 6 alkoxy wherein the heterocyclyl moiety is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, each of which may be unsubstituted or substituted one or more times with R f .
  • R b is hydrogen
  • R b is Ci_ 6 alkyl.
  • R c is hydrogen
  • R c is Ci_ 6 alkyl.
  • R b and R c together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • one of R b and R c together with one of R 7 and R 8 and the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • one of R b and R c together with one of R 5 and R 6 and the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NR a - or -S-, and which may be optionally substituted one or more times with R 1 .
  • R d is hydrogen
  • R d is d_ 6 alkyl.
  • each R e is independently: hydrogen; Ci_ 6 alkyl; halo; or cyano; wherein the Ci_ 6 alkyl moieties may be unsubstituted or substituted one or more times with halo;
  • each R e is independently: hydrogen; Ci_ 6 alkyl; halo; or halo-Ci_ 6 alkyl.
  • each R e is independently: hydrogen; Ci_ 6 alkyl; or halo.
  • each R e is independently: hydrogen; or halo. In certain embodiments of formula I each R e is independently: hydrogen; or fluoro. In certain embodiments of formula I R e is hydrogen.
  • R e is d_ 6 alkyl.
  • R e is halo
  • R e is C ! . 6 alkoxy.
  • R e is cyano
  • R e is halo-Ci -6 alkyl.
  • R f is: Ci_ 6 alkyl; halo; oxo; hydroxy; acetyl; or Ci_
  • R f is C h alky.
  • R f is halo
  • R is Ci_ 6 alkoxy.
  • R f is halo-Ci -6 alkyl.
  • R f is oxo
  • R f is hydroxy
  • R f is acetyl
  • R s is Ci_ 6 alkyl
  • R s is oxo
  • R s is halo
  • R s is halo-Ci_ 6 alkyl
  • R s is hydroxy-Ci_ 6 alkyl
  • R g is Ci_ 6 alkoxy-Ci_ 6 alkyl
  • R g is cyano-C ⁇ alkyl.
  • s is from 0 to 3
  • m, n, p, q, Het, A, W, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are as defined herein.
  • R e is halo
  • R e is fluoro. In certain embodiments of formula II, s is 0 or 1.
  • s is 0.
  • s is 1.
  • s is 1 or 2.
  • s is 2.
  • s is 1, 2 or 3.
  • s is 2 or 3.
  • s is 3.
  • the subject compounds may be of formula II In c e of formula III:
  • the invention also provides a compound selected from [5-[[2,5-difluoro-4-[[(3S,6R)-3-me 1 ,l-dioxo-6-phenyl-tMazinan-2-yl]methyl]phenyl]m
  • the invention also provides a method for treating a disease or condition mediated by or otherwise associated with the RORc receptor, the method comprising administering to a subject in need thereof an effective amount of a compound of the invention.
  • the disease may be arthritis such as rheumatoid arthritis or osteoarthritis.
  • the disease may be asthma or COPD.
  • the disease may be psoriasis.
  • the disease may be muscular distrophy.
  • the starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagentsor Organic Synthesis; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989, Volumes 1-5 and Supplemental; and Organic Reactions , Wiley & Sons: New York, 1991, Volumes 1-40.
  • the following synthetic reaction schemes are merely illustrative of some methods by which the compounds of the present invention can be synthesized, and various modifications to these synthetic reaction schemes can be made and will be suggested to one skilled in the art having referred to the disclosure contained in this Application.
  • the starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.
  • the reactions described herein may be conducted under an inert atmosphere at atmospheric pressure at a reaction temperature range of from about -78 °C to about 150 °C, for example, from about 0 °C to about 125 °C, or conveniently at about room (or ambient) temperature, e.g., about 20 °C.
  • Scheme A illustrates one synthetic procedure usable to prepare specific compounds of formula I, wherein LG is a leaving group such as halo, sulfonate, or the like, and m, n, p, q, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R b and R c are as defined herein.
  • LG is a leaving group such as halo, sulfonate, or the like
  • m, n, p, q, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R b and R c are as defined herein.
  • step 1 of Scheme A alkyl amine a is reacted with benzyl sulfonyl chloride b to form sulfonamide compound c.
  • the reaction of step 1 may be carried out in a polar aprotic solvent such as THF or methylene chloride, and in the presence of a tertiary amine base or weak base such as potassium carbonate.
  • the leaving group of compound a may be bromo in certain embodiments.
  • the chloro group of compound b may in certain embodiments be replaced by other halo or leaving group.
  • a cyclization reaction is carried out in step 2 to afford thiazinane compound d.
  • the cyclization may be achieved in the presence of a strong base such as an alkyl lithium reagent, using polar aprotic solvent under anhydrous conditions.
  • step 3 thiazinane compound c is reacted with aryalkyl halide compound e to yield aralkyl thiazinane f.
  • the reaction of step 3 may be carried out in the presence of a strong base such as sodium hydride under anhydrous polar aprotic solvent conditions.
  • the bromo groups of compound e may be replaced by other suitable leaving groups used in the art.
  • Thiazinane compound f may then be reacted with oxoethyl zinc halide reagent g in step 4 to provide ester compound h.
  • This reaction may be carried out in the presence of suitable palladium catalyst under polar aprotic conditions in a solvent such as dry tetrahydrofuran.
  • step 5 ester compound h is reacted with hydrazine to yield the corresponding hydrazide compound i.
  • step 6 hydrazide compound is reacted with acyl halide reagent j to afford an acyl hydrazide compound k.
  • step 7 a cyclization is carried out to form an oxadiazole group, resulting in the compound 1, whihch is a compound of formula I in accordance with the invention.
  • reagent g may be replaced by the corresponding thionoester to provide a thiadiazole group in the final compound.
  • the group R a may be replaced by an alkyl group, or may omitted from reagent g and introduced (if desired) in a later step.
  • the group R 10 may omitted from acyl reagent j and, if desired, introduced in a later step.
  • step 1 of Scheme B tri-(tert-butyl)-slilyloxy amine m is reacted with benzyl sulfonyl chloride b, as described above with reference to Scheme A, to form sulfonamide compound n.
  • the tri-(tert-butyl)-slilyloxy group may be replaced with other leaving groups.
  • step 2 sulfonamide compound n is reacted with iodochloromethane to provide an alkenylsulfonamide compound o. This reaction may be achieved in the presence of a strong base such as an alkyl lithium reagent, using polar aprotic solvent such as THF under anhydrous conditions.
  • iodochloromethane may be replaced with other methylene reagents.
  • step 3 a cyclization reaction is affected to provide oxathiazepane compound p.
  • the cyclization may be carried out in the presence of an amine base under polar aprotic solvent conditions.
  • step 4 oxathiazepane compound p is reacted with aryalkyl halide compound e to yield aralkyl oxathiazepane compound q, in the manner described above with reference to Scheme A.
  • Steps 5-8 may then be carried out in the manner described above for steps 4-7 of Scheme A. Briefly, oxathiazepane compound q is reacted with zinc halide reagent g in step 5 to provide ester compound r, which is then reacted with hydrazine in step 6 to give the corresponding hydrazide compound s. Hydrazide compound s may then b acylated in step 7 to make compound t, followed by ring closure in step 8, to afford sultam compound u, which is a compound of formula I in accordance with the invention.
  • the invention includes pharmaceutical compositions comprising at least one compound of the present invention, or an individual isomer, racemic or non-racemic mixture of isomers or a
  • the compounds of the invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Suitable dosage ranges are typically 1-500 mg daily, for example 1-100 mg daily, and most preferably 1-30 mg daily, depending upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner involved.
  • One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this Application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease.
  • Compounds of the invention may be administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
  • a particular manner of administration is generally oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
  • a compound or compounds of the invention, together with one or more conventional adjuvants, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages.
  • the pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use.
  • Formulations containing about one (1) milligram of active ingredient or, more broadly, about 0.01 to about one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
  • the compounds of the invention may be formulated in a wide variety of oral administration dosage forms.
  • the pharmaceutical compositions and dosage forms may comprise a compound or compounds of the present invention or pharmaceutically acceptable salts thereof as the active component.
  • the pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier may be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component.
  • the active component In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets may contain from about one (1) to about seventy (70) percent of the active compound.
  • Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation” is intended to include the formulation of the active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges may be as solid forms suitable for oral administration.
  • liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations.
  • Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia.
  • Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents.
  • Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.
  • Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the compounds of the invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol.
  • oily or nonaqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
  • the compounds of the invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
  • Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • the compounds of the invention may be formulated for administration as suppositories.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.
  • the compounds of the invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • the subject compounds may be formulated for nasal administration.
  • the solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray.
  • the formulations may be provided in a single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
  • the compounds of the invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration.
  • the compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
  • the active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example,
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by a metered valve.
  • the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP).
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of e.g., gelatine or blister packs from which the powder may be administered by means of an inhaler.
  • formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.
  • the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial.
  • Compounds in transdermal delivery systems are frequently attached to an skin-adhesive solid support.
  • the compound of interest can also be combined with a penetration enhancer, e.g., Azone (l-dodecylazacycloheptan-2-one).
  • Sustained release delivery systems are inserted subcutaneously into the subdermal layer by surgery or injection.
  • the subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylactic acid.
  • the pharmaceutical preparations may be in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the compounds of the invention are useful for treatment of immune disorders generally.
  • the compounds may be used for treatment of arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, septic arthritis, spondyloarthropathies, gouty arthritis, systemic lupus erythematosus and juvenile arthritis, osteoarthritis, and other arthritic conditions.
  • the compounds may be used for treatment of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, and the like.
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • the compounds may be used for treatment of gastrointestinal disorder ("GI disorder”) such as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, pain associated with GI distension, and the like.
  • GI disorder such as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, pain associated with GI distension, and the like.
  • the compounds may be used for treatment of psoriasis, muscular sclerosis, Sjogren' s disease, lupus, and pulmonary fibrosis.
  • Method A Compounds were analysed using the following conditions: Experiments were performed on a Waters ZMD single quadrupole mass spectrometer linked to a Hewlett Packard HP 1100 LC system with UV diode array detector and 100 position autosampler. The spectrometer has an electrospray source operating in positive and negative ion mode. This system uses a Phenomenex Luna 3 ⁇ CI 8(2) 30 x 4.6 mm column at ambient temperature and a 2.0 mL / minute flow rate.
  • the initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5% acetonitrile containing 0.1% formic acid (solvent B) for the first 0.5 minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 4 minutes. This was maintained for 1 minute before returning to 95% solvent A and 5% solvent B over the next 0.5 minute. Total run time was 6 minutes.
  • Method B Compounds were analysed using the following conditions: Experiments were performed on a Waters Micromass ZQ2000 quadrupole mass spectrometer linked to a Waters Acquity UPLC system with a PDA UV detector.
  • the spectrometer has an electrospray source operating in positive and negative ion mode. This system uses an Acquity BEH C18 1.7 ⁇ 100 x 2.1 mm column, maintained at 40 °C or an Acquity BEH Shield RP18 1.7 ⁇ 100 x 2.1 mm column, maintained at 40 °C and a 0.4 mL / minute flow rate.
  • the initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5% acetonitrile containing 0.1% formic acid (solvent B) for the first 0.4 minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 5.6 minutes. This was maintained for 0.8 minute before returning to 95% solvent A and 5% solvent B over the next 1.2 minutes. Total run time was 8 minutes.
  • 3 ⁇ 4 NMR spectra were recorded at ambient temperature or at 80 °C where indicated using one of the following machines: Varian Unity Inova (400 MHz) spectrometer with a triple resonance 5mm probe, Bruker Avance DRX 400 (400 MHz) spectrometer with a triple resonance 5mm probe, a Bruker Avance DPX 300 (300 MHz) equipped with a standard 5mm dual frequency probe for detection of 1H and 13C, Bruker Fourier 300MHz system equipped with a standard 5mm 1H / 13C probe, a Bruker AVIII (400 MHz) using a BBI Broad Band Inverse 5mm probe, or a Bruker AVIII (500 MHz) using a QNP (Quad Nucleus detect) 5mm probe.
  • Varian Unity Inova 400 MHz
  • Bruker Avance DRX 400 400 MHz
  • a triple resonance 5mm probe a Bruker Avance DPX 300 (300 MHz) equipped with a standard 5mm
  • Microwave reactions were carried out using a Biotage® Initiator® in vials appropriate to the scale of the reaction and at the temperature and time described in the experimental details.
  • Reverse Phase High Pressure Liquid Chromatography was used to purify compounds where indicated. Separation using gradient elution on a Phenomenex Gemini C18 column (250 x 21.2 mm, 5 micron) as stationary phase and using mobile phase indicated, operating at a 18 mL/min flow rate using a Gilson UV/Vis -155 dual channel detector and Gilson GX-271 automated liquid handler.
  • Phase separator cartridges are supplied by Biotage® as Isolute® phase separator cartridges.
  • Step 2 Benzyl jV-i(2,S')-4-hydroxybutan-2-yllcarbamate and Benzyl jV-i(2R)-4-hydroxybutan-2- yllcarbamate
  • a solution of 3-[[(benzyloxy)carbonyl]amino]butanoic acid (102 g, 429.92 mmol, 1.00 equiv) in THF (300 mL)
  • BH 3 /THF ( IN) (645 mL, 1.50 equiv) dropwise with stirring at 0-5°C.
  • Step 1 (R)-3-(Phenylmethylsulfonamido)butyl phenylmethanesulfonate
  • Step 2 (R)-A/-(4-Chlorobutan-2-yl)-l -phenylmethanesulfonamide
  • a ⁇ -(2-bromoethyl)(4-fluorophenyl)methanesulfonamide was also made using the above procedure, replacing phenylmethanesulfonyl chloride with 4-fluoro-phenylmethanesulfonyl chloride.
  • 3 ⁇ 4 NMR 300 MHz, CDC1 3 ) ⁇ 7.43-7.38 (m, 2H), 7.13-7.07 (m, 2H), 4.62 (br s, IH), 4.26 (s, 2H), 3.41-3.32 (m, 4H).
  • a ⁇ -(3-bromopropyl)(4-fluorophenyl)methanesulfonamide was prepared using the above procedure.
  • H NMR 300 MHz, CDC1 3 ) ⁇ 7.42-7.37 (m, 2H), 7.13-7.07 (m, 2H), 4.26 (m, IH), 4.24 (s, 2H), 3.46-3.42 (m, 2H), 3.20-3.16 (m, 2H), 2.05-2.00 (m, 2H).
  • Step 1 A/-(2-((Tert-butyldimethylsilyl)oxy)ethyl)- 1 -phenylmethanesulfonamide
  • Step 2 jV-(2-((Tert-butyldimethylsilyl)oxy)ethyl)- 1 -phenylethenesulfonamid
  • Step 1 (3 ⁇ ,6R -2-(4-Bromo-2,5-difluorobenzyl -3-methyl-6-phenyl-l,2-thiazinane 1,1-dioxide
  • Step 2 ferf-Butyl 2 2,5-difluoro-4-rr(3S,6R)-3-methyl J-dioxo-6-phenyl-thiazinan-2- vHmethyllphenyllacetate
  • Step 3 Methyl 2-r2,5-difluoro-4-rr(3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- vHmethyllphenyllacetate
  • Step 4 Methyl 2-r2,5-difluoro-4-rr(3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yllmethyllphenyllpropanoate
  • Step 5 2- r2,5-Difluoro-4- [ r(3S,6R)-3-methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2- yllmethyllphenyllpropanehydrazide
  • Step 6 5-r i-r2,5-Difluoro-4-rr(3,S',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl1methyl1phenyl1ethyl1- 3 /-l,3,4-oxadiazol-2-one
  • reaction mixture was directly purified by reverse-phase preparative HPLC to give 5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3H-l,3,4-oxadiazol-2-one (91 mg, 0.20 mmol, 47% yield).
  • Step 1 r2,5-Difluoro-4-((3S,6R)-3-methyl J-dioxo-6-phenyl 1ambda*6* 1,21thiazinan-2-ylmethyl)- phenyll -acetic acid
  • Step 2 N-( 2-r2,5-Difluoro-4-((3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- lmethvD-phenyll -acetyl I -hydrazinecarboxylic acid tert-butyl ester
  • Step 3 r2,5-Difluoro-4-((3 t S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2-ylmethyl)- hen yll -acetic acid hvdrazide
  • Step 4 5-r2,5-Difluoro-4-((3 ⁇ 6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21-thiazinan-2-lmethyl)- benzyl)-3H-
  • Step 1 Acetic acid 2-(N-[2-r2,5-difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*- [l,21thiazinan-2-ylmethyl)-phenyll -acetyl I -hydrazino)-2-oxo-ethylester
  • Step 3 f5-r2,5-Difluoro-4-((3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- ylmethyl)-benzyll-[l,3,41oxadiazol-2-yl)methanol
  • Step 1 r2,5-Difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyL ⁇
  • Step 3 Diazo-r2,5-difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- ylmethvD-phenyll -acetic acid methyl ester To a stirred solution of the product from Step 2 (0.360 g, 0.85 mmol) and
  • Step 4 r2,5-Difluoro-4-((3S,6R -3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2-ylmethyl - phenyll-oxetan-3-yl-acetic acid methyl ester
  • Step 5 r2,5-Difluoro-4-((3S,6R -3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2-ylmethyl - phenyl! -oxetan-3-yl-acetic acid hvdrazide
  • Step 6 5-f (R -r2,5-Difluoro-4-((3S,6R -3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- ylmethyl)-phenyl1-oxetan-3-yl-methyli-3H-ri,3,41oxadiazol-2-one and 5-f (S)-r2,5-difluoro-4-((3S,6R)- 3-methyl-l,l-dioxo-6-phenyl-llambda*6*-[l,21thiazinan-2-ylmethyl)-phenylloxetan-3-yl-methyl
  • Examples 7 and 8 5-(2-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)propan-2-yl)-l,3,4-oxadiazol-2(3H)-one and 5-(2-(2,5-difluoro-4-(((3,S , ,6 t S , -3-methyl-
  • Step 1 Methyl 2-(2,5-difluoro-4-(((3,S , -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl methyl phenyl -2-methylpropanoate
  • Step 2 2-(2,5-Difluoro-4-(((3 t S , -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2-yl methvnphenvn-2- methylpropanehydrazide
  • step 1 The product from step 1 was reacted as described in example 1 step 5 to give the title compound.
  • LCMS (ESI): m/z 452 [M+H] + .
  • Step 3 5-(2-(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)propan-2-yl)-L3,4-oxadiazol-2(3H)-one and 5-(2-(2,5-difluoro-4-(((3,S , ,6 t S , -3-methyl- l,l-dioxido-6-phenyl-l,2-thiazinan-2-yl methyl phenyl propan-2-yl -l,3,4-oxadiazol-2(3H)-one
  • Example 9 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3-methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)- 1 ,2-dihvdro-3//-pyrazol-3 -one
  • Step 1 2-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDacetic acid
  • Step 2 Methyl 4-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)-3-oxopentanoate
  • Step 3 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-l,2-dihvdro-3H-pyrazol-3-one
  • step 2 To a solution of the product of step 2 (75 mg, 0.16 mmol) in methanol (0.5 mL) was added hydrazine hydrate (0.04 mL, 0.8 mmol) and the solution was stirred at 60 °C for 2 h. The reaction mixture was then purified by preparative HPLC to give the title compound (9 mg, 0.020 mmol, 12% yield).
  • Example 10 3-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl- l, l-dioxido-6-phenyl-l ,2-thiazinan-2-
  • Step 1 2-(2-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l ,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)propanoyl)hydrazine- 1 -carboxamide
  • Step 2 5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l ,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2,4-dihvdro-3//- 1 ,2,4-triazol-3-one
  • Example 12 5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l, l-dioxido-6-phenyl-l ,2-thiazinan-2-
  • Step 1 2-(2-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l ,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDpropanoyl)- jV-methylhydrazine- 1 -carboxamide
  • Step 2 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-4-methyl-2,4-dihydro-3H-l,2,4-triazol-3-one
  • step 1 The product of step 1 was reacted as described in example 5 step 2 to give the title compound. : H
  • Example 13 5-(1-(2,5- ⁇ 1 ⁇ -4-(((3 ⁇ ,6/? -3- ⁇ 6 ⁇ 1 ⁇ 1-1,1-(1 ⁇ -6- ⁇ 1 ⁇ 6 ⁇ 1-1,2-11 ⁇ -2-
  • Step 1 2-(2-(2,5-Difluoro-4-(((3S,6R)-3-methyl J-dioxido-6-phenyl ,2-thiazinan-2- yl)methyl)phenyl)propanoyl)- 1 -methylhydrazine- 1 -carboxamide
  • Step 2 5-(l-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl methyl phenyl ethyl -2-methyl-2,4-dihvdro-3 /-l,2,4-triazol-3-one
  • step 1 The product of step 1 was reacted as described in example 5 step 2 to give the title compound.
  • Example 14 5-(l-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2-
  • Step 1 2-(2-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)propanoyl)-2-methylhvdrazine- 1 -carboxamide
  • Step 2 5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)- 1 -methyl- 1 ,2-dihydro-3/f- 1 ,2,4-triazol-3-one
  • Step 1 4-(2,5-Difluoro-4-(((3S,6R)-3-methyl-l,l-dioxido-6 ⁇
  • Step 2 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)isoxazol-3(2 /)-one
  • step 1 The product of step 1 (150 mg, 0.31 mmol) was dissolved in MeOH (5 mL) and cone. HC1 (1.5 mL). The reaction was stirred at 80 °C for 2 h. Upon cooling, the mixture was diluted with water, extracted with f-PrOAc (x3), dried over MgS0 4 , filtered, and purified by preparative HPLC to give the title compound (93.5 mg, 65% yield).
  • Example 16 5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2-
  • Example 18 2-(5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-oxo-l,3,4-oxadiazol-3(2H)-yl)acetonitrile
  • Example 20 5-(l-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl- l, l-dioxido-6-phenyl-l ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-3-(2,2,2-trifluoroethyl)-l,3,4-oxadiazol-2(3 f)-one
  • Example 22 2-(5-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l ,l-dioxido-6-phenyl-l ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-oxo-l,3,4-oxadiazol-3(2H)-yl)acetamide 5-[l-[2,5-Difluoro-4 [(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3//-l,3,4-oxadiazol-2-one was reacted with 2-bromoacetamide, as described in example 11, to give the title compound.
  • Example 23 5-(l-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-3-(2-methoxyethyl)-l,3,4-oxadiazol-2(3H)-one
  • Example 24 5-(l-(2,5-Difluoro-4-(((3,S , ,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-methylisoxazol-3(2 /)-one and (3S,6R)-2-(2,5-difluoro-4-( l-(3- methoxyisoxazol-5-yl)ethyl)benzyl)-3-methyl-6-phenyl-l,2-thiazinane 1,1 -dioxide
  • Example 25 3 - ⁇ 1 -r2,5-Difluoro-4- IT(3S,6R)-3 -methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2-
  • Step 1 jV-(l-(4-(((ferf-Butyldimethylsilyl)oxy)methyl)-2,5-difluorophenyl)ethyl)-2-methylpropane-2- sulfinamide
  • Step 2 /V-(l-(2,5-Difluoro-4-(hvdroxymethyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide
  • Step 3 jV-(l-(4-(Chloromethyl)-2,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide
  • Step 4 N-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide
  • step 3 To a solution of the product of step 3 (3.4 g, 11 mmol) in DMF (50mL) was added (35,6R)-3- methyl-6-phenyl-thiazinane 1,1-dioxide (2.9 g, 13 mmol) and cesium carbonate (12.4 g, 38 mmol). The reaction was stirred at 25 °C for 16 h, quenched with saturated NH 4 C1 solution (100 mL), extracted with EtOAc (50mL x 3), dried over sodium sulfate, filtered, and concentrated under reduced pressure.
  • Step 5 l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDethan- 1 -aminium chloride
  • step 4 To a solution of the product of step 4 (4.6 g, 9.2 mmol) in MeOH (20 mL) was added dropwise anhydrous HC1 in 1,4-dioxane (4 M, 6.9 mL, 27.7 mmol) at 0 °C. The reaction was stirred at 0 °C for 30 min. The solvent was removed in vacuo and the crude product was triturated with diethyl ether, filtered, washed with more diethyl ether, dried under a high vacuum system for 1 h to give the title compound (3.8 g, 96% yield) as a white solid.
  • Step 6 /V-(l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-l /-imidazole-l-carboxamide
  • Step 7 3-ri-r2,5-difluoro-4-rr(3,S',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl1methyl1phenyl1ethyl1- l /-imidazol-2-one
  • Example 26 l-ri-r2,5-Difluoro-4-rr(3,S , ,6R -3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-
  • Step l N-(l-(2,5-Difluoro-4-(((3S,6R)-3-methyl J-dioxido-6-phenyl ,2-tMazinan-2 ⁇
  • Step 2 Methyl ⁇ -cyano- ⁇ -(l-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l, l-dioxido-6-phenyl-l ,2-thiazinan-2- yl)methyl)phenyl)ethyl)glvcinate
  • step 1 To a solution of the product of step 1 (100 mg, 0.24 mmol) in THF (10 mL) was added NaH (60%, 10.4 mg, 0.26 mmol), the reaction mixture was stirred at 0 °C for 1 h, and then methyl 2- bromoacetate (36 mg, 0.24 mmol) was added, the reaction mixture was stirred at 25 °C for 16 h. The reaction was quenched with H 2 0 (2 mL), extracted with EA (2 x 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • Step 3 1 - ⁇ 1 - r2,5-Difluoro-4-r ⁇ (3S,6R)-3 -methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2- vHmethvHphenvHethvHimidazolidine-2,4-dione
  • Step 1 (3S,6R)-2-(4-( l-Ethoxyvinyl)-2,5-difluorobenzyl)-3-methyl-6-phenyl- 1 ,2-thiazinane 1 , 1 -dioxide
  • Step 2 l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l, l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethan- 1 -one
  • Step 3 (3£,6R -2-(2,5-Difluoro-4-(l-hydroxyethyD 1,1-dioxide
  • Step 4 l-(2,5-Difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl methanesulfonate
  • step 3 To a solution of the product of step 3 (800 mg, 2.0 mmol) in DCM (40 mL) at 0 °C was added NEt 3 (0.84 mL, 6.1 mmol), and then added dropwise methanesulfonyl chloride (0.31 mL, 4.1 mmol). The mixture was stirred at 15 °C for 2 h, then quenched with saturated NaHC0 3 (20 mL), extracted with DCM (2x30mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the crude product as light yellow oil which was used in the next step without further purification.
  • LCMS (ESI): m/z 496.1 [M+Na] + .
  • Step 5 fert-Butyl 2-(l-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDethvDhydrazine- 1 -carboxylate
  • step 4 To a solution of the product of step 4 (500 mg, 1.1 mmol) in acetonitrile (30 mL) was added tert- butyl hydrazinecarboxylate (277 mg, 2.1 mmol) and Cs 2 C0 3 (1 g, 3.1 mmol). The mixture was stirred at
  • Step 6 fert-Butyl 2-carbamoyl-2-(l-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2- thiazinan-2-yl)methyl)phenyl)ethyl)hydrazine- 1 -carboxylate
  • step 5 To a solution of the product of step 5 (120 mg, 0.24 mmol) in DCM (10 mL) was added triethylamine (0.1 mL, 0.71 mmol) at 0 °C, then bis(trichloromethyl) carbonate (22.8 mg, 0.08 mmol) in DCM (10 mL) was added triethylamine (0.1 mL, 0.71 mmol) at 0 °C, then bis(trichloromethyl) carbonate (22.8 mg, 0.08 mmol) in
  • Step 8 2-r i-r2,5-Difluoro-4-rr(3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- vHmethvHphenvHethvH-4ff-l,2,4-triazol-3-one
  • step 7 To a solution of lthe product of step 7 (100 mg, 0.22 mmol) was added triethoxymethane (6.0 mL, 0.22 mmol), the reaction mixture was stirred at 85 °C for 6 h. The solvent was removed under reduced pressureand the residue was purified by Biotage Flash column (12 g silica, UV254,
  • Step 1 ferf-Butyl ((ferf-butoxycarbonyl)oxy)(l-(2,5-difluoro-4-(((3 ⁇ ,6R)-3-methyl-l,l-dioxido-6-phenyl- l,2-thiazinan-2-yl)methyl)phenyl)ethyl)carbamate
  • Step 2 ferf-Butyl (l-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)(hvdroxy)carbamate
  • Step 3 ferf-Butyl (l-(2,5-difluoro-4-(((3,S , ,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)(propioloyloxy)carbamate
  • step 2 the product of step 2 (80 mg, 0.16 mmol).
  • Step 4 2-ri-r2,5-difluoro-4-rr(3,S , ,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- vHmethvHphenvHethvHisoxazol-5-one
  • This assay was used to determine a compound's potency in inhibiting activity of RORc by determining, Ki app , IC 50 , or percent inhibition values. Consumables used in this Example are shown in Table 5 below.
  • NBS Nonspecific binding
  • 25-hydroxycholesterol (1 uM) was used to determine the level of NSB signal is prepared in DMSO as for compounds above, then diluted in Assay Buffer to give a final concentration of 5 uM.
  • 25-hydroxycholesterol in 25% DMSO/75% Assay Buffer 10 uL per well was used for NSB samples.
  • Wells for Total Binding and No Receptor sample determination contained 10 uL of 25% DMSO/75% Assay Buffer per well.
  • 25-[ 3 H]hydroxycholesterol was diluted in Assay Buffer to obtain 15 nM and vortex to mix. Add 20 uL to all wells to reach 6 nM final concentration in the assay.
  • the optimal concentration for RORc receptor was found to be 0.6 ug/mL.
  • Stock receptor solution was diluted in assay buffer to obtain 1.5 ug/mL in Assay Buffer. 20 uL was added to all wells.
  • Assay plates were 96-well polypropylene V-bottom plates. 10 uL of 5x compound in
  • Buffer was added to all wells. 20 uL of 1.5 ug/mL RORc receptor was added to wells (or 40 uL Assay Buffer to No R wells). Following addition to the wells, the plates were incubated 3 h at 25°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of the formula (I): or a pharmaceutical salt thereof, wherein m, n, p, q, Het, A, W, R1, R2, R3, R4, R5, R6, R7, R8, R and R10are as defined herein are modulators of retinoid-receptor related orphan receptor RORc (RORy). Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Description

HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS
FIELD OF THE INVENTION
The invention pertains to compounds that modulate the function of retinoid-receptor related orphan receptor RORc (RQRy) and use of such compounds for treatment of autoimmune diseases
BACKGROUND OF THE INVENTION
T helper 17 cells (Thl7) are interleukin (IL)-17 secreting CD4+ T cells involved in pathogenesis of autoimmune diseases such as rheumatoid arthritis, irritable bowel disease, psoriasis, psoriatic arthritis and spondyloarthridities. The retinoic acid-related orphan receptor γ (RORy or RORc) is recognized as a transcription factor necessary for Thl7 cell differentiation. RORc is an orphan member of the nuclear hormone receptor subfamily that includes RORa (RORa) and RORp (RORb). RORc controls gene transcription by binding to DNA as a monomer. Selective modulation of RORc has been proposed as a route to discovery and development of Thl7 cell-associated autoimmune diseases.
There is accordingly a need for compounds that inhibit RORc for use in treatment of autoimmune diseases such as rheumatoid arthritis, irritable bowel disease, psoriasis, psoriatic arthritis and spondyloarthriitis.
SUMMARY OF THE INVENTION
The
or a pharmaceutically acceptable salt thereof,
wherein:
m is 0 or 1 ;
n is 0 or 1 ;
p is from 0 to 3;
q is from 0 to 3;
Het is:
a five or six membered heteroaryl selected from:
pyrrolyl;
pyrrazolyl; imidazolyl;
oxazolyl;
thiazolyl;
isoxazolyl;
isothiazolyl;
triazolyl;
oxadiazolyl;
thiadiazolyl;
tetrazolyl;
thiophenyl;
furanyl;
pyridinyl;
pyrimidinyl;
pyridazinyl; or
pyrazinyl; or
a five membered heterocyclyl selected from:
pyrrolidinyl;
oxazolidinyl;
dioxolanyl; or
imidazolidinyl;
A is:
each of which may be unsubstituted or substituted once or twice with Ra;
W is: -CRbRc-; -0-; -S-; -S02-; or -NRd-;
one of X1, X2, X3 and X4 is N and the others are CRe; or two of X1, X2, X3 and X4 are N and the others are CRe; or three of X1, X2, X3 and X4 are N and the other is CRe; or each of X1, X2, X3 and X4 is CRe;
R1, R2, R3, R4, R5, R6, R7 and R8 each independently is: hydro gen; or Ci_6aikyl which may be unsubstituted or substituted one or more times with halo;
or R3 and R4 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf; or R5 and R6 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or R7 and R8 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of R3 and R4 together with one of R5 and R6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of R5 and R6 together with one of R7 and R8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
each R9 is independently:
Ci-6alkyl;
halo;
Ci_6aikoxy; or
cyano;
wherein the C^aUcyl moieties may be unsubstituted or substituted one or more times with halo; each R10 is independently:
Ci-6alkyl;
oxo;
hydroxy
halo;
cyano;
halo-Ci_6alkyl;
hydroxy-Ci_6alkyl;
Ci_6aikoxy-Ci_6alkyl; or
cyano-Ci_6alkyl.
Ra is:
Ci_6aikoxy; Ci.6alkoxy-Ci.6alkyl;
hydroxy-C i .6alkyl ;
C3.6cycloalkyl;
Cs^cycloalkyl-C!^alkyl;
C3.6cycloalkyloxy;
C3.6cycloalkyl-Ci_6alkoxy;
heterocyclyl;
heterocylyl-C!^alkyl; or
heterocylyl-CVealkoxy;
wherein the heterocyclyl moieties are each independently selected from oxetanyl,
tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, and wherein the heterocycyl moieties and C3.6cycloalkyl moieties each may be unsubstituted or substituted one or more times with Rf;
Rb, Rc, and Rd each independent is:
hydrogen;
Ci_6aikyl; or
halo-Ci_6alkyl;
or Rb and Rc together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of Rb and Rc together with one of R7 and R8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of Rb and Rc together with one of R5 and R6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
each Re is independently:
hydrogen;
d.ealkyl;
halo;
C!.6alkoxy; or
cyano; wherein the Ci_6alkyl moieties may be unsubstituted or substituted one or more times with halo; and
Rf is: Ci_6alkyl; halo; oxo; hydroxy; or
The invention also provides and pharmaceutical compositions comprising the compounds, methods of using the compounds, and methods of preparing the compounds.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
Unless otherwise stated, the following terms used in this Application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an," and "the" include plural referents unless the context clearly dictates otherwise. In some instances dashes ("-") may be used interchangeably within definitions (for example, "alkoxyalkyl" omits the dash found in the equivalent term "alkoxyalkyl").
"Alkyl" means the monovalent linear or branched saturated hydrocarbon moiety, consisting solely of carbon and hydrogen atoms, having from one to twelve carbon atoms. "Lower alkyl" refers to an alkyl group of one to six carbon atoms, i.e. Ci-C6alkyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec -butyl, tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like.
"Alkenyl" means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms, containing at least one double bond, e.g. , ethenyl, propenyl, and the like.
"Alkynyl" means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms, containing at least one triple bond, e.g. , ethynyl, propynyl, and the like.
"Alkylene" means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g., methylene, ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene, butylene, pentylene, and the like.
"Alkoxy" and "alkyloxy", which may be used interchangeably, mean a moiety of the formula -OR, wherein R is an alkyl moiety as defined herein. Examples of alkoxy moieties include, but are not limited to, methoxy, ethoxy, isopropoxy, and the like.
"Alkoxyalkyl" means a moiety of the formula Ra-0-Rb-, where Ra is alkyl and Rb is alkylene as defined herein. Exemplary alkoxyalkyl groups include, by way of example, 2-methoxy ethyl, 3-methoxypropyl, 1 -methyl -2 -methoxyethyl, l-(2-methoxyethyl)-3-methoxypropyl, and l-(2- methoxyethyl)-3 -methoxypropyl. "Alkoxyalkoxy' means a group of the formula -O-R-R' wherein R is alkylene and R' is alkoxy as defined herein.
"Alkylcarbonyl" means a moiety of the formula -C(0)-R, wherein R is alkyl as defined herein.
"Alkoxycarbonyl" means a group of the formula -C(0)-R wherein R is alkoxy as defined herein.
"Alkylcarbonylamino" means a group of the formula -R-C(0)-NR'- wherein R is alkyl and R' is hydrogen or alkyl.
"Alkylcarbonylalkyl" means a group of the formula -R-C(0)-R' wherein R is alkylene and R' is alkyl as defined herein.
"Alkoxyalkylcarbonyl" means a moiety of the formula -C(0)-R-R', wherein R is alkylene and R' is alkoxy as defined herein.
"Alkoxycarbonylalkyl" means a group of the formula -R-C(0)-R wherein R is alkylene and R' is alkoxy as defined herein.
"Alkoxycarbonylamino" means a moiety of the formula R-C(0)-NR'-, wherein R is alkoxy and
R' is hydrogen or alkyl as defined herein.
"Alkoxycarbonylaminoalkyl" means a moiety of the formula R-C(0)-NR'-R"-, wherein R is alkoxy, R' is hydrogen or alkyl, and R" is alkylene as defined herein.
"Alkoxycarbonylalkoxy"means a group of the formula -0-R-C(0)-R' wherein R is alkylene and R' is alkoxy as defined herein.
"Hydroxycarbonylalkoxy" means a group of the formula -0-R-C(0)-OH wherein R is alkylene as defined herein.
"Alkylaminocarbonylalkoxy" means a group of the formula -0-R-C(0)-NHR' wherein R is alkylene and R' is alkyl as defined herein.
"Dialkylaminocarbonylalkoxy" means a group of the formula -0-R-C(0)-NR'R" wherein R is alkylene and R' and R" are alkyl as defined herein.
"Alkylaminoalkoxy" means a group of the formula -O-R-NHR' wherein R is alkylene and R' is alkyl as defined herein.
"Dialkylaminoalkoxy" means a group of the formula -O-R-NR'R' wherein R is alkylene and R' and R" are alkyl as defined herein.
"Alkylsulfonyl" means a moiety of the formula - S02-R, wherein R is alkyl as defined herein. "Alkylsulfonylalkyl means a moiety of the formula -R'-S02-R" where where R' is alkylene and R" is alkyl as defined herein. "Alkylsulfonylalkoxy" means a group of the formula -0-R-S02-R' wherein R is alkylene and R' is alkyl as defined herein.
"Amino means a moiety of the formula -NRR' wherein R and R' each independently is hyrdogen or alkyl as defined herein. "Amino thus includes "alkylamino (where one of R and R' is alkyl and the other is hydrogen) and "dialkylamino (where R and R' are both alkyl.
"Aminocarbonyl" means a group of the formula -C(0)-R wherein R is amino as defined herein.
"N-hydroxy-aminocarbonyl" means a group of the formula -C(0)-NR-OH wherein R is hydrogen or alkyl as defined herein.
"N-alkoxy-aminocarbonyl" means a group of the formula -C(0)-NR-R' wherein R is hydrogen or alkyl and R' is alkoxy as defined herein.
"Ammocarbonylaminoalkyl" means a group of the formula R2N-C(0)-NR'-R"- wherein each R is independently hydrogen or alkyl, R' is hydrogen or alkyl, and R" is alkylene as defined herein.
"N-alkyl-aminocarbonyl means a group of the formula -C(0)-NH-R wherein R is alkyl as defined herein.
"N-hydroxy-N-alkylaminocarbonyl means a group of the formula -C(0)-NRR' wherein R is alkyl as defined herein and R' is hydroxy.
"N-alkoxy-N-alkylaminocarbonyl" means a group of the formula -C(0)-NRR' wherein R is alkyl and R' is alkoxy as defined herein.
"N,N-di-Ci.6alkyl-aminocarbonyl" means a group of the formula -C(0)-NRR' wherein R and R' are alkyl as defined herein.
"Aminosulfonyl" means a group of the formula -S02-NH2.
"N-alkylaminosulfonyl" means a group of the formula -S02-NHR wherein R is alkyl as defined herein.
"Ν,Ν-dialkylaminosulfonyl" means a group of the formula -S02-NRR' wherein R and R' are alkyl as defined herein.
"Alkylsulfonylamino" means a group of the formula -NR'-S02-R wherein R id alkyl and R' is hydrogen or alkyl as defined herein.
"N-(alkylsulfonyl)-aminoalkyl" means a group of the formula -R-NH-S02-R' wherein R is alkylene and R' is alkyl as defined herein.
"N-(Alkylsulfonyl)aminocarbonyl" means a group of the formula -C(0)-NH-S02-R wherein wherein R is alkyl as defined herein.
"N-(Alkylsulfonyl)-N-alkylaminocarbonyl" means a group of the formula -C(0)-NR-S02-R' wherein wherein R and R' are alkyl as defined herein. "N-Alkoxyalkyl-aniinocarbonyl" means a group of the formula -C(0)-NR-R'-OR" wherein R is hydrogen or alkyl, R' is alkylene, and R" is alkyl as defined herein.
"N-Hydroxyalkyl-aminocarbonyl" means a group of the formula -C(0)-NR-R'-OH" wherein R is hydrogen or alkyl and R' is alkylene as defined herein.
"Alkoxyamino" means a moiety of the formula -NR-OR' wherein R is hydrogen or alkyl and R' is alkyl as defined herein.
"Alkylsulfanyl" means a moiety of the formula -SR wherein R is alkyl as defined herein.
"Aminoalkyl" means a group -R-R' wherein R' is amino and R is alkylene as defined herein.
"Aminoalkyl" includes aminomethyl, aminoethyl, 1-aminopropyl, 2-aminopropyl, and the like. The amino moiety of "aminoalkyl" may be substituted once or twice with alkyl to provide
"alkylaminoalkyl" and "dialkylaminoalkyl" respectively. "Alkylaminoalkyl" includes
methylaminomethyl, methylaminoethyl, methylaminopropyl, ethylaminoethyl and the like.
"Dialkylaminoalkyl" includes dimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl, N- methyl-N-ethylaminoethyl, and the like.
"Aminoalkoxy" means a group -OR-R' wherein R' is amino and R is alkylene as defined herein.
"Alkylsulfonylamido" means a moiety of the formula -NR'S02-R wherein R is alkyl and R' is hydrogen or alkyl.
"Aminocarbonyloxyalkyl" or "carbamylalkyl" means a group of the formula -R-0-C(0)-NR'R" wherein R is alkylene and R', R" each independently is hydrogen or alkyl as defined herein.
"Alkynylalkoxy" means a group of the formula -O-R-R' wherein R is alkylene and R' is alkynyl as defined herein.
"Aryl" means a monovalent cyclic aromatic hydrocarbon moiety consisting of a mono-, bi- or tricyclic aromatic ring. The aryl group can be optionally substituted as defined herein. Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl, benzomorpholinyl, methylenedioxyphenyl, ethylenedioxyphenyl, and the like, of which may be optionally substituted as defined herein.
"Arylalkyl" and "Aralkyl", which may be used interchangeably, mean a radical-RaRb where Ra is an alkylene group and Rb is an aryl group as defined herein; e.g., phenylalkyls such as benzyl, phenylethyl, 3-(3-chlorophenyl)-2-methylpentyl, and the like are examples of arylalkyl.
"Arylsulfonyl means a group of the formula -S02-R wherein R is aryl as defined herein.
"Aryloxy" means a group of the formula -O-R wherein R is aryl as defined herein. "Aralkyloxy" means a group of the formula -O-R-R" wherein R is alkylene and R' is aryl as defined herein.
"Carboxy" or "hydroxycarbonyl", which may be used interchangeably, means a group of the formula -C(0)-OH.
"Cyanoalkyl" " means a moiety of the formula -R'-R", where R' is alkylene as defined herein and R" is cyano or nitrile.
"Cycloalkyl" means a monovalent saturated carbocyclic moiety consisting of mono- or bicyclic rings. Particular cycloalkyl are unsubstituted or substituted with alkyl. Cycloalkyl can optionally be substituted as defined herein. Unless defined otherwise, cycloalkyl may be optionally substitued with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, including partially unsaturated (cycloalkenyl) derivatives thereof.
"Cycloalkenyl" means a cycloalkyl as defined herein that includes at least one double bond or unsaturation. Exemplary cycloalkenyl include cyclohexenyl, cyclopentenyl, cyclobutenyl and the like.
"Cycloalkylalkyl" means a moiety of the formula -R'-R", where R' is alkylene and R" is cycloalkyl as defined herein.
"Cycloalkylalkoxy" means a group of the formula -O-R-R' wherein R is alkylene and R' is cycloalkyl as defined herein.
"Cycloalkylcarbonyl" means a moiety of the formula -C(0)-R, wherein R is cycloalkyl as defined herein.
"C3_6cycloalkyl-Ci_6alkyl-carbonyl" means a moiety of the formula -C(0)-R, wherein R is cycloalkylalkyl as defined herein.
"Cyanoalkylcarbonyl" means a moiety of the formula -C(0)-R-R' , wherein R is alkylene as defined herein and R' is cyano or nitrile.
"N-Cyano-aminocarbonyl" means a moiety of the formula -C(0)-NHR, wherein R is cyano or nitrile.
"N-Cyano-N-alkyl-aminocarbonyl" means a moiety of the formula -C(0)-NRR' -R, wherein R' is alkyl as defined herein and R is cyano or nitrile.
"Cycloalkylsulfonyl" means a group of the formula -S02-R wherein R is cycloalkyl as defined herein.
"Cycloalkylalkylsulfonyl" means a group of the formula -S02-R wherein R is cycloalkylalkyl as defined herein.
"Formyl" means a moiety of the formula -C(0)-H. "Heteroaryl" means a monocyclic or bicyclic radical of 5 to 12 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, with the understanding that the attachment point of the heteroaryl radical will be on an aromatic ring. The heteroaryl ring may be optionally substituted as defined herein. Examples of heteroaryl moieties include, but are not limited to, optionally substituted imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, thienyl, benzothienyl, thiophenyl, furanyl, pyranyl, pyridyl, pyrrolyl, pyrazolyl, pyrimidyl, quinolinyl, isoquinolinyl, benzofuryl, benzo thiophenyl, benzothiopyranyl, benzimidazolyl, benzooxazolyl, benzooxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzopyranyl, indolyl, isoindolyl, triazolyl, triazinyl, quinoxalinyl, purinyl, quinazolinyl, quinolizinyl, naphthyridinyl, pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl and the like, each of which may be optionally substituted as defined herein.
Heteroarylalkyl" or "heteroaralkyl" means a group of the formula -R-R' wherein R is alkylene and R' is heteroaryl as defined herein.
"Heteroarylsulfonyl means a group of the formula -S02-R wherein R is heteroaryl as defined herein.
"Heteroaryloxy" means a group of the formula -O-R wherein R is heteroaryl as defined herein.
"Heteroaralkyloxy" means a group of the formula -O-R-R" wherein R is alkylene and R' is heteroaryl as defined herein.
The terms "halo", "halogen" and "halide", which may be used interchangeably, refer to a substituent fluoro, chloro, bromo, or iodo.
"Haloalkyl" means alkyl as defined herein in which one or more hydrogen has been replaced with same or different halogen. Exemplary haloalkyls include -CH2C1,
-CH2CF3, -CH2CC13, perfluoroalkyl (e.g., -CF3), and the like.
"Haloalkoxy" means a moiety of the formula -OR, wherein R is a haloalkyl moiety as defined herein. An exemplary haloalkoxy is difluoromethoxy.
"Heterocycloamino" means a saturated ring wherein at least one ring atom is N, NH or N-alkyl and the remaining ring atoms form an alkylene group.
"Heterocyclyl" means a monovalent saturated moiety, consisting of one to three rings, incorporating one, two, or three or four heteroatoms (chosen from nitrogen, oxygen or sulfur). The heterocyclyl ring may be optionally substituted as defined herein. Examples of heterocyclyl moieties include, but are not limited to, optionally substituted piperidinyl, piperazinyl, morpholinyl,
thiomorpholinyl, azepinyl, pyrrolidinyl, azetidinyl, tetrahydropyranyl, tetrahydrofuranyl, oxetanyl and the like. Such heterocyclyl may be optionally substituted as defined herein. "Heterocyclylalkyl" means a moiety of the formula -R-R' wherein R is alkylene and R' is heterocyclyl as defined herein.
"Heterocyclyloxy" means a moiety of the formula -OR wherein R is heterocyclyl as defined herein.
"Heterocyclylalkoxy" means a moiety of the formula -OR-R' wherein R is alkylene and R' is heterocyclyl as defined herein.
"Hydroxyalkoxy" means a moiety of the formula -OR wherein R is hydroxyalkyl as defined herein.
"Hydroxyalkylamino" means a moiety of the formula -NR-R' wherein R is hydrogen or alkyl and R' is hydroxyalkyl as defined herein.
"Hydroxyalkylaminoalkyl" means a moiety of the formula -R-NR'-R" wherein R is alkylene, R' is hydrogen or alkyl, and R" is hydroxyalkyl as defined herein.
"Hydroxycarbonylalkyl" or "carboxyalkyl" means a group of the formula -R-(CO)-OH where R is alkylene as defined herein.
"Hydroxycarbonylalkoxy" means a group of the formula -0-R-C(0)-OH wherein R is alkylene as defined herein.
"Hydroxyalkylcarbonyl" means a moiety of the formula -C(0)-R-R' , wherein R is alkylene as defined herein and R' is hydroxy.
"Hydroxyalkyloxycarbonylalkyl" or "hydroxyalkoxycarbonylalkyl" means a group of the formula -R-C(0)-0-R-OH wherein each R is alkylene and may be the same or different.
"Hydroxyalkyl" means an alkyl moiety as defined herein, substituted with one or more, for example, one, two or three hydroxy groups, provided that the same carbon atom does not carry more than one hydroxy group. Representative examples include, but are not limited to, hydroxymethyl,
2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, l-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 2-hydroxy-l-hydroxymethylethyl,
2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl
"Hydroxycycloalkyl" means a cycloalkyl moiety as defined herein wherein one, two or three hydrogen atoms in the cycloalkyl radical have been replaced with a hydroxy substituent. Representative examples include, but are not limited to, 2-, 3-, or 4-hydroxycyclohexyl, and the like.
"Oxo" means a group of the formula =0 (i.e., an oxygen with a double bond). Thus, for example, a 1-oxo-ethyl group is an acetyl group.
"Alkoxy hydroxyalkyl" and "hydroxy alkoxyalkyl", which may be used interchangeably, means an alkyl as defined herein that is substituted at least once with hydroxy and at least once with alkoxy. "Alkoxy hydroxyalkyl" and "hydroxy alkoxyalkyl" thus encompass, for example, 2-hydroxy-3- methoxy-propan-l-yl and the like.
"Urea'Or "ureido" means a group of the formula -NR'-C(0)-NR"R"' wherein R', R" and R'" each independently is hydrogen or alkyl.
"Carbamate" means a group of the formula -0-C(0)-NR'R" wherein R' and R" each
independently is hydrogen or alkyl.
"Carboxy" means a group of the formula -0-C(0)-OH.
"Sulfonamido" means a group of the formula -S02-NR'R" wherein R', R" and R'" each independently is hydrogen or alkyl.
"Optionally substituted" when used in association with an "aryl", phenyl", "heteroaryl"
"cycloalkyl" or "heterocyclyl" moiety means that such moiety may be unsubstituted (i.e., all open valencies are occupied by a hydrogen atom) or substituted with specific groups as related herein.
"Leaving group" means the group with the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or group displaceable under substitution reaction conditions. Examples of leaving groups include, but are not limited to, halogen, alkane- or arylenesulfonyloxy, such as methanesulfonyloxy, ethanesulfonyloxy, thiomethyl, benzenesulfonyloxy, tosyloxy, and thienyloxy, dihalophosphinoyloxy, optionally substituted benzyloxy, isopropyloxy, acyloxy, and the like.
"Modulator" means a molecule that interacts with a target. The interactions include, but are not limited to, agonist, antagonist, and the like, as defined herein.
"Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
"Disease" and "Disease state" means any disease, condition, symptom, disorder or indication. "Inert organic solvent" or "inert solvent" means the solvent is inert under the conditions of the reaction being described in conjunction therewith, including for example, benzene, toluene, acetonitrile, tetrahydrofuran, Ν,Ν-dimethylformamide, chloroform, methylene chloride or dichloromethane, dichloroethane, diethyl ether, ethyl acetate, acetone, methyl ethyl ketone, methanol, ethanol, propanol, isopropanol, ieri-butanol, dioxane, pyridine, and the like. Unless specified to the contrary, the solvents used in the reactions of the present invention are inert solvents.
"Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use. "Pharmaceutically acceptable salts" of a compound means salts that are pharmaceutically acceptable, as defined herein, and that possess the desired pharmacological activity of the parent compound.
It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same acid addition salt.
"Protective group" or "protecting group" means the group which selectively blocks one reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry. Certain processes of this invention rely upon the protective groups to block reactive nitrogen and/or oxygen atoms present in the reactants. For example, the terms "amino-protecting group" and "nitrogen protecting group" are used interchangeably herein and refer to those organic groups intended to protect the nitrogen atom against undesirable reactions during synthetic procedures. Exemplary nitrogen protecting groups include, but are not limited to, trifluoroacetyl, acetamido, benzyl (Bn), benzyloxycarbonyl
(carbobenzyloxy, CBZ), p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, ferf-butoxycarbonyl (BOC), and the like. The artisan in the art will know how to chose a group for the ease of removal and for the ability to withstand the following reactions.
"Solvates" means solvent additions forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one of the substances in which the water retains its molecular state as H20, such combination being able to form one or more hydrate.
"Arthritis" means a disease or condition that causes damage to joints of the body and pain associated with such joint damage. Arthritis includes rheumatoid arthritis, osteoarthritis, psoriatic arthritis, septic arthritis, spondyloarthropathies, gouty arthritis, systemic lupus erythematosus and juvenile arthritis, osteoarthritis, and other arthritic conditions.
"Respiratory disorder" refers to, without limitation, chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, and the like.
"Subject" means mammals and non-mammals. Mammals means any member of the mammalia class including, but not limited to, humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but are not limited to, birds, and the like. The term "subject" does not denote a particular age or sex. "Therapeutically effective amount" means an amount of a compound that, when administered to a subject for treating a disease state, is sufficient to effect such treatment for the disease state. The "therapeutically effective amount" will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
The terms "those defined above" and "those defined herein" when referring to a variable incorporates by reference the broad definition of the variable as well as particular definitions, if any.
"Treating" or "treatment" of a disease state includes, inter alia, inhibiting the disease state, i.e. , arresting the development of the disease state or its clinical symptoms, and/or relieving the disease state , i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.
The terms "treating", "contacting" and "reacting" when referring to a chemical reaction means adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
Nomenclature and Structures
In general, the nomenclature and chemical names used in this Application are based on
ChembioOffice™ by CambridgeSoft™. Any open valency appearing on a carbon, oxygen sulfur or nitrogen atom in the structures herein indicates the presence of a hydrogen atom unless indicated otherwise. Where a nitrogen-containing heteroaryl ring is shown with an open valency on a nitrogen atom, and variables such as Ra, Rb or Rc are shown on the heteroaryl ring, such variables may be bound or joined to the open valency nitrogen. Where a chiral center exists in a structure but no specific stereochemistry is shown for the chiral center, both enantiomers associated with the chiral center are encompassed by the structure. Where a structure shown herein may exist in multiple tautomeric forms, all such tautomers are encompassed by the structure. The atoms represented in the structures herein are intended to encompass all naturally occurring isotopes of such atoms. Thus, for example, the hydrogen atoms represented herein are meant to include deuterium and tritium, and the carbon atoms are meant to include C13 and C14 isotopes. One or more carbon atom(s) of a compound of the invention may be replaced by a silicon atom(s), and it is contemplated that one or more oxygen atom(s) of a compound of the invention may be replaced by a sulfur or selenium atom(s).
Compounds of the Invention
The invention provides compounds of formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
m is 0 or 1 ;
n is 0 or 1 ;
p is from 0 to 3;
q is from 0 to 3;
Het is:
a five or six membered heteroaryl selected from: pyrrolyl;
pyrrazolyl;
imidazolyl;
oxazolyl;
thiazolyl;
isoxazolyl;
isothiazolyl;
triazolyl;
oxadiazolyl;
thiadiazolyl;
tetrazolyl;
thiophenyl;
furanyl;
pyridinyl;
pyrimidinyl;
pyridazinyl; or pyrazinyl; or
a five membered heterocyclyl selected from: pyrrolidinyl; oxazolidinyl;
dioxolanyl; or
imidazolidinyl;
A is:
Ci_6aikenylene,
each of which may be unsubstituted or substituted once or twice with Ra;
W is: -CRbRc-; -0-; -S-; -S02-; or -NRd-;
one of X1, X2, X3 and X4 is N and the others are CRe; or two of X1, X2, X3 and X4 are N and the others are CRe; or three of X1, X2, X3 and X4 are N and the other is CRe; or each of X1, X2, X3 and X4 is CRe;
R1, R2, R3, R4, R5, R6, R7 and R8 each independently is: hydro gen; or Ci_6alkyl which may be unsubstituted or substituted one or more times with halo;
or R3 and R4 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or R5 and R6 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or R7 and R8 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of R3 and R4 together with one of R5 and R6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of R5 and R6 together with one of R7 and R8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
each R9 is independently: d_6alkyl;
halo;
C!.6alkoxy; or
cyano;
wherein the C^ancyl moieties may be unsubstituted or substituted one or more times with halo; each R10 is independently:
d_6alkyl;
oxo;
hydroxy
halo;
cyano;
halo-Ci_6alkyl;
hydroxy-C i _6alkyl ;
Ci.6alkoxy-Ci_6alkyl; or
cyano-Ci_6alkyl;
Ra is:
Ci_6alkoxy;
Ci.6alkoxy-Ci.6alkyl;
hydroxy-C i .6alkyl ;
C3.6cycloalkyl;
C3.6cycloalkyl-Ci_6alkyl;
C3.6cycloalkyloxy;
Cs^cycloalkyl-C!^alkoxy;
heterocyclyl;
heterocylyl-Ci_6alkyl; or
heterocylyl-Ci^alkoxy;
wherein the heterocyclyl moieties are each independently selected from oxetanyl,
tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, and wherein the heterocycyl moieties and C3.6cycloalkyl moieties each may be unsubstituted or substituted one or more times with Rf;
Rb, Rc, and Rd each independent is:
hydrogen;
Ci_6alkyl; or
halo-Chalky!; or Rb and Rc together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of Rb and Rc together with one of R7 and R8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of Rb and Rc together with one of R5 and R6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
each Re is independently:
hydrogen;
C^alkyl;
halo;
Ci_6aikoxy; or
cyano;
wherein the Ci_6aikyl moieties may be unsubstituted or substituted one or more times with halo; and
Rf is: Ci_6aikyl; halo-Ci_6aikyl; halo; oxo; hydroxy; or Ci_6alkoxy.
In certain embodiments of formula ] , m is 0.
In certain embodiments of formula ] , m is 1.
In certain embodiments of formula ] , n is 0.
In certain embodiments of formula ] , n is 1.
In certain embodiments of formula ] , p is from 0 to 2
In certain embodiments of formula ] , p is O or 1.
In certain embodiments of formula ] , p is 0.
In certain embodiments of formula ] , p is 1.
In certain embodiments of formula ] , p is 2.
In certain embodiments of formula ] , p is 3.
In certain embodiments of formula ] , q is 0.
In certain embodiments of formula ] , q is 1.
In certain embodiments of formula ] , q is 2. In certain embodiments of formula I, q is 0 or 1.
In certain embodiments of formula I, q is 0, 1 or 2.
In certain embodiments of formula I, Het is a five or six membered heteroaryl selected from:
pyrrolyl;
pyrrazolyl;
imidazolyl;
oxazolyl;
thiazolyl;
isoxazolyl;
isothiazolyl;
triazolyl;
oxadiazolyl;
thiadiazolyl;
tetrazolyl;
thiophenyl;
furanyl;
pyridinyl;
pyrimidinyl;
pyridazinyl; or
pyrazinyl.
In certain embodiments of formula I, Het is : oxadiazolyl
In certain embodiments of formula I, Het is imidazolyl .
In certain embodiments of formula I, Het is pyrazolyl .
In certain embodiments of formula I, Het is isoxazolyl .
In certain embodiments of formula I, Het is oxazolyl .
In certain embodiments of formula I, Het is thiazolyl .
In certain embodiments of formula I, Het is oxadiazolyl .
In certain embodiments of formula I, Het is triazolyl.
In certain embodiments of formula I, Het is tetrazolyl .
In certain embodiments of formula I, Het is thiophenyl .
In certain embodiments of formula I, Het is furanyl .
In certain embodiments of formula I, Het is pyridinyl .
In certain embodiments of formula I, Het is pyrimidinyl . In certain embodiments of formula I, Het is pyridazinyl .
In certain embodiments of formula I, Het is pyrazinyl .
In certain embodiments of formula I, Het is 3H-l,3,4-oxadiazol-2-one-5-yl.
In certain embodiments of formula I, Het is 2-hydroxymethyl-l,3,4-oxadiazol-5-yl. In certain embodiments of formula I, Het is a five membered heterocyclyl selected from:
pyrrolidinyl;
oxazolidinyl;
dioxolanyl;
imidazolidinyl.
In certain embodiments of formula I, Het is pyrrolidinyl.
In certain embodiments of formula I, Het is oxazolidinyl.
In certain embodiments of formula I, Het is dioxolanyl
In certain embodiments of formula I, Het is imidazolidinyl.
In certain embodiments of formula I, A is:Ci_6alkylene which may be unsubstituted or substituted once or twice with Ra.
In certain embodiments of formula I, A is:Ci_6alkenylene which may be unsubstituted or substituted once or twice with Ra.
In certain embodiments of formula I, A is: methylene; or ethylene; each of which may be unsubstituted or substituted with Ra.
In certain embodiments of formula I, A is: -CH2-; -C(CH3)2-; -CHCH3-; or -CHRa-.
In certain embodiments of formula I, A is methylene which may be unsubstituted or substituted with Ra.
In certain embodiments of formula I, A is ethylene which may be unsubstituted or substituted with Ra.
In certain embodiments of formula I, A is methylene
In certain embodiments of formula I, A is ethylene.
In certain embodiments of formula I, A is -CH2- -.
In certain embodiments of formula I, A is -CHCH3-.
In certain embodiments of formula I, A is -C(CH3)2-.
In certain embodiments of formula I, A is -CHRa-.
In certain embodiments of formula I, W is -CRbRc- or -0-.
In certain embodiments of formula I, W is -CRbRc-.
In certain embodiments of formula I, W is -0-.
In certain embodiments of formula I, W is -NRd-. n certain embodiments of formula W is -S-.
n certain embodiments of formula W is -SO2-.
n certain embodiments of formula W is -CH2-.
n certain embodiments of formula one or two of X1, X2, X3 and X4 is N and the others are CR'
n certain embodiments of formula three of X1, X2, X3 and X4 are CRe and the other is
N.
n certain embodiments of formula X\ X2, X3 and X4 are CRe.
n certain embodiments of formula X1 is N and X2, X3 and X4 are CRe. n certain embodiments of formula X2 is N and X1, X3 and X4 are CRe. n certain embodiments of formula X1 and X4 are N, and X2 and X3 are CRa.
n certain embodiments of formula X2 and X3 are N, and X1 and X4 are CRe.
n certain embodiments of formula X1 and X2 are N, and X3 and X4 are CRe.
n certain embodiments of formula R1 is hydrogen,
n certain embodiments of formula R1 is Ci_6aikyl.
n certain embodiments of formula R2 is hydrogen,
n certain embodiments of formula R2 is Ci_6aikyl.
n certain embodiments of formula R3 is hydrogen,
n certain embodiments of formula R3 is Ci_6aikyl.
n certain embodiments of formula R4 is hydrogen,
n certain embodiments of formula R4 is Ci_6aikyl.
n certain embodiments of formula R5 is hydrogen,
n certain embodiments of formula R5 is Ci_6alkyl.
n certain embodiments of formula R6 is hydrogen,
n certain embodiments of formula R6 is Ci_6aikyl.
n certain embodiments of formula R7 is hydrogen,
n certain embodiments of formula R7 is Ci_6alkyl.
n certain embodiments of formula R8 is hydrogen,
n certain embodiments of formula R8 is Ci_6aikyl.
n certain embodiments of formula R3 and R4 together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be optionally substituted one or more times with R1. In certain embodiments of formula I, R3 and R4 together with the atoms to which they are attached form a three, four or five membered saturated ring.
In certain embodiments of formula I, R5 and R6 together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be optionally substituted one or more times with R1.
In certain embodiments of formula I, R5 and R6 together with the atoms to which they are attached form a three, four or five membered saturated ring.
In certain embodiments of formula I, R7 and R8 together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be optionally substituted one or more times with R1.
In certain embodiments of formula I, R7 and R8 together with the atoms to which they are attached form a three, four or five membered saturated ring.
In certain embodiments of formula I, one of R3 and R4 together with one of R5 and R6 and the atoms to which they are attached form a three, four, five, six or seven membered ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be optionally substituted one or more times with R1.
In certain embodiments of formula I, one of R5 and R6 together with one of R7 and R8 and the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be optionally substituted one or more times with R1.
In certain embodiments of formula I, each R9 is independently: Chalky!; halo; or halo-
Ci-ealkyl.
In certain embodiments of formula I, R9 is Ci_6alkyl.
In certain embodiments of formula I, R9 is halo.
In certain embodiments of formula I, R9 is
In certain embodiments of formula I, R9 is cyano.
In certain embodiments of formula I, R9 is halo-Ci_6alkyl.
In certain embodiments of formula I, each R9 is independently: fluoro; chloro; or trifluoromethyl.
In certain embodiments of formula I, R is: Ci_6alkyl; hydroxy; oxo; or hydroxy-Ci.
6alkyl.
In certain embodiments of formula I, R is hydroxy. In certain embodiments of formula I, R is oxo.
In certain embodiments of formula I, R10 is cyano.
In certain embodiments of formula I, R10 is halo.
In certain embodiments of formula I, R10 is
In certain embodiments of formula I, R10 is
In certain embodiments of formula I, R10 is Ci_6alkyl.
In certain embodiments of formula I, R10 is halo-Ci_6alkyl.
In certain embodiments of formula I, R10 is cyano-Ci_6alkyl.
In certain embodiments of formula I, Ra is: C3. 6cycloalkyloxy; C^ecycloalkyl-C!^alkoxy; heterocylyl-C!^alkyl; or heterocylyl-C!^alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl,
tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, and wherein the heterocycyl moieties and C3_ 6cycloalkyl each may be unsubstituted or substituted one or more times with Rf.
In certain embodiments of formula I, Ra is: Ci_6alkoxy; heterocylyl-Ci_6alkyl; or heterocylyl-Ci_6alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, and wherein the heterocycyl moieties each may be unsubstituted or substituted one or more times with Rf.
In certain embodiments of formula I, Ra is: Ci_6alkoxy; heterocylyl-Ci_6alkyl; or heterocylyl-Ci_6alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and azetidinyl.
In certain embodiments of formula I, Ra is Ci_6alkoxy.
In certain embodiments of formula I, Ra isC^alkoxy-C ealkyl.
In certain embodiments of formula I, Ra is
In certain embodiments of formula I, Ra is C3.6cycloalkyl which may be unsubstituted or substituted one or more times with Rf.
In certain embodiments of formula I, Ra is C^cycloalkyl-CVealkyl wherein the C3_ 6cycloalkyl moiety may be unsubstituted or substituted one or more times with Rf.
In certain embodiments of formula I, Ra is C3.6cycloalkyloxy; C ecycloalkyl-C ealkoxy; heterocyclyl; heterocylyl-Ci_6alkyl; or heterocylyl-Ci_6alkoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, and wherein the heterocycyl moieties and C3.6cycloalkyl each may be unsubstituted or substituted one or more times with Rf.
In certain embodiments of formula I, Ra is C^cycloalkyl-CVealkoxy wherein the C3_ 6cycloalkyl moiety may be unsubstituted or substituted one or more times with Rf. In certain embodiments of formula I, Ra is heterocyclyl selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, each of which may be unsubstituted or substituted one or more times with Rf.
In certain embodiments of formula I, Ra is heterocylyl-C^alkyl wherein the heterocyclyl moiety is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, each of which may be unsubstituted or substituted one or more times with Rf.
In certain embodiments of formula I, Ra is heterocylyl-Ci_6alkoxy wherein the heterocyclyl moiety is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, each of which may be unsubstituted or substituted one or more times with Rf.
In certain embodiments of formula I, Rb is hydrogen.
In certain embodiments of formula I, Rb is Ci_6alkyl.
In certain embodiments of formula I, Rc is hydrogen.
In certain embodiments of formula I, Rc is Ci_6alkyl.
In certain embodiments of formula I, Rb and Rc together with the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be optionally substituted one or more times with R1.
In certain embodiments of formula I, one of Rb and Rc together with one of R7 and R8 and the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be optionally substituted one or more times with R1.
In certain embodiments of formula I, one of Rb and Rc together with one of R5 and R6 and the atoms to which they are attached form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be optionally substituted one or more times with R1.
In certain embodiments of formula I, Rd is hydrogen.
In certain embodiments of formula I, Rd is d_6alkyl.
In certain embodiments of formula I, each Re is independently: hydrogen; Ci_6alkyl; halo; or cyano; wherein the Ci_6alkyl moieties may be unsubstituted or substituted one or more times with halo;
In certain embodiments of formula I, each Re is independently: hydrogen; Ci_6alkyl; halo; or halo-Ci_6alkyl.
In certain embodiments of formula I, each Re is independently: hydrogen; Ci_6alkyl; or halo.
In certain embodiments of formula I, each Re is independently: hydrogen; or halo. In certain embodiments of formula I each Re is independently: hydrogen; or fluoro. In certain embodiments of formula I Re is hydrogen.
In certain embodiments of formula I Re is d_6alkyl.
In certain embodiments of formula I Re is halo.
In certain embodiments of formula I Re is C!.6alkoxy.
In certain embodiments of formula I Re is cyano.
In certain embodiments of formula I Re is halo-Ci-6alkyl.
In certain embodiments of formula I Rf is: Ci_6alkyl; halo; oxo; hydroxy; acetyl; or Ci_
6alkoxy.
In certain embodiments of formula I, Rf is Chalky..
In certain embodiments of formula I, Rf is halo.
In certain embodiments of formula I, R is Ci_6alkoxy.
In certain embodiments of formula I, Rf is halo-Ci-6alkyl.
In certain embodiments of formula I, Rf is oxo.
In certain embodiments of formula I, Rf is hydroxy.
In certain embodiments of formula I, Rf is acetyl.
In certain embodiments of formula I, Rs is Ci_6alkyl;
In certain embodiments of formula I, Rs is oxo;
In certain embodiments of formula I, Rs is halo;
In certain embodiments of formula I, Rs is halo-Ci_6alkyl;
In certain embodiments of formula I, Rs is hydroxy-Ci_6alkyl;
In certain embodiments of formula I, Rg is Ci_6alkoxy-Ci_6alkyl; or
In certain embodiments of formula I, Rg is cyano-C^alkyl.
In c of formula II:
wherein s is from 0 to 3, and m, n, p, q, Het, A, W, R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined herein.
In certain embodiments of formula II, Re is halo.
In certain embodiments of formula II, Re is fluoro. In certain embodiments of formula II, s is 0 or 1.
In certain embodiments of formula II, s is 0.
In certain embodiments of formula II, s is 1.
In certain embodiments of formula II, s is 1 or 2.
In certain embodiments of formula II, s is 2.
In certain embodiments of formula II, s is 1, 2 or 3.
In certain embodiments of formula II, s is 2 or 3.
In certain embodiments of formula II, s is 3.
In certain embodiments of formula I, the subject compounds may be of formula II In c e of formula III:
wherein p, q, s, Het, A, R3, R9, R10 and and Re are as defined herein.
In c e of formula IV:
wherein p, q, s, Het, A, R3, R9, R10 and Re are as defined herein.
In c be of formula V:
wherein q, Het, A, R3, R10 and Re are as defined herein.
In certain embodiments the invention also provides a compound selected from [5-[[2,5-difluoro-4-[[(3S,6R)-3-me 1 ,l-dioxo-6-phenyl-tMazinan-2-yl]methyl]phenyl]m
oxadiazol-2-yl]methanol;
5-[[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]methyl]-3H- l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3H- l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3H- l,3,4-oxadiazol-2-one;
5-[(lR) -[2,5-difluoro-4-[[(3S,6R)-3-methyl J-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-2- (oxetan-3-yl)ethyl]-3H-l,3,4-oxadiazol-2-one;
5-[(R)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-(oxetan-3- yloxy)methyl]-3H-l,3,4-oxadiazol-2-one;
5-[(S)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-(oxetan-3- yloxy)methyl]-3H-l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4-[[(3S,6S)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-l-methyl- ethyl]-3H-l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-l-methyl- ethyl]-3H-l,3,4-oxadiazol-2-one;
5-[(R) 2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]- tetrahydropyran-4-yloxy-methyl]-3H-l,3,4-oxadiazol-2-one;
3-[[2,5-difluoro-4-[[(3S,6S)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]methyl]-l,4- dihydro- 1 ,2,4-triazol-5-one;
3-[[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]methyl]-l,4- dihydro- 1 ,2,4-triazol-5-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl] ,2- dihydropyrazol-3 -one ;
3-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-2H- isoxazol-5-one;
3-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]4,4- dihydro4,2,4-triazol-5-one;
3-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-4- methyl4H4,2,4-triazol-5-one;
5-[(lS)4-[2,5-difluoro-4-[[(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]propyl]- 3H4,3,4-oxadiazol-2-one; 5-[(lR)-l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]propyl]- 3H-l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-2- methyl-4H- 1 ,2,4-triazol-3 -one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-2- methyl-4H- 1 ,2,4-triazol-3 -one;
3-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-2- methyl- lH-l,2,4-triazol-5-one;
5-[(R)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]- isopropoxy-methyl]-3H-l,3,4-oxadiazol-2-one;
5-[(S)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-isopropoxy- methyl]-3H-l,3,4-oxadiazol-2-one;
5-[(R)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-methoxy- methyl]-3H-l,3,4-oxadiazol-2-one;
5-[(S)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-methoxy- methyl]-3H-l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]isoxazol-3-one;
3-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-lH- imidazol-2-one;
1- [l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]imidazolidine-2,4-dione;
5-[(lS)-l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-3- methoxy-propyl]-3H-l,3,4-oxadiazol-2-one;
5-[(lR)-l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-3- methoxy-propyl]-3H-l,3,4-oxadiazol-2-one;
2- [5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-2- oxo- 1 , 3 ,4-oxadiazol-3 -yl ] acetonitrile ;
5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-3-(2- hydroxyethyl)-l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-3H- oxazol-2-one;
5-[(lS)-l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-3- hydroxy-propyl]-3H-l,3,4-oxadiazol-2-one; 5-[(lR) -[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-3- hydroxy-propyl]-3H-l,3,4-oxadiazol-2-one;
5-[(R)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-ethoxy- methyl]-3H-l,3,4-oxadiazol-2-one;
5-[(S)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-ethoxy- methyl]-3H-l,3,4-oxadiazol-2-one;
2-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-4H- l,2,4-triazol-3-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3- (2,2,2-trifluoroethyl)-l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3-eto^^ l,3,4-oxadiazol-2-one;
2 5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl 4-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-2- oxo- 1 , 3 ,4-oxadiazol-3 -yl ] acetamide ;
5 1-[2,5-difluoro-4 [(3S,6R)-3-methyl4J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3 2 methoxyethyl)4 ,3 ,4-oxadiazol-2-one;
1- [l-[2,5-difluoro-4-[[(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]imidazolidin-2-one;
2- [l-[2,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]4H- pyrazol-3-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3- methyl4,3,4-oxadiazol-2-one;
2-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]isoxazol-5-one;
(3S,6R)-2-[[2,5-difluoro-4-[l-(3-methoxyisoxazol-5-yl)ethyl]phenyl]methyl]-3-methyl-6-phenyl- thiazinane 1 -dioxide;
54142,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-2- methyl-isoxazol-3-one;
4-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl4 -dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethylidene]- l,3-dioxolan-2-one;
24142,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]4H- pyrazol-5-one;
54142,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-3- methyl-oxazol-2-one; 5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]oxazolidin-2-one;
5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]oxazolidin-2-one;
N-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-lH- pyrazole-4-carboxaniide;
1- [l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-5,5 dimethyl-imidazol-4-one;formic acid;
2- [l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl] H l,2,4-triazol-5-one;
(3S,6R)-2-[[2,5-difluoro-4-[1^3-methoxy4,2,4 riazol4-yl)ethyl]phenyl]methyl]-3-methyl-6-phenyl- thiazinane 1 -dioxide;
44142,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3H- oxazol-2-one;
44142,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3H- oxazol-2-one;
14142,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-2- methyl4,2,4-triazol-3-one;
(3S)44142,5-difluoro-44[(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl] hydroxy-pyrrolidin-2-one;
and pharmaceutically acceptable salts thereof.
Methods
The invention also provides a method for treating a disease or condition mediated by or otherwise associated with the RORc receptor, the method comprising administering to a subject in need thereof an effective amount of a compound of the invention.
The disease may be arthritis such as rheumatoid arthritis or osteoarthritis.
The disease may be asthma or COPD.
The disease may be psoriasis.
The disease may be muscular distrophy.
Representative compounds in accordance with the methods of the invention are shown in the experimental examples below.
Synthesis Compounds of the present invention can be made by a variety of methods depicted in the illustrative synthetic reaction schemes shown and described below.
The starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagentsor Organic Synthesis; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989, Volumes 1-5 and Supplemental; and Organic Reactions , Wiley & Sons: New York, 1991, Volumes 1-40. The following synthetic reaction schemes are merely illustrative of some methods by which the compounds of the present invention can be synthesized, and various modifications to these synthetic reaction schemes can be made and will be suggested to one skilled in the art having referred to the disclosure contained in this Application.
The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.
Unless specified to the contrary, the reactions described herein may be conducted under an inert atmosphere at atmospheric pressure at a reaction temperature range of from about -78 °C to about 150 °C, for example, from about 0 °C to about 125 °C, or conveniently at about room (or ambient) temperature, e.g., about 20 °C.
Scheme A below illustrates one synthetic procedure usable to prepare specific compounds of formula I, wherein LG is a leaving group such as halo, sulfonate, or the like, and m, n, p, q, X1, X2, X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, Rb and Rc are as defined herein.
SCHEME A
In step 1 of Scheme A, alkyl amine a is reacted with benzyl sulfonyl chloride b to form sulfonamide compound c. The reaction of step 1 may be carried out in a polar aprotic solvent such as THF or methylene chloride, and in the presence of a tertiary amine base or weak base such as potassium carbonate. The leaving group of compound a may be bromo in certain embodiments. Similarly, the chloro group of compound b may in certain embodiments be replaced by other halo or leaving group.
A cyclization reaction is carried out in step 2 to afford thiazinane compound d. The cyclization may be achieved in the presence of a strong base such as an alkyl lithium reagent, using polar aprotic solvent under anhydrous conditions.
In step 3, thiazinane compound c is reacted with aryalkyl halide compound e to yield aralkyl thiazinane f. The reaction of step 3 may be carried out in the presence of a strong base such as sodium hydride under anhydrous polar aprotic solvent conditions. The bromo groups of compound e may be replaced by other suitable leaving groups used in the art.
Thiazinane compound f may then be reacted with oxoethyl zinc halide reagent g in step 4 to provide ester compound h. This reaction may be carried out in the presence of suitable palladium catalyst under polar aprotic conditions in a solvent such as dry tetrahydrofuran.
In step 5, ester compound h is reacted with hydrazine to yield the corresponding hydrazide compound i.
In step 6, hydrazide compound is reacted with acyl halide reagent j to afford an acyl hydrazide compound k.
In step 7 a cyclization is carried out to form an oxadiazole group, resulting in the compound 1, whihch is a compound of formula I in accordance with the invention.
Many variations in the above procedure are possible and will suggest themselves to those skilled in the art. For example, reagent g may be replaced by the corresponding thionoester to provide a thiadiazole group in the final compound. The group Ra may be replaced by an alkyl group, or may omitted from reagent g and introduced (if desired) in a later step. Similarly, the group R10 may omitted from acyl reagent j and, if desired, introduced in a later step.
Scheme B below shows another synthetic procedure usable to prepare specific
1 2 3 4 1 2 3 compounds of formula I, wherein TBS is tri-(tert-butyl)-silyl, and m, n, p, q, X , X , X , X , Y, R , R , R\ R4, R5, R6, R9 and R10 are as defined herein.
SCHEME B
In step 1 of Scheme B, tri-(tert-butyl)-slilyloxy amine m is reacted with benzyl sulfonyl chloride b, as described above with reference to Scheme A, to form sulfonamide compound n. In certain embodiments the tri-(tert-butyl)-slilyloxy group may be replaced with other leaving groups. In step 2, sulfonamide compound n is reacted with iodochloromethane to provide an alkenylsulfonamide compound o. This reaction may be achieved in the presence of a strong base such as an alkyl lithium reagent, using polar aprotic solvent such as THF under anhydrous conditions. In certain embodiments iodochloromethane may be replaced with other methylene reagents.
In step 3, a cyclization reaction is affected to provide oxathiazepane compound p. The cyclization may be carried out in the presence of an amine base under polar aprotic solvent conditions.
In step 4, oxathiazepane compound p is reacted with aryalkyl halide compound e to yield aralkyl oxathiazepane compound q, in the manner described above with reference to Scheme A.
Steps 5-8 may then be carried out in the manner described above for steps 4-7 of Scheme A. Briefly, oxathiazepane compound q is reacted with zinc halide reagent g in step 5 to provide ester compound r, which is then reacted with hydrazine in step 6 to give the corresponding hydrazide compound s. Hydrazide compound s may then b acylated in step 7 to make compound t, followed by ring closure in step 8, to afford sultam compound u, which is a compound of formula I in accordance with the invention.
Many variations on the procedure Scheme B are possible and will suggest themselves to those skilled in the art. Specific details for producing compounds of the invention are described in the Examples below.
Administration and Pharmaceutical Composition
The invention includes pharmaceutical compositions comprising at least one compound of the present invention, or an individual isomer, racemic or non-racemic mixture of isomers or a
pharmaceutically acceptable salt or solvate thereof, together with at least one pharmaceutically acceptable carrier, and optionally other therapeutic and/or prophylactic ingredients.
In general, the compounds of the invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Suitable dosage ranges are typically 1-500 mg daily, for example 1-100 mg daily, and most preferably 1-30 mg daily, depending upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner involved. One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this Application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease.
Compounds of the invention may be administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. A particular manner of administration is generally oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
A compound or compounds of the invention, together with one or more conventional adjuvants, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use.
Formulations containing about one (1) milligram of active ingredient or, more broadly, about 0.01 to about one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
The compounds of the invention may be formulated in a wide variety of oral administration dosage forms. The pharmaceutical compositions and dosage forms may comprise a compound or compounds of the present invention or pharmaceutically acceptable salts thereof as the active component. The pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The powders and tablets may contain from about one (1) to about seventy (70) percent of the active compound. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges may be as solid forms suitable for oral administration.
Other forms suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents. Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The compounds of the invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
The compounds of the invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
The compounds of the invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify. The compounds of the invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
The subject compounds may be formulated for nasal administration. The solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray. The formulations may be provided in a single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
The compounds of the invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration. The compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. The active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example,
dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by a metered valve. Alternatively the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP). The powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of e.g., gelatine or blister packs from which the powder may be administered by means of an inhaler.
When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient. For example, the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial. Compounds in transdermal delivery systems are frequently attached to an skin-adhesive solid support. The compound of interest can also be combined with a penetration enhancer, e.g., Azone (l-dodecylazacycloheptan-2-one). Sustained release delivery systems are inserted subcutaneously into the subdermal layer by surgery or injection. The subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylactic acid.
The pharmaceutical preparations may be in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
Other suitable pharmaceutical carriers and their formulations are described in Remington: The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pennsylvania. Representative pharmaceutical formulations containing a compound of the present invention are described below.
Utility
The compounds of the invention are useful for treatment of immune disorders generally. The compounds may be used for treatment of arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, septic arthritis, spondyloarthropathies, gouty arthritis, systemic lupus erythematosus and juvenile arthritis, osteoarthritis, and other arthritic conditions.
The compounds may be used for treatment of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, and the like.
The compounds may be used for treatment of gastrointestinal disorder ("GI disorder") such as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic and other biliary disorders, renal colic, diarrhea-dominant IBS, pain associated with GI distension, and the like.
The compounds may be used for treatment of psoriasis, muscular sclerosis, Sjogren' s disease, lupus, and pulmonary fibrosis.
GENERAL EXPERIMENTAL LCMS methods:
High Pressure Liquid Chromatography - Mass Spectrometry (LCMS) experiments to determine retention times (RT) and associated mass ions were performed using one of the following methods:
Method A: Compounds were analysed using the following conditions: Experiments were performed on a Waters ZMD single quadrupole mass spectrometer linked to a Hewlett Packard HP 1100 LC system with UV diode array detector and 100 position autosampler. The spectrometer has an electrospray source operating in positive and negative ion mode. This system uses a Phenomenex Luna 3 μιη CI 8(2) 30 x 4.6 mm column at ambient temperature and a 2.0 mL / minute flow rate. The initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5% acetonitrile containing 0.1% formic acid (solvent B) for the first 0.5 minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 4 minutes. This was maintained for 1 minute before returning to 95% solvent A and 5% solvent B over the next 0.5 minute. Total run time was 6 minutes.
Method B: Compounds were analysed using the following conditions: Experiments were performed on a Waters Micromass ZQ2000 quadrupole mass spectrometer linked to a Waters Acquity UPLC system with a PDA UV detector. The spectrometer has an electrospray source operating in positive and negative ion mode. This system uses an Acquity BEH C18 1.7 μιη 100 x 2.1 mm column, maintained at 40 °C or an Acquity BEH Shield RP18 1.7 μιη 100 x 2.1 mm column, maintained at 40 °C and a 0.4 mL / minute flow rate. The initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5% acetonitrile containing 0.1% formic acid (solvent B) for the first 0.4 minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 5.6 minutes. This was maintained for 0.8 minute before returning to 95% solvent A and 5% solvent B over the next 1.2 minutes. Total run time was 8 minutes.
NMR methods:
¾ NMR spectra were recorded at ambient temperature or at 80 °C where indicated using one of the following machines: Varian Unity Inova (400 MHz) spectrometer with a triple resonance 5mm probe, Bruker Avance DRX 400 (400 MHz) spectrometer with a triple resonance 5mm probe, a Bruker Avance DPX 300 (300 MHz) equipped with a standard 5mm dual frequency probe for detection of 1H and 13C, Bruker Fourier 300MHz system equipped with a standard 5mm 1H / 13C probe, a Bruker AVIII (400 MHz) using a BBI Broad Band Inverse 5mm probe, or a Bruker AVIII (500 MHz) using a QNP (Quad Nucleus detect) 5mm probe. Chemical shifts are expressed in ppm relative to an internal standard, tetramethylsilane (ppm = 0.00). The following abbreviations have been used: br = broad signal, s = singlet, d = doublet, dd = double doublet, t = triplet, td = triplet doublet, dddd = doublet doublet doublet doublet, q = quartet, m = multiplet, or any combination of.
Microwave reactor:
Microwave reactions were carried out using a Biotage® Initiator® in vials appropriate to the scale of the reaction and at the temperature and time described in the experimental details.
Purification Equipment:
Purifications were carried out using pre-packed silica gel cartridges either on a Teledyne ISCO
CombiFlash® or Biotage® Isolera Four® or using compressed air to apply external pressure. Solvents and gradients shown in the experimental details were used.
Reverse Phase High Pressure Liquid Chromatography (HPLC) was used to purify compounds where indicated. Separation using gradient elution on a Phenomenex Gemini C18 column (250 x 21.2 mm, 5 micron) as stationary phase and using mobile phase indicated, operating at a 18 mL/min flow rate using a Gilson UV/Vis -155 dual channel detector and Gilson GX-271 automated liquid handler.
Phase separator cartridges are supplied by Biotage® as Isolute® phase separator cartridges.
LIST OF ABBREVIATIONS
AcOH Acetic acid
AIBN 2,2'-Azobis(2-methylpropionitrile) Atm. Atmosphere
BOC ferf-Butyloxycarbonyl group
(BOC)20 Di-ferf-butyl dicarbonate
Cr03 Chromium (VI) oxide
CDC13 Deuterated chloroform
DavePhos 2-Dicyclohexylphosphino-2'-(A^N-dimethylamino)biphenyl
DCM Dichloromethane / methylene chloride
DMA N, Af-Dimethylacetamide
DIAD Diisopropyl azodicarboxylate
DIPEA DIPEA
DMAP 4-Dimethylaminopyridine
DME 1 ,2-Dimethoxyethane
DMF AfN-Dimethylformamide
DMSO Dimethyl sulfoxide
DPPF 1 , l'-Bis(diphenylphosphino)ferrocene
ES Electrospray
Et20 Diethyl ether
Et3N Triethylamine
EtOH Ethanol/Ethyl alcohol
EtOAc Ethyl acetate
H20 Water
H2S04 Sulfuric acid
HATU 2-(l//-7-Azabenzotriazol-l-yl)— 1,1,3, 3-tetramethyl uronium hexafluorophosphate methanaminium
HBTU 0-Benzotriazol-l-yl-A, W,W-tetramethyluronium hexafluorophosphate
HC02H Formic acid
HC1 Hydrochloric acid
HOBT 1 -Hydroxybenzotriazole
HPLC High pressure liquid chromatography
RP HPLC Reverse phase high pressure liquid chromatography
IBX 2-Iodoxybenzoic acid
IMS Industrial methylated spirit
KOH Potassium hydroxide
2C03 Potassium carbonate
LDA Lithium diisopropylamide
f-PrOH Isopropanol / isopropyl alcohol / propan-2-ol
LCMS Liquid Chromatograph / Mass Spectroscopy
LiOH Lithium hydroxide
MgS04 Magnesium sulphate
MeOH Methanol / Methyl alcohol
MW Microwaves
NaH Sodium hydride
NaCl Sodium chloride
NaOH Sodium hydroxide
Na2S04 Sodium sulfate
Na2C03 Sodium carbonate
NaHC03 Sodium bicarbonate / Sodium hydrogen carbonate
NBS Af-Bromosuccinimide
NH4CI Ammonium chloride
NMP 1 -Methyl -2 -pyrrolidinone
POCI3 Phosphorus oxychloride PhCH3 Toluene
Pd2(dba)3 Tris(dibenzylideneacetone)dipalladium (0)
PSI Pound per square inch
RT Room temperature
sat. Saturated
SCX-2 Pre-packed Isolute® silica-based sorbent with a chemically
bonded propylsulfonic acid functional group
SFC Supercritical fluid chromatography
TBDMS ferf-Butyldimethylsilyl
TFA Trifluoroacetic acid
THF Tetrahydrofuran
TIPS Triisopropylsilyl
TLC Thin layer chromatography
TMSC1 Chlorotrimethylsilane
XantPhos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene
Prepar -3-Aminobutan-l-ol and (3S)-3-Aminobutan-l-ol
Step 1 3-[[(Benzyloxy)carbonyllaminolbutanoic acid
Into a 2000-mL 4-necked round-bottom flask was placed a solution of 3-aminobutanoic acid (100 g, 969.75 mmol, 1.00 equiv) in water (1000 mL), followed by the addition of potassium hydroxide (136 g, 2.42 mol, 2.50 equiv) in several batches. To this was added benzyl chloroformate (247 g, 1.45 mol, 1.50 equiv) dropwise with stirring at 0-5°C. The resulting solution was stirred at 25°C for 5 h. The reaction progress was monitored by LCMS. The resulting solution was extracted with 3x250 mL of dichloromethane and the aqueous layers were combined. The pH value of the water phase was adjusted to 3 with hydrogen chloride (2 mol/L). The precipitates were collected by filtration and dried to afford 102 g (44%) of 3-[[(benzyloxy)carbonyl]amino]butanoic acid as a white solid.
Step 2: Benzyl jV-i(2,S')-4-hydroxybutan-2-yllcarbamate and Benzyl jV-i(2R)-4-hydroxybutan-2- yllcarbamate Into a 2000-mL 3 -necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of 3-[[(benzyloxy)carbonyl]amino]butanoic acid (102 g, 429.92 mmol, 1.00 equiv) in THF (300 mL), followed by the addition of BH3/THF ( IN) (645 mL, 1.50 equiv) dropwise with stirring at 0-5°C. The resulting solution was stirred at 40°C for 2 h, quenched by the addition of 200 mL of methanol and concentrated under vacuum. The residue was purified on a silica gel column eluting with ethyl acetate: petroleum ether (1 :2). The crude product (70 g) was purified by Prep- SFC with the following conditions (prep SFC): Column, Phenomenex Lux 5u Cellulose-4, 2.12*25,5um; mobile phase, C02 (85%), ethanol (15%); Detector, UV 254nm. This resulted in 30 g (31.5%) of benzyl N-[(2R)-4-hydroxybutan-2-yl]carbamate as an off-white solid and 30 g (31.5%) of benzyl N-[(2S)-4- hydroxybutan-2-yl]carbamate as an off-white solid.
Step 3: (3R)-3-Aminobutan-l-ol and (3y)-3-Aminobutan-l-ol
Into a 1000-mL round-bottom flask was placed a solution of benzyl N-[(2S)-4- hydroxybutan-2-yl]carbamate (30 g, 134.4 mmol, 1.00 equiv) in methanol (500 mL) and palladium carbon (3 g, 0.10 equiv). The resulting solution was stirred at 25°C for 12 h under an atmosphere of hydrogen. The solids were filtered out and the filtrate was concentrated under vacuum to afford 11.7 g (92%) of (35)-3-aminobutan-l-ol as an oil. *H NMR (300MHz, DMSO, ppm): δ 4.48 (3H, s), 3.47 (2H, s), 2.96 (1H, s), 1.47-1.41 (2H, q), 1.02-0.99 (3H, d); LCMS (ESI), m/z, 90 [M+H] +; measured [a]D 20 2 +11.65° (C=1.22g/100mL in EtOH), lit. [a]D 20 +16.3° (c=4.5 in EtOH) (J. Org. Chem. 1996, 61 , 2293- 2304.).
Using the above procedure, 12.0 g 12 g (94%) of (3R)-3-aminobutan-l-ol was isolated as an oil. lU NMR (300MHz, DMSO, ppm): δ 4.48 (3H, s), 3.47 (2H, s), 2.96 (1H, s), 1.47-1.41 (2H, q), 1.02-0.99 (3H, d); LCMS (ESI), m/z, 90 [M+H] +; measured [a]D 20 2 -11.1° (C = 0.32g/100mL in EtOH), lit. [a]D 25 -25° (c= 1.25 in EtOH) (Tetrahedron: Asymmetry 1999, 10, 2213-2224).
Prep -N-(4-Chlorobutan-2-yl)- 1 -phenylmethanesulfonamide
Step 1 : (R)-3-(Phenylmethylsulfonamido)butyl phenylmethanesulfonate
To a solution of (3R)-3-aminobutan-l-ol (1.0 g, 11.2 mmol) and triethylamine (3.3 mL, 23.6 mmol) in tetrahydrofuran (37 mL) at 0 °C was slowly added phenylmethanesulfonyl chloride (4.49 g, 23.6 mmol) and the reaction was stirred at room temperature for 16 hours. MTBE (100 mL) was then added and the Et3N- HC1 salt was removed by filtration. The filtrate was then concentrated to give crude (R)-3-(phenylmethylsulfonamido)butyl phenylmethanesulfonate which was used without purification. LCMS (ESI), m/z, 398 [M+H] +.
Step 2: (R)-A/-(4-Chlorobutan-2-yl)-l -phenylmethanesulfonamide
To the crude (R)-3-(phenylmethylsulfonamido)butyl phenylmethanesulfonate (23.6 mmol) was added sodium chloride (984 mg, 16.8 mmol) and dimethylformamide (37 mL) and the reaction was stirred at 80 °C for 16 hours. The reaction was then diluted with EtOAc, washed with water (x2) and brine, dried with MgS04, concentrated and purified by silica gel column chromatography (0- 50% Acetone in Heptane, 216 nM) to give (R)-A/-(4-chlorobutan-2-yl)-l -phenylmethanesulfonamide (1.71 g, 6.53 mmol, 58% yield over 2 steps). LCMS (ESI), m/z, 261 [M+H] +.
Additional compounds made using the above procedure are shown in Table 1.
Table 1
Preparation 7: N-(2-bromoethyl)(phenyl)methanesulfonamide
K2C03 (8.7 g, 62 mmol) was added into a mixture of phenylmethanesulfonyl chloride (6 g, 31 mmol) and 2-bromoethanamine hydrobromide (6.4 g, 31 mmol) in DCM (100 mL) at 0°C. And the resulting mixture was stirred at r.t. for 4 hours and left standing overnight. Upon the completion of reaction, water (100 mL) was added in and DCM phase was separated. The aqueous phase was extracted with DCM. The combined organic phase was dried over Na2S04, filetered and concentrated in vacuo to provide a crude which was separated with column chromatography (silica gel with 200 - 300 mesh, 0 to 50% of EtOAc in petroleum ether) to provide compound /V-(2-bromoethyl)(phenyl)methanesulfonamide (7.0 g, 80%) as a pale yellow solid. H NMR (300 MHz, CDC13) δ 7.40 (m, 5H), 4.58 (m, IH), 4.29 (s, 2H), 3.34-3.29 (m, 4H). LCMS (ESI), 300, 302 [M+Na]+, Br pattern found.
Preparation 8 Af-(2-bromoethyl)(4-fluorophenyl)methanesulfonamide
A^-(2-bromoethyl)(4-fluorophenyl)methanesulfonamide was also made using the above procedure, replacing phenylmethanesulfonyl chloride with 4-fluoro-phenylmethanesulfonyl chloride. ¾ NMR (300 MHz, CDC13) δ 7.43-7.38 (m, 2H), 7.13-7.07 (m, 2H), 4.62 (br s, IH), 4.26 (s, 2H), 3.41-3.32 (m, 4H).
A solution of phenylmethanesulfonyl chloride (2.19 g, 10 mmol) was added into a suspension of 3-bromopropan-l-amine hydrobromide (2.19 g, 10 mmol) and Et3N (2.02 g, 20 mmol) in THF (50 mL) at 0 °C. The mixture was stirred at 0 °C for 5 min. TLC confirmed the completion of reaction. Solid was filtered out with suction, and the filtrate was concentrated to provide compound N-(3- bromopropyl)(phenyl)methanesulfonamide (2.7 g, quant.) as a pale yellow solid which was used in the next step without further purification. ¾ NMR (300 MHz, CDC13) δ 7.40 (m, 5H), 4.48 (m, IH), 4.27 (s, 2H), 3.41 (t, J = 6.6 Hz, 2H), 3.16 (q, 2H), 2.01 (m, 2H). LCMS (ESI), m/z, 314 and 316 [M+Na]+, Br pattern found.
A^-(3-bromopropyl)(4-fluorophenyl)methanesulfonamide was prepared using the above procedure. H NMR (300 MHz, CDC13) δ 7.42-7.37 (m, 2H), 7.13-7.07 (m, 2H), 4.26 (m, IH), 4.24 (s, 2H), 3.46-3.42 (m, 2H), 3.20-3.16 (m, 2H), 2.05-2.00 (m, 2H).
Preparation 11 : 6-Pheny -l,2-thiazinane 1,1-dioxide To a solution of A/-(3-bromopropyl)-l-phenylmethanesulfonamide (2.3 g, 7.9 mmol), diisopropylamine (0.28 mL, 2.0 mmol) and 1,10-phenanthroline (3.6 mg, 0.02 mmol) in tetrahydrofuran (26 mL) at -78 °C was added n-BuLi (6.8 mL, 2.5 M in hexanes) dropwise and the reaction was stirred for 16 hours. Saturated NLLCl was then added and the reaction was diluted with EtOAc, washed with water and brine, dried with MgS04, concentrated and purified by silica gel column chromatography (0- 50% EtOAc/heptane) to 6-Phenyl-l,2-thiazinane 1,1-dioxide (1.3 g, 80% yield). lU NMR (300 MHz, DMSO-de) δ 7.40-7.35 (m, 5H), 6.98 (m, IH), 4.12 (dd, IH), 3.26-3.20 (m, 2H), 2.40-2.30 (m, IH), 2.16- 2.12 (m, IH), 1.77-1.65 (m, 2H). LCMS (ESI), m/z, 234 [M+Na]+. (Reference: D. Askin, et al. Org. Lett. 2003, 4175.)
Additional compounds made using the above procedure are shown in Table 2.
Table 2
Preparation 19: 3-Phenyl-l ,4,5-oxathiazepane 4,4-dioxide
Step 1 : A/-(2-((Tert-butyldimethylsilyl)oxy)ethyl)- 1 -phenylmethanesulfonamide
To a solution of 2-((tert-butyldimethylsilyl)oxy)ethanamine (11.7 g, 66.6 mmol) and triethylamine (11.2 mL, 79.9 mmol) in tetrahydrofuran (222 mL) at 0 °C was slowly added
phenylmethanesulfonyl chloride (12.7 g, 66.6 mmol) portion wise and the reaction was stirred at room temperature for 16 hours. MTBE was then added and the Et3N HCl salt was removed by filtration. The filtrate was then concentrated and purified by silica gel solumn chromatography (0-30% Acetone in heptane, 216 nM) to A^-(2-((tert-butyldimethylsilyl)oxy)ethyl)-l-phenylmethanesulfonamide (17.8 g, 81 % yield). LCMS (ESI), m/z, 330. [M+H] +.
Step 2: jV-(2-((Tert-butyldimethylsilyl)oxy)ethyl)- 1 -phenylethenesulfonamid
To a solution of A^-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-l-phenyl-methanesulfonamide (33 g, 100.2 mmol) in tetrahydrofuran (334 mL) at -78 °C was slowly added n-BuLi (2.5 M in hexanes) (100 mL, 250 mmol) via cannula and the reaction was stirred at -78 °C was 2 hours. Chloroiodomethane (8.3 mL, 110 mmol) was then slowly added and the reaction was stirred at -78 °C for one hour, then allowed to warm to room temperature and aged for 16 hours. The reaction was then quenched with saturated NH4C1 and extracted with dichloromethane, dried with MgS04, concentrated and purified by silica gel column chromatography (0-60% EtOAc in heptane) to give N-[2-[tert- butyl(dimethyl)silyl]oxyethyl]-l-phenyl-ethenesulfonamide (24 g, 70 % yield). LCMS (ESI), m/z, 342. [M+H] +.
Step 3: 3-Phenyl-l,4,5-oxathiazepane 4,4-dioxide
To a solution of /V-(2-((Tert-butyldimethylsilyl)oxy)ethyl)-l-phenylethenesulfonamide (717 mg, 2.1 mmol) in tetrahydrofuran (7 mL) at 0 °C was added tetrabutylammonium fluoride (1.0 M in THF) (2.2 mL, 2.2 mmol) dropwise and the reaction was stirred at room temperature for 16 hours. Saturated NH4C1 was then added and the product was extracted with dichloromethane (x2), dried with MgS04, concentrated and purified by silica gel column chromatography (0-100% EtOAc in heptane) to give 3-phenyl-l,4,5-oxathiazepane 4,4-dioxide (401 mg, 84 % yield). (24 g, 70 % yield). LCMS (ESI), m/z, 228. [M+H] +. (Reference: P. Hansen, et al. Org. Lett. 2008, 2951).
Additional compounds made using the above procedure are shown in Table 3.
Table 3
Preparation 24 2-(4-Bromo-2-fluorobenzyl)-6-phenyl-l,2-thiazinane 1,1 -dioxide
To a solution of 6-phenyl-l,2-thiazinane 1,1-dioxide (300 mg, 1.42 mmol) and 4-bromo- l-(bromomethyl)-2-fluorobenzene (456 mg, 1.7 mmol) in A,A -dimethylacetamide (5 mL) at 0 °C was added sodium hydride (60% in mineral oil) (68 mg, 1.85 mmol) and the reaction was stirred at room temperature for 2 hours. Water was added and the reaction was diluted with EtOAc, washed with brine, dried with MgS04, filtered and purified by silica gel column chromatography (0-60% EtOAc heptane) to give 2-(4-bromo-2-fluorobenzyl)-6-phenyl-l,2-thiazinane 1,1-dioxide as a mixture of diastereomers (396 mg, 70% yield). LCMS (ESI), m/z, 398 [M+H] +. Similarly prepared was (3S)-2-(4-bromo-2-fluorobenzyl)-3-methyl-6-ph(
thiazinane 1, 1-dioxide.
Examples 1 and 2 : [l-[2,5-Difluoro-4-[[(3^,6R)-3-methyl-l , l-dioxo-6-phenyl-thiazinan-2-
Step 1 : (3^,6R -2-(4-Bromo-2,5-difluorobenzyl -3-methyl-6-phenyl-l,2-thiazinane 1,1-dioxide
A 3 L flask was mounted with a mechanical stirrer and was charged with (35,6R)-3-methyl-6- phenyl-thiazinane 1,1-dioxide (100 g, 444 mmol), l-bromo-4-(chloromethyl)-2,5-difluorobenzene (122 g, 488 mmol) in A N-dimethylformamide (800 mL) under a nitrogen atmosphere and the solution was cooled to 0 °C. Under mechanical stirring, sodium hydride (60% in mineral oil, 18.6 g, 466 mmol) was added in small portions and the reaction was stirred at 0 °C for 30 minutes before being allowed to warm to RT. The reaction was further stirred at that temperature for an additional 2 hours. Water (1.5 L) was then added and the precipitate was collected by filtration and dried under vacuum for 16 hours to give crude material. The precipitate was suspended into 2.5 L of heptane:ethyl acetate:methanol (1 : 1 :0.5) and the suspension was heated at reflux. Acetone (100 mL) was then added to complete the dissolution of the material, and the solution was slowly cooled down to room temperature over 1 hour and then stored at -23 °C for 16 hours. The resulting crystals were collected by filtration to give (35,6R)-2-[(4-bromo-2,5- difluoro-phenyl)methyl]-3-methyl-6-phenyl-thiazinane 1, 1-dioxide (145 g, 76% yield). ¾ NMR (400 MHz, DMSO-de) δ 7.71 (dd, J = 9.2, 5.6 Hz, 1H), 7.50 - 7.44 (m, 2H), 7.44 - 7.33 (m, 4H), 4.58 (dd, J = 12.8, 3.5 Hz, 1H), 4.51 (d, J = 17.9 Hz, 1H), 4.37 (d, / = 17.8 Hz, 1H), 4.20 - 4.06 (m, 1H), 2.48 - 2.38 (m, 1H), 2.15 - 2.07 (m, 1H), 1.90 - 1.73 (m, 1H), 1.72 - 1.62 (m, 1H), 1.12 (d, J = 6.8 Hz, 3H).
Step 2: ferf-Butyl 2 2,5-difluoro-4-rr(3S,6R)-3-methyl J-dioxo-6-phenyl-thiazinan-2- vHmethyllphenyllacetate
A 500-mL flask was charged with (35',6R)-2-[(4-bromo-2,5-difluoro-phenyl)methyl]-3-methyl-6- phenyl-thiazinane 1,1-dioxide (10.0 g, 23.2 mmol), bis(dibenzylidene)palladium (352 mg, 0.58 mmol) and l,2,3,4,5-pentaphenyl-l'-(di-ieri-butylphosphino)ferrocene (435 mg, 0.58 mmol) and the flask was purged with nitrogen for 2 minutes. Tetrahydrofuran (50 mL) and 2-ferf-butoxy-2-oxoethylzinc chloride (0.5 M in Et20, 60 mL, 30 mmol) were then added and the reaction was stirred at RT for 4 hours. Upon completion, the reaction was quenched with saturated aqueous NH4C1 and extracted with
dichloromethane (x2), dried over MgS04, filtered, concentrated, and purified by silica gel column chromatography (0% to 60% acetone in heptane) to give ferf-butyl 2-[2,5-difluoro-4-[[(3S,6R)-3-methyl- l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]acetate (10.6 g, 98% yield). H NMR (400 MHz, CDC13) δ 7.50 - 7.43 (m, 2H), 7.43 - 7.33 (m, 4H), 6.94 (dd, / = 10.0, 5.8 Hz, 1H), 4.52 (d, / = 17.0 Hz, 1H), 4.39 (d, / = 17.1 Hz, 1H), 4.33 - 4.20 (m, 1H), 3.98 (dd, / = 13.0, 3.5 Hz, 1H), 3.53 (s, 2H), 2.74 - 2.58 (m, 1H), 2.28 - 2.18 (m, 1H), 1.81 - 1.72 (m, 2H), 1.44 (s, 9H), 1.14 (d, / = 6.9 Hz, 3H)
Step 3: Methyl 2-r2,5-difluoro-4-rr(3,S,,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- vHmethyllphenyllacetate
ieri-Butyl 2-[2,5-difluoro-4-[[(35',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]acetate (2.68 g, 5.76 mmol) was suspended into a solution of hydrogen chloride in methanol (100 mL). The HC1 solution was prepared by bubbling HC1 gas, which was generated from the slow addition of sulfuric acid onto sodium chloride, into methanol for 15 minutes. The reaction was heated to 55 °C and stirred at that temperature for 16 hours, until complete dissolution of the material occurred. The solvent was evaporated under reduced pressure and the resulting solid was dissolved in ethyl acetate (250 mL) and washed with saturated aqueous sodium bicarbonate (100 mL) and brine (100 mL), dried over MgS04, filtered, and concentrated to give methyl 2-[2,5-difluoro-4-[[(3S,6R)-3-methyl- l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]acetate (2.46 g, >99% yield) which was used without further purification. LCMS (ESI), m/z, 424.3 [M+H]+.
Step 4: Methyl 2-r2,5-difluoro-4-rr(3,S,,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yllmethyllphenyllpropanoate
A vial was charged with methyl 2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]acetate (300 mg, 0.71 mmol) and Λ,Λ^-dimethylformamide (3.5 mL) and the solution was cooled to 0 °C. Sodium hydride (60% in mineral oil, 40 mg, 0.99 mmol) was added and the solution was stirred at 0 °C for 15 minutes. lodomethane (0.055 mL., 0.89 mmol) was then added and the reaction was warmed up to RT and stirred at that temperature for 30 minutes. The reaction was quenched with saturated aqueous ammonium chloride (15 mL) and the product was extracted with ethyl acetate (2 x 15 mL), dried over MgS04, filtered, concentrated, and purified by silica gel column chromatography (0% to 60% EtOAc in heptane) to give methyl 2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]propanoate (184 mg, 59% yield). LCMS (ESI), m/z, 438.3 [M+H]+. Step 5 : 2- r2,5-Difluoro-4- [ r(3S,6R)-3-methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2- yllmethyllphenyllpropanehydrazide
To a suspension of methyl 2-[2,5-difluoro-4-[[(35',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]propanoate (184 mg, 0.42 mmol) in methanol (3 mL) was added hydrazine hydrate (0.13 mL, 4.2 mmol) and the reaction was stirred at 65 °C for 48 hours. The reaction was then concentrated under reduced pressure to give 2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]propanehydrazide (184 mg, >99% yield) which was used without further purification. LCMS (ESI), m/z, 438.3 [M+H]+.
Step 6: 5-r i-r2,5-Difluoro-4-rr(3,S',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl1methyl1phenyl1ethyl1- 3 /-l,3,4-oxadiazol-2-one
A solution of 2-[2,5-difluoro-4-[[(35',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]propanehydrazide (184 mg, 0.42 mmol) and triethylamine (0.089 mL, 0.63 mmol) in Λ^,Λ^-dimethylformamide (3 mL) was cooled to 0 °C. l,l'-Carbonyldiimidazole (139 mg, 0.84 mmol) was then added and the reaction was stirred at 0 °C for 1 hour, warmed up to RT, and stirred at that temperature for an additional hour. The reaction mixture was directly purified by reverse-phase preparative HPLC to give 5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3H-l,3,4-oxadiazol-2-one (91 mg, 0.20 mmol, 47% yield). The isomers were separated by chiral column chromatography to give 5-[l-[2,5-difluoro-4-[[(35',6R)-3-methyl-l,l-dioxo-6- phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-3H-l,3,4-oxadiazol-2-one (35.1 mg, 18% yield) (Isomer A) and 5-[l-[2,5-difluoro-4-[[(35,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-3H- l,3,4-oxadiazol-2-one (Isomer B) (40.0 mg, 21% yield).
5-[l-[2,5-difluoro-4-[[(35',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]- 3//-l,3,4-oxadiazol-2-one (Isomer A): ¾ NMR (400 MHz, DMSO-d6) δ 12.21 (s, 1H), 7.49 - 7.44 (m, 2H), 7.44 - 7.34 (m, 3H), 7.31 - 7.23 (m, 2H), 4.60 - 4.48 (m, 2H), 4.42 - 4.30 (m, 2H), 4.19 - 4.06 (m, 1H), 2.48 - 2.37 (m, 1H), 2.18 - 2.04 (m, 1H), 1.89 - 1.72 (m, 1H), 1.72 - 1.61 (m, 1H), 1.52 (d, / = 7.1 Hz, 3H), 1.12 (d, / = 6.9 Hz, 3H); LCMS (ESI), m/z, 464.2 [M+H]+.
5-[l-[2,5-difluoro-4-[[(35',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]- 3//-l,3,4-oxadiazol-2-one (Isomer B): ¾ NMR (400 MHz, DMSO- ) δ 12.21 (s, 1H), 7.50 - 7.44 (m, 2H), 7.44 - 7.33 (m, 3H), 7.27 (dd, / = 10.0, 6.5 Hz, 2H), 4.63 - 4.48 (m, 2H), 4.43 - 4.29 (m, 2H), 4.20 - 4.08 (m, 1H), 2.47 - 2.37 (m, 1H), 2.16 - 2.04 (m, 1H), 1.88 - 1.73 (m, 1H), 1.72 - 1.63 (m, 1H), 1.52 (d, / = 7.2 Hz, 3H), 1.13 (d, / = 6.8 Hz, 3H); LCMS (ESI), m/z, 464.2 [M+H]+.
Example 3 : 5-[2,5-Difluoro-4-((3^,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-il,21-thiazinan-2- ylmethyl)-benzyl)-3H-|T,3,41oxadiazol-2-one
Step 1: r2,5-Difluoro-4-((3S,6R)-3-methyl J-dioxo-6-phenyl 1ambda*6* 1,21thiazinan-2-ylmethyl)- phenyll -acetic acid
A mixture of [2,5-difluoro-4-((35',6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-[l,2]thiazinan- 2-lmethyl)-phenyl] -acetic acid tert-butyl ester (Example 1, Step 2); 300 mg, 0.64 mmol) and /^-toluene sulfonic acid monohydrate (25 mg, 0.13 mmol) in toluene (15 mL) was stirred and heated at 90 °C.
Solvent was removed in vacuo after 1.5 hours and the residue triturated using H20. Solids were removed by filteration, then washed with H20, and dried to give a white solid (245 mg, 93% yield). ¾ NMR (300 MHz, CDC13)□ 7.49 - 7.34 (6H, m), 7.00 - 6.92 (1H, m), 4.52 (1H, d, J = 17.2 Hz), 4.39 (1H, d, J = 17.1 Hz), 4.33 - 4.19 (1H, m), 3.98 (1H, dd, J = 12.9, 3.5 Hz), 3.67 (2H, s), 2.73 - 2.56 (1H, m), 2.28 - 2.17 (1H, m), 1.82 - 1.71 (2H, m), 1.14 (3H, d, J = 6.9 Hz). LCMS (Method A), m/z, 432 [M+Na]+. Step 2: N-( 2-r2,5-Difluoro-4-((3,S,,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- lmethvD-phenyll -acetyl I -hydrazinecarboxylic acid tert-butyl ester
A stirred solution of [2,5-difluoro-4-((3S,6/?)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*- [l,2]thiazinan-2-ylmethyl)-phenyl] -acetic acid (0.32 g, 0.78 mmol) in DCM (7 mL) at RT under argon was treated with DMF (1 drop) followed by oxalylchloride (136 DL, 1.56 mmol). After 1 hour, solvent was removed in vacuo and the resultant solid re-dissolved in DCM (5 mL). This solution was added to tert-butylcarbazate (155 mg, 1.17 mmol) and triethylamine (327 DL, 2.35 mmol) in DCM (5 mL) stirred at 0 °C under argon. The mixture was allowed to warm to RT and solvent removed in vacuo after 2 hours. Residue was partitioned between EtOAc and H20, and the EtOAc extracts were washed with 0.5 M aqueous citric acid, H20, NaHC03, brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography using a gradient of MeOH in DCM (0-4%) to yield an off-white solid of the title compound (0.35 g, 85% yield). LCMS (Method A), m/z, 522 [M-l]\
Step 3: r2,5-Difluoro-4-((3tS,,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2-ylmethyl)- hen yll -acetic acid hvdrazide
A stirred solution of N-{2-[2,5-difluoro-4-((35',6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*- [l,2]thiazinan-2-lmethyl)-phenyl] -acetyl} -hydrazinecarboxylic acid tert-butyl ester (0.35 g, 0.67 mmol) in MeOH (8 mL) at RT was treated with HC1 (4 N in 1,4-dioxane, 3 mL). Solvent was removed in vacuo after 2 hours, the residue re-dissolved in MeOH, applied to a SCX-2 cartridge, washed through with MeOH, then the product recovered using 2 M ammonia solution in MeOH. Evaporation yielded a yellow solid of the title compound (0.18 g, 64% yield). LCMS (Method A), m/z, 424 [M+H]+.
Step 4: 5-r2,5-Difluoro-4-((3^6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21-thiazinan-2-lmethyl)- benzyl)-3H-|T,3,41oxadiazol-2-one
A stirred solution of [2,5-difluoro-4-((35',6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-
[l,2]thiazinan-2-ylmethyl)-henyl] -acetic acid hydrazide (90 mg, 0.21 mmol) and triethylamine (45 DL, 0.32 mmol) in DMF (1.5 mL) at 0 °C under argon was treated with Ι,Γ-carbonyldiimidazole (69 mg, 0.42 mmol). After 1 hour the mixture was partitioned between EtOAc and H20, and the EtOAc extracts were washed with H20, brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography using a gradient of EtOAc in DCM (0-10%) to yield a white solid of the title compound (38 mg, 40% yield). ¾ NMR (400 MHz, DMSO-d6)□ 12.20 (1H, br s), 7.44 (2H, m), 7.36 (3H, m), 7.26 (2H, m), 4.52 (2H, m, / = 13.9 Hz), 4.36 (1H, d, / = 16.2 Hz), 4.14 - 4.06 (1H, m), 3.96 (2H, s), 2.41 (1H, m), 2.08 (1H, m), 1.78 (1H, m), 1.64 (1H, m), 1.09 (3H, d, / = 5.0 Hz); LCMS (Method B), m/z, 450.1 [M+H]+.
Example 4: f5-r2,5-Difluoro-4-((3,S,,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2-
Step 1: Acetic acid 2-(N-[2-r2,5-difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*- [l,21thiazinan-2-ylmethyl)-phenyll -acetyl I -hydrazino)-2-oxo-ethylester
A stirred solution of [2,5-difluoro-4-((35',6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-
[l,2]thiazinan-2-ylmethyl)-henyl] -acetic acid hydrazide (Example 1, Step 5);228 mg, 0.54 mmol) and triethylamine (150 DL, 1.07 mmol) in DCM (7 mL) at RT under argon was treated with
acetoxyacetylchloride (60 DL, 0.54 mmol). After 1.5 hours solvent was removed in vacuo and the residue partitioned between EtOAc and 0.5 M aqueous citric acid. The EtOAc extracts were washed with H20, brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography using a gradient of MeOH in DCM (0-2.5%) to yield a white solid of the title compound (0.10 g, 35% yield). LCMS (Method A), m/z, 522 [M-l]\ Step 2: Acetic acid 5-r2,5-difluoro-4-((3£,6R)-3-methyl-l ,l-dioxo-6-phenyl-llambda*6*-[l,21thiazinan-
2- ylmethyl -benzyll-[l,3,41oxadiazol-2-ylmethyl ester
A mixture of acetic acid 2-(N-{2-[2,5-difluoro-4-((35',6R)-3-methyl-l,l-dioxo-6-phenyl- llambda*6*-[l,2]thiazinan-2-ylmethyl)-phenyl]-acetyl}-hydrazino)-2-oxo-ethylester (0.10 g, 0.19 mmol), triethylamine (55 DL, 0.39 mmol) and ^-toluenesulfonylchloride (73 mg, 0.38 mmol) in DCM (4 mL) was stirred at RT under argon for 18 hours. Solvent was removed in vacuo and the residue partitioned between EtOAc and 0.5 M aqueous citric acid. The EtOAc extracts were washed with H20, brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography using a gradient of EtOAc in DCM (0-25%) to yield a white solid of the title compound (61 mg, 63% yield). LCMS (Method A), m/z, 506 [M+H]+.
Step 3: f5-r2,5-Difluoro-4-((3,S,,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- ylmethyl)-benzyll-[l,3,41oxadiazol-2-yl)methanol
A stirred solution of acetic acid 5-[2,5-difluoro-4-((35',6R)-3-methyl-l,l-dioxo-6-phenyl- llambda*6*-[l,2]thiazinan-2-ylmethyl)-benzyl]-[l,3,4]oxadiazol-2-ylmethyl ester (61 mg, 0.12 mmol) in MeOH (3 mL) at RT was treated with 1 M aqueous NaOH (130 DL, 0.13 mmol). After 1 hour 0.5 M aqueous citric acid was added and the solvent removed in vacuo. The residue was partitioned between EtOAc and 0.5 M aqueous citric acid. The EtOAc extracts were washed with H20, brine, dried over MgS04, filtered and concentrated. Crude product was purified by flash chromatography using a gradient of EtOAc in DCM (0-20%) to yield a white solid of the title compound (37 mg, 66% yield). H NMR (400 MHz, DMSO-de)□ Π7.43 (2H, m), 7.36 (3H, m), 7.27 (2H, m), 5.79 (1H, t, J = 7.1 Hz), 4.53 (4H, m), 4.36 (1H, d, / = 17.2 Hz), 4.27 (2H, s), 4.09 (1H, m), 2.43 (1H, m), 2.06 (1H, m), 1.78 (1H, m), 1.65 (1H, m), 1.10 (3H, d, / = 6.7 Hz); LCMS (Method B), m/z, 464.1 [M+H]+.
Examples 5 and 6: 5-f (R)-[2,5-Difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*- [l,21thiazinan-2-ylmethyl)-phenyll-oxetan-3-yl-methyl|-3H-[l,3,41oxadiazol-2-one and 5-f (S)-[2,5- difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-[l,21thiazinan-2-ylmethyl)-phenylloxetan-
3- yl-methyl|-3H-|T,3,41oxadiazol-2-one
Step 1: r2,5-Difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyL^
phenyll -acetic acid
A mixture of [2,5-difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-[l,2]thiazinan- 2-lmethyl)-phenyl] -acetic acid ferf-butyl ester (300 mg, 0.64 mmol) and /^-toluene sulfonic acid monohydrate (25 mg, 0.13 mmol) in PhCH3 (15 mL) was stirred and heated at 90 °C. Solvent was removed in vacuo after 1.5 hours and the residue triturated with H20. Solids were removed by filtration, washed with H20, and dried over MgS04 to give the title compound as a white solid (245 mg, 93%). ¾ NMR (300 MHz, CDC13)□ 7.49-7.34 (6H, m), 7.00-6.92 (1H, m), 4.52 (1H, d, J = 17.2 Hz), 4.39 (1H, d, J = 17.1 Hz), 4.33 - 4.19 (1H, m), 3.98 (1H, dd, J = 12.9, 3.5 Hz), 3.67 (2H, s), 2.73-2.56 (1H, m),
2.28-2.17 (1H, m), 1.82-1.71 (2H, m), 1.14 (3H, d, J = 6.9 Hz). LCMS (Method A): m/z, 432[M+Na]+. Step 2: r2,5-Difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2-ylmethyl)- phenyll -acetic acid methyl ester
A stirred solution of the product from Step 1 (1.0 g, 2.2 mmol) in DCM (15 mL) at RT under argon was treated with DMF (1 drop) followed by oxalyl chloride (220 DL, 2.6 mmol). After 1 hour, the solvent was removed in vacuo and the resultant solid re-dissolved in DCM (5 mL) and added dropwise to anhydrous MeOH (10 mL). After stirring for 0.5h, the solvent was removed in vacuo and the resulting solid triturated with ether and filtered to give the title compound as a beige solid (780 mg, 84%, 2 steps). Ή NMR (300 MHz, CDC13)□ D7.49-7.43 (2H), 7.41-7.36 (3H, m), 6.99-6.93 (2H, m), 4.46 (2H, dd, / = 16.6, 39.9), 4.26 (1H, m), 3.99 (1H, dd, / = 3.7, 13.0 Hz), 3.72 (3H, s), 3.62 (2H, s), 2.65 (1H, m), 2.23 (1H, m), 1.77 (2H, m), 1.15 (3H, d, 7 = 7.3 Hz).
Step 3: Diazo-r2,5-difluoro-4-((3S,6R)-3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- ylmethvD-phenyll -acetic acid methyl ester To a stirred solution of the product from Step 2 (0.360 g, 0.85 mmol) and
^-acetamidobenzenesulfonyl azide (0.245 g, 1.02 mmol) in CH3CN (8mL) under argon, was added DBU drop wise (0.18 mL, 1.2 mmol). The reaction was stirred for 4h, concentrated in vacuo and purified by purified by silica gel column chromatography (5% to 40% EtOAc/cyclohexane) to give the title compound as a yellow solid (0.350g, 92%).
Step 4:r2,5-Difluoro-4-((3S,6R -3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2-ylmethyl - phenyll-oxetan-3-yl-acetic acid methyl ester
To a degassed solution of 3-hydroxyoxetane (0.065 g, 0.88mmol) and Rh(OAc)4 (9 mg, 0.02mmol) under argon, was added drop wise, a degassed solution of the product from Step 3 (0.200 g, 0.44 mmol) in DCM (3 mL). The green solution was stirred for lh, concentrated in vacuo and purified by silica gel column chromatography (7% to 40% EtOAc/cyclohexane) the to give the title compound (Product A) together with a by-product (Product B) (combined yield: 0.180g, A:B-2.5:1). LC/MS (Method A): Product A, m/z, 518 [M+Na]+; Product B, m/z, 462 [M+Na]+.
Step 5: r2,5-Difluoro-4-((3S,6R -3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2-ylmethyl - phenyl! -oxetan-3-yl-acetic acid hvdrazide
A solution of the product from Step 4 (0.102 g) in IMS (5 mL) was added hydrazine monohydrate (0.1 mL) and the solution heated to 80 °C for 16 h. The solvent was removed in vacuo and the residue partitioned between 10% MeOH/EtOAc and water (3:1, 100 mL). The organic layer was washed with H20, brine, and dried over MgS04, filtered, and concentrated under vacuum to give a white solid (0.1 g) which was taken on directly to the next step. LC/MS (Method A): m/z, 518 [M+Na]+.
Step 6: 5-f (R -r2,5-Difluoro-4-((3S,6R -3-methyl-l,l-dioxo-6-phenyl-llambda*6*-ri,21thiazinan-2- ylmethyl)-phenyl1-oxetan-3-yl-methyli-3H-ri,3,41oxadiazol-2-one and 5-f (S)-r2,5-difluoro-4-((3S,6R)- 3-methyl-l,l-dioxo-6-phenyl-llambda*6*-[l,21thiazinan-2-ylmethyl)-phenylloxetan-3-yl-methyl|-3H- Γ 1 ,3 ,41oxadiazol-2-one
A solution of the product from Step 5 (0.1 g) in DMF (5 mL) at 0 °C was treated with Et3N
(0.04 mL, 0.3 mmol) and Ι,Γ-carbonyldiimidazole (0.1 g, 0.6 mmol). After stirring for 1 h the mixture was partitioned between EtOAc and H20, and the EtOAc extracts were washed with H20, brine, dried over MgS04, filtered, and concentrated under vacuum. The residue was purified by silica gel column chromatography (0% to 10% EtOAc/DCM) to give the title compound as a mixture of diastereomers (32 mg) which were separated using SFC.
Stereoisomer A: Ή NMR (400 MHz, DMSO-d6)□ 12.5 (IH, br s), 7.48-7.45 (2H, m), 7.42-7.37 (3H, m), 7.33-7.29 (2H, m), 5.72 (IH, s), 4.84-4.78 (IH, m), 4.68-4.54 (4H, m), 4.47-4.38 (3H, m), 4.17- 4.09 (IH, m), 2.45 (IH, m), 2.11 (IH, m), 1.86-1.75 (IH, m), 1.70-1.65 (IH, m), 1.13 (3H, d, / = 6.9 Hz). LC/MS (Method B): m/z, 522 [M+H]+, 521 [M-H]\ Stereoisomer Β:Ή NMR (400 MHz, DMSO- )□□ 12.5 (IH, br s), 7.47-7.45(2H, m), 7.40-7.35 (3H, m), 7.32-7.28 (2H, m), 5.71 (IH, s), 4.84-4.78 (IH, m), 4.68-4.52 (4H, m), 4.47-4.39 (3H, m), 4.18- 4.08 (IH, m), 2.45 (IH, m), 2.11 (IH, m), 1.87-1.76 (IH, m), 1.70-1.60 (IH, m), 1.12 (3H, d, / = 6.9 Hz). LC/MS (Method B): m/z, 522 [M+H]+, 521 [M-H]\
Examples 7 and 8: 5-(2-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)propan-2-yl)-l,3,4-oxadiazol-2(3H)-one and 5-(2-(2,5-difluoro-4-(((3,S,,6tS, -3-methyl-
Step 1: Methyl 2-(2,5-difluoro-4-(((3,S, -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl methyl phenyl -2-methylpropanoate
A vial was charged with methyl 2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]acetate (300 mg, 0.71 mmol) and Λ,Λ^-dimethylformamide (3.5 mL) and the solution was cooled to 0 °C. Sodium hydride (60% in mineral oil, 142 mg, 3.5 mmol) was added and the solution was stirred at 0 °C for 15 min. Iodomethane (0.266 mL, 4.2 mmol) was then added and the reaction was warmed up to RT and stirred at that temperature for 30 min. The reaction was quenched with saturated aqueous ammonium chloride (15 mL) and the product was extracted with ethyl acetate (2 x 15 mL), dried over MgS04, filtered, concentrated and purified by silica gel column chromatography to give the title compound (203 mg, 63% yield). LCMS (ESI): m/z = 452 [M+H]+.
Step 2: 2-(2,5-Difluoro-4-(((3tS, -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2-yl methvnphenvn-2- methylpropanehydrazide
The product from step 1 was reacted as described in example 1 step 5 to give the title compound. LCMS (ESI): m/z = 452 [M+H]+.
Step 3 : 5-(2-(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)propan-2-yl)-L3,4-oxadiazol-2(3H)-one and 5-(2-(2,5-difluoro-4-(((3,S,,6tS, -3-methyl- l,l-dioxido-6-phenyl-l,2-thiazinan-2-yl methyl phenyl propan-2-yl -l,3,4-oxadiazol-2(3H)-one
The product from step 2 was reacted as described in example 1 step 6 to give the title compound. The two epimers were separated by chiral SFC. 5-(2-(2,5-Difluoro-4-(((3S,6R)-3-methyl-l,l-dioxido-6- phenyl-l,2-thiazinan-2-yl)methyl)phenyl)propan-2-yl)-l,3,4-oxadiazol-2(3H)-one: H NMR (400 MHz, DMSO-de) δ 11.21 (s, 1H), 7.50 - 7.44 (m, 2H), 7.43 - 7.35 (m, 3H), 7.32 (dd, / = 11.1, 6.6 Hz, 1H), 7.22 (dd, / = 12.2, 6.3 Hz, 1H), 4.64 - 4.47 (m, 2H), 4.38 (d, / = 17.8 Hz, 1H), 4.21 - 4.04 (m, 1H), 2.47 - 2.36 (m, 1H), 2.18 - 2.06 (m, 1H), 1.89 - 1.75 (m, 1H), 1.72 - 1.52 (m, 7H), 1.13 (d, / = 6.8 Hz, 3H). 5- (2-(2,5-Difluoro-4-(((35,6¾-3-methyl-l,l-dioxido-6-phenyl-l,2 hiazinan-2-yl)methyl)phe
yl)-l,3,4-oxadiazol-2(3H)-one: ¾ NMR (400 MHz, DMSO-d6) δ 12.24 (s, 1H), 7.50 - 7.44 (m, 2H), 7.43 - 7.32 (m, 4H), 7.25 (dd, / = 11.8, 6.2 Hz, 1H), 4.54 (dd, / = 12.6, 3.3 Hz, 1H), 4.48 (s, 2H), 3.73 - 3.56 (m, 1H), 2.83 - 2.66 (m, 1H), 2.28 - 2.12 (m, 1H), 2.12 - 2.02 (m, 1H), 1.73 - 1.55 (m, 7H), 1.41 (d, / = 7.0 Hz, 3H).
Example 9: 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3-methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)- 1 ,2-dihvdro-3//-pyrazol-3 -one
Step 1: 2-(2,5-Difluoro-4-(((3,S,,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDacetic acid
To a solution of ieri-butyl 2-(2,5-difluoro-4-(((35',6R)-3-methyl-l,l-dioxido-6-phenyl-l,2- thiazinan-2-yl)methyl)phenyl)propanoate (5 g, 10.4 mmol) in DCM (100 mL) was added trifluoroacetic acid (10 mL) and the reaction was stirred at RT for 2 h. The reaction was concentrated and dissolved in methyl ieri-butyl ether (20 mL) and DCM (2 mL). Heptane (500 mL) was added to the solution and the precipitate that formed was collected by filtration and dried under vacuum to give the title compound (4.20 g, 95% yield). lU NMR (400 MHz, DMSO- ) δ 12.54 (s, 1H), 7.50 - 7.43 (m, 2H), 7.43 - 7.33 (m, 3H), 7.26 - 7.15 (m, 2H), 4.63 - 4.45 (m, 2H), 4.36 (d, J = 17.8 Hz, 1H), 4.19 - 4.05 (m, 1H), 3.87 (q, / = 7.2 Hz, 1H), 2.48 - 2.37 (m, 1H), 2.16 - 2.04 (m, 1H), 1.87 - 1.72 (m, 1H), 1.71 - 1.62 (m, 1H), 1.39 (dd, 7 = 7.5, 1.3 Hz, 3H), 1.12 (dd, / = 7.0, 3.5 Hz, 3H).
Step 2: Methyl 4-(2,5-difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)-3-oxopentanoate
To a solution of the product of step 1 (2.73 g, 6.4 mmol) in THF (20 mL) was added 1,1'- carbonyldiimidazole (1.12 g, 6.7 mmol) and the reaction was stirred at RT for 2 h. Magnesium chloride (706 mg, 7.4 mmol) and potassium 3-methoxy-3-oxopropanoate (1.18 g, 7.4 mmol) were then added and the reaction was stirred at 50 °C for 16 h. The reaction mixture was filtered, concentrated on silica gel and purified by silica gel column chromatography to give the title compound (1.78 g, 58% yield) as white solid. LCMS (ESI): m/z = 480 [M+H]+.
Step 3 : 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-l,2-dihvdro-3H-pyrazol-3-one
To a solution of the product of step 2 (75 mg, 0.16 mmol) in methanol (0.5 mL) was added hydrazine hydrate (0.04 mL, 0.8 mmol) and the solution was stirred at 60 °C for 2 h. The reaction mixture was then purified by preparative HPLC to give the title compound (9 mg, 0.020 mmol, 12% yield). ¾ NMR (400 MHz, DMSO-d6) δ 11.42 (br s, 1H), 9.45 (br s, 1H), 7.50 - 7.43 (m, 2H), 7.43 - 7.34 (m, 3H), 7.20 (dd, / = 10.2, 6.5 Hz, 1H), 7.08 - 6.99 (m, 1H), 5.30 (s, 1H), 4.59 - 4.45 (m, 2H), 4.40 - 4.30 (m, 1H), 4.29 - 4.21 (m, 1H), 4.18 - 4.06 (m, 1H), 2.46 - 2.38 (m, 1H), 2.14 - 2.05 (m, 1H), 1.86 - 1.72 (m, 1H), 1.71 - 1.61 (m, 1H), 1.49 (d, J = 6.7 Hz, 3H), 1.10 (dd, J = 6.9, 4.3 Hz, 3H).
Example 10: 3-(l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl- l, l-dioxido-6-phenyl-l ,2-thiazinan-2-
To a solution of methyl 4-(2,5-difluoro-4-(((35',6R)-3-methyl-l, l-dioxido-6-phenyl-l ,2-thiazinan- 2-yl)methyl)phenyl)-3-oxopentanoate (110 mg, 0.23 mmol) and hydroxylamine hydrochloride (42 mg, 0.57 mmol) in methanol (1 mL) was added triethylamine (0.08 mL, 0.6 mmol) and the reaction was stirred at 60 °C for 16 h. The reaction was then purified by preparative HPLC to give the title compound (10 mg, 9% yield). ¾ NMR (400 MHz, DMSO-d6) δ 7.50 - 7.44 (m, 2H), 7.44 - 7.35 (m, 3H), 7.26 -
7.13 (m, 2H), 6.51 (s, 1H), 4.59 - 4.46 (m, 2H), 4.41 - 4.31 (m, 1H), 4.20 - 4.05 (m, 2H), 2.47 - 2.37 (m, 1H), 2.15 - 2.04 (m, 1H), 1.88 - 1.74 (m, 1H), 1.71 - 1.63 (m, 1H), 1.49 - 1.41 (m, 3H), 1.11 (d, J = 7.0 Hz, 3H).
Example 11 : 5-(l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl- l, l-dioxido-6-phenyl-l ,2-thiazinan-2-
Step 1 : 2-(2-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l ,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)propanoyl)hydrazine- 1 -carboxamide
To a solution of 2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l, l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]propanoic acid (300 mg, 0.71 mmol) and triethylamine (0.5 mL 3.5 mmol) in DMF (3.5 mL) at 0 °C was added HATU (416 mg, 1.1 mmol) and the reaction was stirred at that temperature for 10 min. Semibarbazide hydrochloride (118 mg, 1.1 mmol) was then added and the reaction was stirred at room temperature for 1 h. Saturated aqueous NaHC03 was added, the mixture was diluted with f-PrOAc, washed with water and brine, concentrated, and purified by silica gel column chromatography to give the title compound (216 mg, 64% yield). LCMS (ESI): m/z = 481 [M+H]+.
Step 2: 5-(l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l ,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2,4-dihvdro-3//- 1 ,2,4-triazol-3-one
The product of step 1 (216 mg, 0.45 mmol) was dissolved in 1 M NaOH (10 mL) and the reaction was stirred at 110 °C for 3 h. The reaction was acidified to pH = 1 with cone. HC1 and extracted with
DCM (x3), dried over MgS04, filtered, concentrated and purified by silica gel column chromatography to give the title compound (31 mg, 15% yield). ¾ NMR (400 MHz, DMSO-d6) δ 11.33 (s, 1H), 11.25 - 11.20 (m, 1H), 7.49 - 7.45 (m, 2H), 7.42 - 7.36 (m, 3H), 7.23 (dd, J = 10.6, 6.2 Hz, 1H), 7.14 - 7.06 (m, 1H), 4.58 - 4.46 (m, 2H), 4.36 (d, J = 17.8 Hz, 1H), 4.20 - 4.09 (m, 2H), 2.47 - 2.42 (m, 1H), 2.13 - 2.06 (m, 1H), 1.85 - 1.73 (m, 1H), 1.72 - 1.60 (m, 1H), 1.48 (dd, J = 7.3, 5.0 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H).
Example 12 : 5-(l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l, l-dioxido-6-phenyl-l ,2-thiazinan-2-
Step 1 : 2-(2-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l ,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDpropanoyl)- jV-methylhydrazine- 1 -carboxamide
2-(2,5-Difluoro-4-(((35',6R)-3-methyl-l, l-dioxido-6-phenyl-l ,2-thiazinan-2- yl)methyl)phenyl)propanoic acid was reacted with Af-methylhydrazinecarboxamide as described in example 5 step 1 to give the title compound. LCMS (ESI): m/z = 495 [M+H]+.
Step 2: 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-4-methyl-2,4-dihydro-3H-l,2,4-triazol-3-one
The product of step 1 was reacted as described in example 5 step 2 to give the title compound. :H
NMR (400 MHz, DMSO- ) δ 11.58 (s, 1H), 7.50 - 7.43 (m, 2H), 7.43 - 7.33 (m, 3H), 7.27 (dd, 7 = 10.6,
6.1 Hz, 1H), 6.98 (dd, / = 10.3, 6.0 Hz, 1H), 4.60 - 4.44 (m, 2H), 4.43 - 4.26 (m, 2H), 4.18 - 4.03 (m, 1H), 2.88 (d, / = 2.5 Hz, 3H), 2.47 - 2.37 (m, 1H), 2.15 - 2.04 (m, 1H), 1.86 - 1.73 (m, 1H), 1.70 - 1.62
(m, 1H), 1.49 (d, / = 6.9 Hz, 3H), 1.11 (d, / = 6.8 Hz, 3H). Example 13 : 5-(1-(2,5-Ρί1ΊηοΓθ-4-(((3^,6/? -3-ηΐ6ΐ1ιν1-1,1-(1ίοχίάο-6-ρ1ΐ6ην1-1,2-11ιίΒζίηΒη-2-
Step 1: 2-(2-(2,5-Difluoro-4-(((3S,6R)-3-methyl J-dioxido-6-phenyl ,2-thiazinan-2- yl)methyl)phenyl)propanoyl)- 1 -methylhydrazine- 1 -carboxamide
2-(2,5-Difluoro-4-(((35',6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)propanoic acid was reacted with 1 -methylhydrazine- 1 -carboxamide as described in example 5 step 1 to give the title compound. LCMS (ESI): mJz = 495 [M+H]+.
Step 2: 5-(l-(2,5-Difluoro-4-(((3,S,,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl methyl phenyl ethyl -2-methyl-2,4-dihvdro-3 /-l,2,4-triazol-3-one
The product of step 1 was reacted as described in example 5 step 2 to give the title compound. ¾ NMR (400 MHz, DMSO- ) δ 11.51 (s, 1H), 7.53 - 7.43 (m, 2H), 7.43 - 7.33 (m, 3H), 7.24 (dd, / = 10.6, 6.1 Hz, 1H), 7.13 (dd, / = 10.5, 6.0 Hz, 1H), 4.66 - 4.45 (m, 2H), 4.41 - 4.28 (m, 1H), 4.26 - 4.02 (m, 2H), 3.22 (d, / = 2.4 Hz, 3H), 2.44 - 2.35 (m, 1H), 2.21 - 2.03 (m, 1H), 1.94 - 1.72 (m, 1H), 1.72 - 1.55 (m, 1H), 1.48 (d, 7 = 7.3 Hz, 3H), 1.12 (d, / = 6.9 Hz, 3H).
Example 14: 5-(l-(2,5-Difluoro-4-(((3,S,,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2-
Step 1: 2-(2-(2,5-Difluoro-4-(((3,S,,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)propanoyl)-2-methylhvdrazine- 1 -carboxamide
2-(2,5-Difluoro-4-(((35',6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)propanoic acid was reacted with 2-methylhydrazine-l -carboxamide as described in example 5 step 1 to give the title compound. LCMS (ESI): mJz = 495 [M+H]+.
Step 2: 5-(l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)- 1 -methyl- 1 ,2-dihydro-3/f- 1 ,2,4-triazol-3-one
The product from step 1 was reacted as described in example 5 step 2 to give the title compound. ¾ NMR (400 MHz, DMSO- ) δ 10.77 (s, 1H), 7.49 - 7.43 (m, 2H), 7.42 - 7.34 (m, 3H), 7.27 - 7.20 (m, 1H), 7.15 - 7.07 (m, 1H), 4.62 - 4.45 (m, 3H), 4.35 (dd, / = 17.8, 4.0 Hz, 1H), 4.18 - 4.05 (m, 1H), 3.53 (d, 7 = 2.8 Hz, 3H), 2.47 - 2.37 (m, 1H), 2.15 - 2.06 (m, 1H), 1.86 - 1.72 (m, 1H), 1.70 - 1.62 (m, 1H), 1.53 (dd, / = 7.0, 1.3 Hz, 3H), 1.11 (dd, / = 7.0, 2.4 Hz, 3H). Example 15: 5-(l-(2,5-Difluoro-4-(((3S,6R)-3-methyl-l J-dioxido-6-phenyl ,2-thiazinan-2-
Step 1: 4-(2,5-Difluoro-4-(((3S,6R)-3-methyl-l,l-dioxido-6^
hydroxy-3-oxopentanamide
To a -30 °C suspension of methyl 4-[2,5-difluoro-4-[[(35',6R)-3-methyl-l,l-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-3-oxo-pentanoate (1.78 g, 3.7 mmol) in methanol (15 mL) was added sodium hydroxide (16 mL, 0.25 M in MeOH) and the reaction was stirred at -30 °C for 10 min. A solution of hydroxylamine hydrochloride (672 mg, 9.3 mmol), sodium hydroxide (37 mL, 0.25 M in MeOH) and water (5 mL) was then added dropwise at -30 °C and the reaction was stirred at that temperature for 2 h. The reaction was diluted with water and acidified with cone. HC1, extracted with DCM (x3), concentrated, and purified by silica gel column chromatography to give the title compound (1.06 g, 59% yield). LCMS (ESI): mJz = 481 [M+H]+.
Step 2: 5-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)isoxazol-3(2 /)-one
The product of step 1 (150 mg, 0.31 mmol) was dissolved in MeOH (5 mL) and cone. HC1 (1.5 mL). The reaction was stirred at 80 °C for 2 h. Upon cooling, the mixture was diluted with water, extracted with f-PrOAc (x3), dried over MgS04, filtered, and purified by preparative HPLC to give the title compound (93.5 mg, 65% yield). ¾ NMR (400 MHz, DMSO-d6) 5 11.18 (s, 1H), 7.50 - 7.43 (m, 2H), 7.43 - 7.30 (m, 3H), 7.25 (dd, / = 10.4, 6.4 Hz, 1H), 7.21 - 7.11 (m, 1H), 5.87 (d, 7 = 6.0 Hz, 1H), 4.62 - 4.46 (m, 2H), 4.45 - 4.32 (m, 2H),4.19 - 4.06 (m, 1H), 2.47 - 2.37 (m, 1H), 2.15 - 2.06 (m, 1H), 1.86 - 1.73 (m, 1H), 1.71 - 1.62 (m, 1H), 1.54 (d, 7 = 7.2 Hz, 3H), 1.12 (d, / = 6.8 Hz, 3H).
Example 16: 5-(l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2-
To a solution of 4-[2,5-difluoro-4-[[(35',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]-3-oxo-pentanehydroxamic acid (1.1 g, 2.2 mmol) in THF (22 mL) at 0 °C was added Λ,Λ^-diisopropylethylamine (0.97 mL, 5.5 mmol), followed by 4-nitrobenzenesulfonyl chloride (598 mg, 2.4 mmol) and the reaction was stirred at 0 °C to RT over 3 h. The reaction was quenched with saturated aqueous NH4C1, extracted with DCM (x3), dried over MgS04, filtered, and purified by preparative HPLC to give the title compound (390 mg, 38% yield). H NMR (400 MHz, DMSO- ) δ 10.41 (s, 1H), 7.51 - 7.44 (m, 2H), 7.44 - 7.31 (m, 3H), 7.24 (dd, / = 10.6, 6.1 Hz, 1H), 7.16 - 7.05 (m, 1H), 6.73 (dd, J = 9.1, 1.3 Hz, 1H), 4.61 - 4.46 (m, 2H), 4.36 (dd, 7 = 17.8, 3.1 Hz, 1H), 4.18 - 4.07 (m, 2H), 2.48 - 2.37 (m, 1H), 2.15 - 2.06 (m, 1H), 1.87 - 1.73 (m, 1H), 1.71 - 1.61 (m, 1H), 1.41 (dd, / = 7.1, 3.0 Hz, 3H), 1.12 (dd, 7 = 7.0, 3.0 Hz, 3H).
Example 17: 5-(1-(2,5-ΡίΑυοΓθ-4-(((3^,6/? -3^6Λν1-1,1-άίοχίάο-6^6ην1-1,2-ίΜΒζίηΒη-2-
To a solution of 5-[l-[2,5-difluoro-4-[[(35',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3//-l,3,4-oxadiazol-2-one (150 mg, 0.32 mmol) in DMF was added potassium carbonate (112 mg, 0.81 mmol) and iodomethane (91 mg, 0.64 mmol) and the reaction was stirred at RT for 2 h. The base was removed by filtration and the filtrate was purified by preparative HPLC to give the title compound (34 mg, 22% yield). 1H NMR (400 MHz, DMSO- ) δ 7.50 - 7.43 (m, 2H), 7.43 - 7.34 (m, 3H), 7.34 - 7.23 (m, 2H), 4.61 - 4.47 (m, 2H), 4.43 - 4.33 (m, 2H), 4.20 - 4.06 (m, 1H), 3.29 (d, / = 1.8 Hz, 3H), 2.48 - 2.36 (m, 1H), 2.15 - 2.05 (m, 1H), 1.87 - 1.73 (m, 1H), 1.72 - 1.62 (m, 1H), 1.52 (dd, 7 = 7.2, 2.1 Hz, 3H), 1.13 (dd, / = 6.9, 2.6 Hz, 3H).
Example 18: 2-(5-(l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-oxo-l,3,4-oxadiazol-3(2H)-yl)acetonitrile
5-[l-[2,5-Difluoro-4-[[(35',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3//-l,3,4-oxadiazol-2-one was reacted with 2-bromoacetonitrile, as described in example 11, to give the title compound. lU NMR (400 MHz, DMSO-d6) δ 7.49 - 7.43 (m, 2H), 7.43 - 7.25 (m, 5H), 5.03 (d, / = 1.7 Hz, 2H), 4.61 - 4.47 (m, 2H), 4.47 - 4.32 (m, 2H), 4.19 - 4.05 (m, 1H), 2.48 - 2.35 (m, 1H), 2.15 - 2.03 (m, 1H), 1.86 - 1.72 (m, 1H), 1.71 - 1.62 (m, 1H), 1.54 (dd, / = 7.1, 2.4 Hz, 3H), 1.13 (dd, 7 = 7.0, 2.6 Hz, 3H).
Example 19: 5-(l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2-
5-[l-[2,5-Difluoro-4 [(3S,6R)-3-methyl-l, l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3//-l,3,4-oxadiazol-2-one was reacted with 2-bromoethanol, as described in example 11, to give the title compound. ¾ NMR (400 MHz, DMSO-d6) δ 7.49 - 7.44 (m, 2H), 7.43 - 7.35 (m, 3H), 7.32 - 7.19 (m, 2H), 4.87 (s, 1H), 4.63 - 4.47 (m, 2H), 4.44 - 4.31 (m, 2H), 4.19 - 4.06 (m, 1H), 3.76 - 3.55 (m, 4H), 2.47 - 2.38 (m, 1H), 2.16 - 2.04 (m, 1H), 1.87 - 1.72 (m, 1H), 1.73 - 1.62 (m, 1H), 1.53 (dd, 7 = 7.1, 2.4 Hz, 3H), 1.17 - 1.07 (m, 3H).
Example 20: 5-(l-(2,5-Difluoro-4-(((3,S,,6R -3-methyl- l, l-dioxido-6-phenyl-l ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-3-(2,2,2-trifluoroethyl)-l,3,4-oxadiazol-2(3 f)-one
5- [ 1 - [2,5-Difluoro-4-[ [(35,6R)-3-methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3//-l,3,4-oxadiazol-2-one was reacted with 2,2,2-trifluoroethyl
trifluoromethanesulfonate, as described in example 11, to give the title compound. lH NMR (400 MHz, DMSO-de) δ 7.49 - 7.43 (m, 2H), 7.43 - 7.35 (m, 3H), 7.35 - 7.25 (m, 2H), 4.71 - 4.61 (m, 2H), 4.61 - 4.49 (m, 2H), 4.48 - 4.34 (m, 2H), 4.19 - 4.07 (m, 1H), 2.47 - 2.37 (m, 1H), 2.15 - 2.05 (m, 1H), 1.88 - 1.72 (m, 1H), 1.72 - 1.62 (m, 1H), 1.53 (dd, / = 7.2, 2.4 Hz, 3H), 1.13 (dd, / = 7.0, 2.5 Hz, 3H).
Example 21 : 5-(l-(2,5-Difluoro-4-(((3,S,,6R -3-methyl- l, l-dioxido-6-phenyl-l ,2-thiazinan-2-
5-[l-[2,5-Difluoro-4-[[(35,6R)-3-methyl-l, l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3//-l,3,4-oxadiazol-2-one was reacted with bromoethane, as described in example 11, to give the title compound. ¾ NMR (400 MHz, DMSO-d6) δ 7.51 - 7.43 (m, 2H), 7.43 - 7.33 (m, 3H), 7.33 - 7.23 (m, 2H), 4.62 - 4.47 (m, 2H), 4.44 - 4.33 (m, 2H), 4.22 - 4.04 (m, 1H), 3.73 - 3.60 (m, 2H), 2.48 - 2.36 (m, 1H), 2.16 - 2.04 (m, 1H), 1.89 - 1.73 (m, 1H), 1.72 - 1.62 (m, 1H), 1.53 (dd, 7 = 7.0, 2.2 Hz, 3H), 1.21 (td, / = 7.2, 2.3 Hz, 3H), 1.13 (dd, / = 6.8, 2.6 Hz, 3H).
Example 22: 2-(5-(l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l ,l-dioxido-6-phenyl-l ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-oxo-l,3,4-oxadiazol-3(2H)-yl)acetamide 5-[l-[2,5-Difluoro-4 [(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3//-l,3,4-oxadiazol-2-one was reacted with 2-bromoacetamide, as described in example 11, to give the title compound. ¾ NMR (400 MHz, DMSO-d6) δ 7.62 (s, 1H), 7.53 - 7.43 (m, 2H), 7.43 - 7.35 (m, 3H), 7.35 - 7.22 (m, 3H), 4.61 - 4.48 (m, 2H), 4.44 - 4.33 (m, 2H), 4.26 (d, / = 2.7 Hz, 2H), 4.19 - 4.06 (m, 1H), 2.48 - 2.38 (m, 1H), 2.15 - 2.08 (m, 1H), 1.88 - 1.72 (m, 1H), 1.72 - 1.63 (m, 1H), 1.52 (dd, 7 = 7.1, 2.6 Hz, 3H), 1.13 (dd, / = 6.8, 3.2 Hz, 3H).
Example 23: 5-(l-(2,5-Difluoro-4-(((3,S,,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-3-(2-methoxyethyl)-l,3,4-oxadiazol-2(3H)-one
5- [ 1 - [2,5-Difluoro-4-[ [(35,6R)-3-methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]-3H-l,3,4-oxadiazol-2-one was reacted with l-bromo-2-methoxy-ethane, as described in example 11, to give the title compound. H NMR (400 MHz, DMSO-d6) δ 7.49 - 7.43 (m, 2H), 7.43 - 7.34 (m, 3H), 7.31 - 7.23 (m, 2H), 4.61 - 4.48 (m, 2H), 4.46 - 4.31 (m, 2H), 4.20 - 4.06 (m, 1H), 3.79 (td, / = 5.2, 1.9 Hz, 2H), 3.56 (td, / = 5.3, 2.3 Hz, 2H), 3.23 (d, / = 1.0 Hz, 3H), 2.47 - 2.35 (m, 1H), 2.17 - 2.03 (m, 1H), 1.89 - 1.72 (m, 1H), 1.72 - 1.62 (m, 1H), 1.53 (dd, / = 7.1, 2.0 Hz, 3H), 1.13 (dd, 7 = 7.0, 2.4 Hz, 3H).
Example 24: 5-(l-(2,5-Difluoro-4-(((3,S,,6R -3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-methylisoxazol-3(2 /)-one and (3S,6R)-2-(2,5-difluoro-4-( l-(3- methoxyisoxazol-5-yl)ethyl)benzyl)-3-methyl-6-phenyl-l,2-thiazinane 1,1 -dioxide
To a solution of 5-[l-[2,5-difluoro-4-[[(35',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]isoxazol-3-one (93.5 mg, 0.20 mmol) in methanol (1 mL) and tetrahydrofuran (1 mL) was added (trimethylsilyl)diazomethane (2.0 M in hexanes, ca. 0.5 mL) dropwise until a yellow color persisted for more than 10 s. The reaction was stirred at RT for 30 min, then was partitioned between water and f-PrOAc, and extracted with f-PrOAc. The organic extract was dried over MgS04, filtered, concentrated and purified by supercritical fluid chromatography to give 5-[l-[2,5-difluoro-4- [[(35',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-2-methyl-isoxazol-3-one (11.6 mg, 12% yield): ¾ NMR (400 MHz, DMSCW6) δ 7.51 - 7.43 (m, 2H), 7.43 - 7.32 (m, 3H), 7.31 - 7.17 (m, 2H), 5.81 (s, 1H), 4.62 - 4.48 (m, 2H), 4.37 (d, / = 18.0 Hz, 1H), 4.30 (q, / = 7.1 Hz, 1H), 4.19 - 4.05 (m, 1H), 3.32 (s, 3H), 2.48 - 2.36 (m, 1H), 2.15 - 2.05 (m, 1H), 1.90 - 1.72 (m, 1H), 1.72 - 1.62 (m, 1H), 1.52 (dd, / = 7.3, 1.4 Hz, 3H), 1.12 (dd, / = 6.8, 3.3 Hz, 3H); and (3S,6R)-2-[[2,5-difluoro-4-[l-(3- methoxyisoxazol-5-yl)ethyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide (17.7 mg, 18% yield): ¾ NMR (400 MHz, DMSO-d6) δ 7.50 - 7.43 (m, 2H), 7.43 - 7.33 (m, 3H), 7.29 - 7.11 (m, 2H), 6.14 (d, J = 6.5 Hz, 1H), 4.59 - 4.47 (m, 2H), 4.43 (q, J = 7.1 Hz, 1H), 4.36 (dd, 7 = 17.6, 2.5 Hz, 1H), 4.18 - 4.07 (m, 1H), 3.85 (d, / = 3.6 Hz, 3H), 2.47 - 2.37 (m, 1H), 2.14 - 2.05 (m, 1H), 1.88 - 1.72 (m, 1H), 1.71 - 1.62 (m, 1H), 1.56 (dd, 7 = 7.2, 1.6 Hz, 3H), 1.12 (d, / = 6.9 Hz, 3H).
Example 25 : 3 - Γ 1 -r2,5-Difluoro-4- IT(3S,6R)-3 -methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2-
Step 1: jV-(l-(4-(((ferf-Butyldimethylsilyl)oxy)methyl)-2,5-difluorophenyl)ethyl)-2-methylpropane-2- sulfinamide
To a solution of ((4-bromo-2,5-difluorobenzyl)oxy)(ieri-butyl)dimethylsilane (10 g, 29.8 mmol) in diethyl ether (200 mL) at -78 °C was added dropwise n-butyllithium (2.5 M, 14.2 mL, 35.6 mmol). The resulting mixture was stirred at -78 °C for 1 h, then a solution of (£)-A/-ethylidene-2-methylpropane-2- sulfinamide (5.8 g, 39.4 mmol) in diethyl ether (30 mL) was added dropwise at -78 °C, the reaction mixture was stirred at -78 °C for 30 min. The reaction was quenched with saturated ammonium chloride solution (100 mL), extracted with EtOAc (2 x 100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Biotage Flash column (40 g silica, UV254, 0-30% PE/EA) to obtain the title product (10 g, 83% yield) as colorless oil. LCMS (ESI): m/z = 406.2 [M+H]+.
Step 2: /V-(l-(2,5-Difluoro-4-(hvdroxymethyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide
To a solution of the product of step 1 (7.7 g, 19 mmol) in THF (100 mL) was added TBAF (38 mL, 38 mmol), the reaction mixture was stirred at 25 °C for 1 h. The solvent was removed and diluted with EtOAc (100 mL), then washed with water (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography eluting with 0-50% EtOAc in PE to afford the title compound (4.9 g, 76 % yield) as colorless oil. LCMS (ESI): m z = 292.1 [M+H]+.
Step 3: jV-(l-(4-(Chloromethyl)-2,5-difluorophenyl)ethyl)-2-methylpropane-2-sulfinamide
To a solution of the product of step 2 (4.9 g, 16.8 mmol) in DCM (100 mL) was added triethylamine (5.1 g, 50.5 mmol) and methanesulfonyl chloride (3.9 g, 33.6 mmol) at 0 °C. The reaction mixture was stirred at 25 °C overnight then quenched with water (50 mL), extracted with DCM (2 x 50 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Biotage Flash column (40 g silica, UV254, PE/EA=l :0-2:3) to give the title compound (3.4 g, 65% yield) as a white solid. LCMS (ESI): m/z = 310.0 [M+H]+.
Step 4: N-( 1 -(2,5-Difluoro-4-(((3S,6R)-3 -methyl- 1 , 1 -dioxido-6-phenyl- 1 ,2-thiazinan-2- yl)methyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide
To a solution of the product of step 3 (3.4 g, 11 mmol) in DMF (50mL) was added (35,6R)-3- methyl-6-phenyl-thiazinane 1,1-dioxide (2.9 g, 13 mmol) and cesium carbonate (12.4 g, 38 mmol). The reaction was stirred at 25 °C for 16 h, quenched with saturated NH4C1 solution (100 mL), extracted with EtOAc (50mL x 3), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Biotage Flash column (40 g silica, UV254, 0-50% PE/EA) to give the title compound (4.6 g, 84% yield) as light yellow oil. LCMS (ESI): m/z = 499.2 [M+H]+.
Step 5: l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDethan- 1 -aminium chloride
To a solution of the product of step 4 (4.6 g, 9.2 mmol) in MeOH (20 mL) was added dropwise anhydrous HC1 in 1,4-dioxane (4 M, 6.9 mL, 27.7 mmol) at 0 °C. The reaction was stirred at 0 °C for 30 min. The solvent was removed in vacuo and the crude product was triturated with diethyl ether, filtered, washed with more diethyl ether, dried under a high vacuum system for 1 h to give the title compound (3.8 g, 96% yield) as a white solid.
LCMS (ESI): m/z = 395.2 [M+H]+; *H NMR (400 MHz, DMSO-d6) δ 8.46 (s, 3H), 7.54-7.50 (m, IH), 7.47-7.46 (m, 2H), 7.40-7.31 (m, 4H), 4.61-4.52 (m, 3H), 4.43-4.37 (m, IH), 4.16-4.10 (m, IH), 2.47- 2.44 (m, IH), 2.13-2.08 (m, IH), 1.82-1.79 (m, IH), 1.69-1.66 (m, IH), 1.52-1.50 (m, 3H),1.15-1.11 (m, 3H).
Step 6: /V-(l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-l /-imidazole-l-carboxamide
To a solution of the product of step 5 (150 mg, 0.38 mmol) in THF (10 mL) was added CDI (74 mg, 0.46 mmol). The reaction was stirred at 20 °C for 2 h, then quenched with water (20 mL), extracted with EA (2x30mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography eluting with 0-30% EtOAc in PE to afford the title compound (250 mg, 98% yield) as colorless oil. LCMS (ESI): m/z = 489.1 [M+H]+.
Step 7: 3-ri-r2,5-difluoro-4-rr(3,S',6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl1methyl1phenyl1ethyl1- l /-imidazol-2-one
To a solution of the product of step 6 (250 mg, 0.45 mmol) in THF (15 mL) was added 2,2- dimethoxyethan-1 -amine (568 mg, 5.4 mmol). The reaction was stirred at 20 °C for 2 h, then the solvent was removed under reduced pressure, the residue was dissolved in MeOH (4mL) and water (2 mL), and added anhydrous HCl in methanol (1.1 mL, 4.2 mmol). The reaction mixture was stirred at 25 °C for 48 h. The solvent was removed and diluted with EA and H20 (20 mL, 1 :1), extracted with EA (20 mL x 2), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by prep-
HPLC eluting with 25-55% CH3CN/H20 (0.1% NH4HC03 in H20) to afford the title compound (180 mg, 93% yield) as a white solid. LCMS (ESI): m/z = 462.0 [M+H]+; ¾ NMR (400 MHz, DMSO- ) δ 10.02 (s, IH), 7.47-7.45 (m, 2H), 7.41-7.36 (m, 3H), 7.25-7.21 (m, IH), 7.11-7.06 (m, IH), 6.68-6.65 (m, IH), 6.42-6.39 (m, IH), 5.42-5.37 (m, IH), 4.59-4.48 (m, 2H), 4.38-4.33 (m, IH), 4.15-4.08 (m, IH), 2.46- 2.39 (m, IH), 2.11-2.08 (m, IH), 1.81-1.73 (m, IH), 1.68-1.63 (m, IH), 1.59 (d, / = 7.2 Hz, 3H), 1.11 (d, 7 = 6.8 Hz, 3H).
Example 26: l-ri-r2,5-Difluoro-4-rr(3,S,,6R -3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-
To a solution of l-(l-(2,5-difluoro-4-(((35,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)-l,3-dihydro-2//-imidazol-2-one (150 mg, 0.33 mmol) in MeOH (10 mL) was added Pd/C (50 mg), the reaction was stirred under a hydrogen gas atmosphere (1 atm) at 25 °C for 12 h. The reaction mixture was filtered through a celite pad and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC eluting with 25-55% CH3CN/H20 (0.1% NH4HC03 in H20) afford the title product (70 mg, 46% yield) as a white solid. LCMS (ESI): m/z = 464.1 [M+H]+; ¾ NMR (400 MHz, DMSO-d6) δ 7.47-7.46 (m, 2H), 7.42-7.36 (m, 3H),7.28-7.22 (m, 2H), 6.35 (d, / = 3.2 Hz, IH), 5.16-5.11 (m, IH), 4.59-4.49 (m, 2H) , 4.39-4.35 (m, IH), 4.15-4.10 (m, IH), 3.43-3.37 (m, IH), 3.23-3.18 (m, 2H), 3.14-3.05 (m, IH), 2.47-2.39 (m, IH), 2.12-2.07 (m, IH), 1.82-1.75 (m, IH), 1.68- 1.65 (m , IH), 1.42 (d, / = 6.8 Hz, 3H), 1.13-1.10 (m, 3H);
Example 27 HI- r2,5-Difluoro-4- [[(3^,6R)-3-methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2- vHmethvHphenvHethvHimidazolidine-2,4-dione
Step l : N-(l-(2,5-Difluoro-4-(((3S,6R)-3-methyl J-dioxido-6-phenyl ,2-tMazinan-2^
yl)methyl)phenyl)ethyl)cyanamide
To a solution of (35,6R)-2-(4-(l-aniinoethyl)-2,5-difluorobenzyl)-3-methyl-6-phenyl4 ,2- thiazinane 1, 1-dioxide (120 mg, 0.3 mmol) in MeOH (20 mL) was added BrCN (35 mg, 0.33 mmol) and NaOAc (50 mg, 0.61 mmol). The reaction mixture was stirred at 25 °C for 16 h. The solvent was removed and the residue was purified by silica gel chromatography using eluting 0-5% MeOH in DCM to afford the title compound (100 mg, 78 %) as a white solid. LCMS (ESI): m/z = 437 [M+Na]+.
Step 2: Methyl ^-cyano-^-(l-(2,5-difluoro-4-(((3,S,,6R)-3-methyl-l, l-dioxido-6-phenyl-l ,2-thiazinan-2- yl)methyl)phenyl)ethyl)glvcinate
To a solution of the product of step 1 (100 mg, 0.24 mmol) in THF (10 mL) was added NaH (60%, 10.4 mg, 0.26 mmol), the reaction mixture was stirred at 0 °C for 1 h, and then methyl 2- bromoacetate (36 mg, 0.24 mmol) was added, the reaction mixture was stirred at 25 °C for 16 h. The reaction was quenched with H20 (2 mL), extracted with EA (2 x 10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using 0-5% MeOH/DCM as eluting solvents to afford the title compound (115 mg, 98 %) as a white solid. LCMS (ESI): m/z = 509 [M+Na]+.
Step 3 : 1 - Γ 1 - r2,5-Difluoro-4-r \(3S,6R)-3 -methyl- 1 , 1 -dioxo-6-phenyl-thiazinan-2- vHmethvHphenvHethvHimidazolidine-2,4-dione
To a solution of the product of step 2 (80 mg, 0.16 mmol) in THF (10 mL) was added H2S04 (32 mg, 0.16 mmol) and the reaction mixture was stirred at 25 °C for 16 h. Then the mixture was diluted with EA (20 mL), washed with saturated NaHC03 solution (50 mLx2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by prep-HPLC eluting with 25-55% CH3CN/H20 (0.1% NH4HC03 in H20) to give the title product (40 mg, 52 % yield). LCMS
(ESI): m/z = 495.2 [M+NH4]+; H NMR (400 MHz, CD3OD): δ 7.52-7.50 (m, 2H), 7.40-7.34 (m, 4H), 7.24-7.19 (m, IH), 5.46-5.44 (m, IH), 4.59-4.46 (m, 2H), 4.38-4.34 (m, IH), 4.28-4.23 (m, IH), 4.13- 4.07 (m, IH), 3.80-3.73 (m, IH), 2.64-2.60 (m, IH), 2.24-2.19 (m, IH), 1.91-1.87 (m, IH), 1.79-1.74 (m IH), 1.61 (d, / = 7.2 Hz, 3H), 1.18 (d, / = 6.8 Hz, 3H). Example 28: 2 1-r2,5-Difluoro-4-rr(3S,6R)-3-methyl- l J-dioxo-6-phenyl-thiazinan-2-
Step 1 : (3S,6R)-2-(4-( l-Ethoxyvinyl)-2,5-difluorobenzyl)-3-methyl-6-phenyl- 1 ,2-thiazinane 1 , 1 -dioxide To a solution of (35',6R)-2-[(4-bromo-2,5-difluoro-phenyl)methyl]-3-methyl-6-phenyl-thiazinane
1, 1- dioxide (6.8 g, 15.8 mmol) and dichlorobis(triphenylphosphine)palladium(II) ( 1.66 g, 2.37 mmol) in DMF (200 mL) was added tributyl(l-ethoxyvinyl)tin (8.56 g, 23.7 mmol) and the mixture was stirred under nitrogen for 16 h at 80 °C. The reaction was quenched with sat. KF (300 mL) and stirred at 25 °C for 6 h. The resulting black solid was removed by filtration and the filtrate was extracted with EtOAc (50 mLx3), washed with brine (50 mLx3), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by Biotage Flash column (40 g silica, UV254, PE/EA=1 :0~1 : 1) to give the title compound (6 g, 79% yield) as a brown solid. LCMS (ESI): mJz = 422.2 [M+Na]+.
Step 2: l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l, l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethan- 1 -one
To a solution of the product from step 1 (6.0 g, 14.2 mmol) in THF (200 mL) was added 2 M aqueous HC1 (200 mL) and the solution was stirred at 10 °C for 16 h. The pH was adjusted to 8 with saturated NaHC03 solution, then extracted with EtOAc (40 mL x 3), dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the desired product (5.5 g, 96.2% yield) as brown oil. LCMS (ESI): m/z = 394.2 [M+Na]+.
Step 3: (3£,6R -2-(2,5-Difluoro-4-(l-hydroxyethyD 1,1-dioxide
To a solution of the product of step 2 (5.8 g, 14.7 mmol) in THF (60 mL) and MeOH (60 mL) was added NaBH4 (1.4 g, 36.9 mmol) in portions and the mixture was stirred at 10 °C for 1 h. The reaction was quenched with H20 (40 mL), extracted with EtOAc (30 mL x 3), the organic phase was dried over Na2S04, filtered, and evaporated. The residue was purified by Biotage Flash column (40 g silica, UV254, PE/EtOAc 1:0-1: 1) to give the title compound (5.1 g, 85% yield) as light yellow oil. LCMS (ESI): m/z = 418.2 [M+Na]+.
Step 4: l-(2,5-Difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl methanesulfonate
To a solution of the product of step 3 (800 mg, 2.0 mmol) in DCM (40 mL) at 0 °C was added NEt3 (0.84 mL, 6.1 mmol), and then added dropwise methanesulfonyl chloride (0.31 mL, 4.1 mmol). The mixture was stirred at 15 °C for 2 h, then quenched with saturated NaHC03 (20 mL), extracted with DCM (2x30mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the crude product as light yellow oil which was used in the next step without further purification. LCMS (ESI): m/z = 496.1 [M+Na]+.
Step 5: fert-Butyl 2-(l-(2,5-difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- vDmethvDphenvDethvDhydrazine- 1 -carboxylate
To a solution of the product of step 4 (500 mg, 1.1 mmol) in acetonitrile (30 mL) was added tert- butyl hydrazinecarboxylate (277 mg, 2.1 mmol) and Cs2C03 (1 g, 3.1 mmol). The mixture was stirred at
130 °C for 3 h. The solid was removed by filtration and the filtrate was evaporated. The resulting residue was purified by Biotage Flash column (20 g silica, UV254, PE/EtOAc= 1:0-2: 1) to afford the title compound (279 mg, 50% yield) as a white solid.
LCMS (ESI): m/z = 510.1 [M+Na]+.
Step 6: fert-Butyl 2-carbamoyl-2-(l-(2,5-difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2- thiazinan-2-yl)methyl)phenyl)ethyl)hydrazine- 1 -carboxylate
To a solution of the product of step 5 (120 mg, 0.24 mmol) in DCM (10 mL) was added triethylamine (0.1 mL, 0.71 mmol) at 0 °C, then bis(trichloromethyl) carbonate (22.8 mg, 0.08 mmol) in
DCM (1 mL) was added dropwise. The mixture was stirred at 0 °C for 1 h, then NH3 in 1,4-dioxane (6.0 mL, 12 mmol) was added and the mixture was stirred at 15 °C for 2 h. The reaction was quenched with saturated NaHC03 (3 mL), extracted with DCM (2 x 10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude was then purified by Biotage Flash column (12 g silica,
UV254, DCM/MeOH=l:0-20: l) to afford the title compound (116 mg, 42% yield) as a brown solid.
LCMS (ESI): m/z = 575.0 [M+Na]+. Step 7: 1-(1-(2,5-Ρί1ΊηοΓθ-4-(((3^,6/? -3-ηΐ6ΐ1ιν1-1,1-(1ίοχίάο-6-ρ1ΐ6ην1-1,2-11ιίΒζίηΒη-2- yl)methyl)phenyl)ethyl)hydrazine- 1 -carboxamide
To a solution of the product of step 6 (116 mg, 0.21 mmol) was added 4 M HC1 in MeOH (4.0 mL, 16 mmol). The mixture was stirred at 15 °C for 16 h then the solvents were evaporated and diluted with DCM and H20 (20 mL, 1:1), the pH value adjusted to 8-9 with saturated NaHC03 solution, extracted with DCM (20 mLx2), dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford the product (89 mg, 94% yield) as a brown solid. LCMS (ESI): m/z = 453.1 [M+l]+. Step 8 : 2-r i-r2,5-Difluoro-4-rr(3,S,,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- vHmethvHphenvHethvH-4ff-l,2,4-triazol-3-one
To a solution of lthe product of step 7 (100 mg, 0.22 mmol) was added triethoxymethane (6.0 mL, 0.22 mmol), the reaction mixture was stirred at 85 °C for 6 h. The solvent was removed under reduced pressureand the residue was purified by Biotage Flash column (12 g silica, UV254,
DCM/MeOH= 1:0- 10: 1) to afford the crude product. The crude product was purified by prep-HPLC eluting with 25-55% CH3CN/H20 (0.1% NH4HC03 in H20) to afford the title compound (35 mg, 34% yield) as white solid. LCMS (ESI): m/z = 463.1 [M+Na]+; ¾ NMR(400 MHz, DMSO- ) δ 7.89-7.88 (m, 1H), 7.47-7.36 (m, 5H), 7.26-7.23 (m, 1H), 7.19-7.14 (m, 1H), 5.54-5.49 (m, 1H), 4.59-4.33 (m, 3H), 4.14-4.10 (m, 1H), 2.50-2.40 (m, 2H), 2.11-2.08 (m, 1H), 1.86-1.73 (m, 1H), 1.68-1.59 (m, 4H), 1.12- 1.10 (m, 3H).
Example 29: 2-r i -r2,5-difluoro-4-rr(3,S,,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-
Step 1: ferf-Butyl ((ferf-butoxycarbonyl)oxy)(l-(2,5-difluoro-4-(((3^,6R)-3-methyl-l,l-dioxido-6-phenyl- l,2-thiazinan-2-yl)methyl)phenyl)ethyl)carbamate
To a solution of l-(2,5-difluoro-4-(((35',6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl methanesulfonate (500 mg, 1.1 mmol) in acetonitrile (30 mL) was added tert- butyl ferf-butoxycarbonyloxycarbamate (492 mg, 2.1 mmol) and Cs2C03 (1 g, 3.1 mmol). The mixture was stirred at 130 °C for 3 h. The solid was removed by filtration and the filtrate was evaporated. The resulting residue was purified by Biotage Flash column (20 g silica, UV254, PE/EA= 1:0-2: 1) to afford the title compound (363 mg, 50% yield) as a white solid. LCMS (ESI): m/z = 633.0 [M+Na]+.
Step 2: ferf-Butyl (l-(2,5-difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)(hvdroxy)carbamate
To a solution of the product of step 1 (100 mg, 0.16 mmol) in a sealed tube was added 7 M NH3 in MeOH (6.3 mL, 43.8 mmol). The reaction mixture was sealed and stirred at 100 °C for 2 h. The solvent was removed under reduced pressure to afford the crude title compound (80 mg, 85% yield) as a light yellow solid, and the crude product was used for next step without further purification. LCMS (ESI): m/z = 533.0 [M+Na]+.
Step 3: ferf-Butyl (l-(2,5-difluoro-4-(((3,S,,6R)-3-methyl-l,l-dioxido-6-phenyl-l,2-thiazinan-2- yl)methyl)phenyl)ethyl)(propioloyloxy)carbamate
To a solution of propiolic acid (22 mg, 0.31 mmol) in DCM (10 mL) was added DCC (80 mg,
0.39 mmol) and the product of step 2 (80 mg, 0.16 mmol). The reaction mixture was stirred at 20 °C for 16 h. Then the solvent was removed and the residue was purified by Biotage Flash column (12 g silica, UV254, PE/EA=1 :0-1: 1) to afford the title compound (60 mg, 56% yield) as a light yellow solid.
LCMS (ESI): m/z = 585.1 [M+Na]+.
Step 4: 2-ri-r2,5-difluoro-4-rr(3,S,,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- vHmethvHphenvHethvHisoxazol-5-one
To a solution of formic acid (2 mL) was added the product of step 3 (60 mg, 0.11 mmol) and the reaction mixture was stirred at 20 °C for 3 h. The solvent was removed, and the resulting residue was diluted with saturated aqueous NaHC03 (10 mL) and EA (10 mL), then extracted with EA (30 mLx2), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Biotage Flash column (12 g silica, UV254, PE/EtOAc=l:0-l :l) to afford the crude product. The crude product was purified by prep-HPLC eluting with 25-55% CH3CN/H20 (0.1% NH4HC03 in H20) to afford the title compound (40 mg, 78% yield) as a white solid. LCMS (ESI): m/z = 463.1 [M+H]+; lU NMR(400 MHz, DMSO- ) δ 8.69- 8.63 (m, 1H), 7.46 - 7.24 (m, 7H), 5.43-5.37 (m, 1H), 5.32-5.30 (m, 1H), 4.62 - 4.56 (m, 2H), 4.40-4.39 (m, 1H), 4.17-4.08 (m, 1H), 2.50-2.38 (m, 1H), 2.11-2.06 (m, 1H), 1.82-1.77 (m, 1H), 1.68-1.62 (m, 4H), 1.13-1.09 (m, 3H).
The above compounds, together with additional compounds made using the above procedures, are shown in Table 4 below, together with IC50 values for RORc.
Table 4
l,2,4-triazol-3-one
2,4-dione
r° F l,3,4-oxadiazol-2-one
yl]methyl]phenyl]ethyl]isoxazol-5-one
phenyl-thiazinane 1,1 -dioxide
Table 4
Proton NMR data for selected compounds in Table 4 are shown below, with compound numbers corresponding to those shown in Table 4.
Compound 17: Ή NMR (400 MHz, DMSO) 7.48 - 7.23 (6H, m), 4.60 - 4.49 (2H, m), 4.41 - 4.35 (1H, m), 4.16 - 4.08 (2H, m), 2.47 - 2.33 (1H, m), 2.14 - 2.05 (2H, m), 1.90 - 1.75 (2H, m), 1.67 (1H, dd, J=2.2, 14.3 Hz), 1.14 - 1.10 (3H, m), 0.86 (3H, t, J=7.3 Hz).
Compound 18: Ή NMR (400 MHz, DMSO) 7.48 - 7.23 (6H, m), 4.60 - 4.50 (2H, m), 4.38 (1H, d, J=17.9 Hz), 4.16 - 4.08 (2H, m), 2.14 - 2.05 (2H, m), 1.91 - 1.74 (2H, m), 1.70 - 1.63 (1H, m), 1.12 (3H, d, J=6.9 Hz), 0.85 (3H, t, J=7.3 Hz).
Compound 24: Ή NMR (400 MHz, DMSO) 12.56 - 12.46 (1H, m), 7.49 - 7.28 (6H, m), 5.56
(1H, s), 4.62 - 4.53 (2H, m), 4.40 (1H, d, J=18.0 Hz), 4.17 - 4.09 (1H, m), 3.40 (3H, s), 2.48 - 2.38 (1H, m), 2.14 - 2.07 (1H, m), 1.87 - 1.74 (1H, m), 1.67 (1H, dd, J=2.3, 14.2 Hz), 1.13 (3H, d, J=6.9 Hz).
Compound 25: Ή NMR (400 MHz, DMSO) 7.49 - 7.27 (6H, m), 5.56 (1H, s), 4.61 - 4.52 (2H, m), 4.41 (1H, d, J=17.9 Hz), 4.17 - 4.08 (1H, m), 3.29 (1H, s), 3.23 - 3.22 (1H, m), 2.48 - 2.39 (1H, m), 2.08 - 2.07 (2H, m), 1.91 - 1.75 (1H, m), 1.67 (1H, dd, J=2.2, 14.2 Hz), 1.12 (3H, d, J=6.9 Hz).
Compound 29: Ή NMR (400 MHz, DMSO) 7.48 - 7.24 (6H, m), 4.60 - 4.50 (2H, m), 4.41 - 4.28 (2H, m), 4.17 - 4.09 (1H, m), 3.40 - 3.35 (1H, m), 3.26 - 3.19 (2H, m), 3.17 (3H, s), 2.48 - 2.27 (2H, m), 2.14 - 2.04 (2H, m), 1.91 - 1.74 (1H, m), 1.67 (1H, dd, J=2.2, 14.2 Hz), 1.12 (3H, d, J=6.8 Hz).
Compound 30: Ή NMR (400 MHz, DMSO) 7.48 - 7.24 (6H, m), 4.60 - 4.49 (2H, m), 4.41 - 4.28 (2H, m), 4.17 - 4.08 (1H, m), 3.26 - 3.19 (2H, m), 3.16 (3H, s), 2.48 - 2.28 (2H, m), 2.14 - 2.02 (2H, m), 1.91 - 1.74 (2H, m), 1.71 - 1.63 (1H, m), 1.12 (3H, d, J=6.8 Hz). Compound 36: Ή NMR (400 MHz, DMSO) 7.49 - 7.27 (6H, m), 5.63 - 5.61 (1H, m), 4.62 - 4.52 (2H, m), 4.40 (1H, d, J=17.9 Hz), 4.17 - 4.02 (1H, m), 3.66 - 3.53 (3H, m), 2.48 - 2.39 (1H, m), 2.14 - 2.06 (1H, m), 1.86 - 1.74 (1H, m), 1.67 (1H, dd, J=2.2, 14.1 Hz), 1.20 - 1.11 (6H, m).
Compound 37: Ή NMR (400 MHz, DMSO) 7.48 - 7.26 (6H, m), 5.60 (1H, s), 4.61 - 4.51 (2H, m), 4.40 (1H, d, J=17.9 Hz), 4.17 - 4.09 (1H, m), 3.65 - 3.53 (3H, m), 2.48 - 2.39 (1H, m), 2.13 - 2.08 (1H, m), 1.88 - 1.75 (1H, m), 1.71 - 1.63 (1H, m), 1.20 - 1.10 (6H, m).
Example 30 In vitro RORc Ligand Binding Assay
This assay was used to determine a compound's potency in inhibiting activity of RORc by determining, Kiapp, IC50, or percent inhibition values. Consumables used in this Example are shown in Table 5 below.
Table 5
Table 5
Filter Plate Preparation
On day of the assay, 100 uL of 0.05% CHAPS (in deionized H20) was added to all wells of the GFB Unifilter plate and allowed soak for 1 h. A wash buffer of 50 mM HEPES (pH 7.4), 150 mM NaCl, and 5 mM MgCl2 was prepared to wash the filter plate. To prepare an assay buffer, BSA was added to the wash buffer to reach 0.01% and DTT was added to reach 1 mM.
Compounds
For IC50 mode, 10 mM compound stocks were serially diluted in DMSO with DMSO to give 20x required final concentration in DMSO (15 uL compound + 30 uL DMSO). The 20x compound stocks were diluted in DMSO with Assay Buffer 4-fold to reach 5x the final test concentration in 25% DMSO (10 uL compound + 30 uL Assay Buffer). Solutions were mixed by aspiration several times with a pipette set on 50 uL volume. For the assay, 10 uL of 5x compound stock solutions in 25% DMSO were added to the assay plate in duplicate.
For two point screening, 10 mM stock compound solutions were diluted in DMSO to obtain 200 uM (20x the high test concentration) and then diluted 10-fold further to reach 20 uM (20x the low test concentration). The 20x stocks were diluted 4-fold with Assay Buffer (10 uL compound + 30 uL Assay Buffer) to reach 5x the test concentrations (50 uM and 5 uM) and 10 uL were added to two assay plates for the duplicate wells. With each concentration tested on 2 plates, each set of 80 compounds used 4 assay plates (1 uM and 10 uM, with n=2).
Nonspecific binding (NSB) samples. Total Binding (TB) samples and No Receptor (No R) samples
25-hydroxycholesterol (1 uM) was used to determine the level of NSB signal is prepared in DMSO as for compounds above, then diluted in Assay Buffer to give a final concentration of 5 uM. For 25-hydroxycholesterol in 25% DMSO/75% Assay Buffer; 10 uL per well was used for NSB samples. Wells for Total Binding and No Receptor sample determination contained 10 uL of 25% DMSO/75% Assay Buffer per well.
Radioligand (25-[3Hlhvdroxycholesterol) Preparation
25-[3H]hydroxycholesterol was diluted in Assay Buffer to obtain 15 nM and vortex to mix. Add 20 uL to all wells to reach 6 nM final concentration in the assay.
Receptor Preparation
The optimal concentration for RORc receptor was found to be 0.6 ug/mL. Stock receptor solution was diluted in assay buffer to obtain 1.5 ug/mL in Assay Buffer. 20 uL was added to all wells.
For No Receptor samples, 20 uL Assay Buffer was substituted for receptor solution.
Sample addition to Plates and Incubation
Assay plates were 96-well polypropylene V-bottom plates. 10 uL of 5x compound in
25% DMSO/75% Assay Buffer was added to Test wells. 10 uL of 25% DMSO/75% Assay Buffer was added to Total Binding or No Receptor wells. 10 uL of 5 uM 25-hydroxycholesterol in 25% DMSO/75%
Assay Buffer was added to NSB wells. 20 uL of 15 nM 25-[3H]hydroxycholesterol prepared in Assay
Buffer was added to all wells. 20 uL of 1.5 ug/mL RORc receptor was added to wells (or 40 uL Assay Buffer to No R wells). Following addition to the wells, the plates were incubated 3 h at 25°C.
Filtration
Using a Packard Filtermate Harvester, the filter plate were washed 4 times following transfer of the incubated samples. Plates were dry-filtered completely (2 h at 50 °C or overnight at room temperature). 50 uL Microscint 0 was added to all wells and read on Topcount protocol Inverted. Final concentrations
Final concentrations were as follows: 50 mM HEPES buffer (pH 7.4); 150 mM NaCl; 1 niM DTT; 5 mM MgCl2; 0.01% BSA; 5% DMSO; 0.6 ug/mL RORc receptor; 6 nM 25- [3H]hydroxycholesterol. For NSB wells, 1 uM 25-hydroxycholesterol was also present.
Example 31 : RORc Coactivator Peptide Binding Assay
Assays were carried out in 16-microL reaction volumes in black 384 Plus F Proxiplates (Perkin- Elmer 6008269). All assay components except test ligand were mixed in coregulator buffer D (Invitrogen PV4420) containing 5 mM DTT and added to the plate at twice their final concentrations in a volume of 8 microL. Test ligands at 2x the final concentration were then added to the wells in 8 DL of coregulator buffer D containing 5 mM DTT and 4% DMSO. Final incubations contained lx coregulator buffer D, 5 mM DTT, test ligand, 2% DMSO, 50 nM biotinyl-CPSSHSSLTERKHKILHRLLQEGSPS (American Peptide Company; Vista, CA), 2 nM Europium anti-GST (Cisbio 61GSTKLB), 12.5 nM streptavidin-D2 (Cisbio 610SADAB), 50 mM KF, and 10 nM of bacterially-expressed human RORc ligand binding domain protein containing an ^-terminal 6xHis-GST-tag and residues 262-507 of Accession NP_005051. Ten test ligand concentrations were tested in duplicate. After the reaction plates were incubated for 3 h in the dark at room temperature (22-23 °C), the plate was read on an EnVision plate reader (PerkinElmer) following the Europium/D2 HTRF protocol (ex 320, em 615 and 665, 100 D s lag time, 100 flashes, 500 μ8 window). The time-resolved FRET signal at 665 nm was divided by that at 615 nm to generate the signal ratio of each well. The signal ratio of wells containing RORc and peptide but no test ligand were averaged and set to 0% Effect while the signal ratios of the blank wells containing coactivator peptide but no RORc were averaged and set to -100% Effect. RORc exhibits a basal (constitutive) signal in this assay and test ligands can increase or decrease the signal ratio relative to this basal signal level. RORc agonists increase the signal ratio in this assay and result in a positive % Effect value. Inverse agonists decrease the signal ratio, and result in a negative % Effect value. The EC50 value is the concentration of test compound that provides half-maximal effect (increased or decreased assay signal) and is calculated by Genedata Screener® software (Genedata; Basel, Switzerland) using the following equation:
% Effect = So + {(Sinf - S0)/[l+(10logEC5o/10c)n] }
where S0 equals the activity level at zero concentration of test compound, Sinf is the activity level at infinite concentration of test compound, EC50 is the concentration at which the activity reaches 50% of the maximal effect, c is the concentration in logarithmic units corresponding to the values on the x-axis of the dose-response curve plot, and n is the Hill coefficient (the slope of the curve at the EC50).
Example 32: Arthritis Mouse Model
8 to 10-week old male DBA/1 (DBA/lOlaHsd, Harlan Laboratories) mice are housed in a specific pathogen free (SPF) animal facility. Arthritis is induced by two injections of collagen subcutaneously in the base of the tail. The initial injection (on day 0) uses bovine type II collagen (2 mg/ml from Chondrex, Redmond, Wash.) emulsified in equal volume of CFA containing 4 mg/ml of M. tuberculosis (Chondrex). The CII booster injection on Day 29 is emulsified in incomplete Freund's adjuvant (IF A). Each animal receives 0.1 ml of emulsion by subcutaneous/intradermal injection in the tail 2 to 3 cm from the body of the mouse. The booster injection site is in the vicinity of but different from the initial injection site and closer to the body of the animal. OR- 1050 was formulated in HRC-6 as above. On weekdays, the animals receive two doses (a.m. and p.m.) of HRC-6 or 50 mg/kg OR-1050 p.o. (2.5 mls/kg). On weekends, a single dose of 100 mg/kg is administered (5 mls/kg).
The mice are observed daily for clinical symptoms of CIA based on the following qualitative scale. Each paw was examined individually and scored. Grade 0, normal; grade 1, mild but definite redness and swelling of the ankle or wrist, or apparent redness and swelling limited to individual digits, regardless of the number of affected digits; grade 2, moderate redness and swelling of ankle or wrist; grade 3, severe redness and swelling of the entire paw including digits; grade 4, maximally inflamed limb with involvement of multiple joints. To estimate cumulative disease severity for each animal, an area under the curve score is calculated for each animal by totaling the sum of the daily hind paw measurements betweens days 24 and 48.
Example 33: Muscular Sclerosis Mouse Model I
Experiments are conducted on female mice aged 4-6 weeks belong to the C57BL/6 strain weighing 17-20 g. Experimental autoimmune encephalomyelitis (EAE) is actively induced using 95% pure synthetic myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35.55) (Invitrogen). Each mouse is anesthetized and receives 200 ug of MOG35.55 peptide and 15 ug of Saponin extract from Quilija bark emulsified in 100 uL of phosphate-buffered saline. A 25 uL volume is injected subcutaneously over four flank areas. Mice are also intraperitoneally injected with 200 ng of pertussis toxin in 200 uL of PBS. A second, identical injection of pertussis toxin is given after 48 h.
A compound of the invention is administered at selected doses. Control animals receive
25 uL of DMSO. Daily treatment extends from day 26 to day 36 post-immunization. Clinical scores are obtained daily from day 0 post-immunization until day 60. Clinical signs are scored using the following protocol: 0, no detectable signs; 0.5, distal tail limpness, hunched appearance and quiet demeanor; 1, completely limp tail; 1.5, limp tail and hindlimb weakness (unsteady gait and poor grip with hind limbs); 2, unilateral partial hind limb paralysis; 2.5, bilateral hind limb paralysis; 3, complete bilateral hindlimb paralysis; 3.5, complete hindlimb paralysis and unilateral forelimb paralysis; 4, total paralysis of hind limbs and forelimbs (Eugster et al., Eur J Immunol 2001, 31, 2302-2312).
Inflammation and demyelination may be assessed by histology on sections from the CNS of EAE mice. Mice are sacrificed after 30 or 60 days and whole spinal cords are removed and placed in 0.32 M sucrose solution at 4° C. overnight. Tissues are prepared and sectioned. Luxol fast blue stain is used to observe areas of demyelination. Haematoxylin and eosin staining is used to highlight areas of inflammation by darkly staining the nuclei of mononuclear cells. Immune cells stained with H&E are counted in a blinded manner under a light microscope. Sections are separated into gray and white matter and each sector is counted manually before being combined to give a total for the section. T cells are immunolabeled with anti-CD3+ monoclonal antibody. After washing, sections are incubated with goat anti-rat HRP secondary antibody. Sections are then washed and counterstained with methyl green.
Splenocytes isolated from mice at 30 and 60 days post-immunization are treated with lysis buffer to remove red blood cells. Cells are then re-suspended in PBS and counted. Cells at a density of about 3xl06 cells/mL are incubated overnight with 20 ug/mL of MOG peptide. Supernatants from stimulated cells are assayed for IFNgamma protein levels using an appropriate mouse IFN-gamma immunoassay system. Example 34: Muscular Sclerosis Mouse Model II
In this model, female rodents are anesthetized with isoflurane and injected with Freund's Incomplete Adjuvant containing 1 mg/niL neuronal antigen (e.g. myelin basic protein, myelin oligodendrocyte glycoprotein, proteolipid protein) and 4 mg/niL mycobacterium tuberculosis at two sites on the back on day 0 of this study. A compound of interest is then dosed daily in a sub-cutaneous, intra- peritoneally, or oral manner from day 0 until the end of study at an efficacious dose. Daily observations of degree of paralysis are taken as measures of efficacy.
Example 35: Psoriasis Mouse Model I
The severe, combined immunodeficient (SCID) mouse model can be used to evaluate the efficacy of compounds for treating psoriasis in humans (Boehncke, Ernst Schering Res Found Workshop 2005, 50, 213-34; and Bhagavathula et al., J Pharmacol Expt'l Therapeutics 2008, 324(3), 938-947). Briefly, SCID mice are used as tissue recipients. One biopsy for each normal or psoriatic volunteer (human) is transplanted onto the dorsal surface of a recipient mouse. Treatment is initiated 1 to 2 weeks after transplantation. Animals with the human skin transplants are divided into treatment groups. Animals are treated twice daily for 14 days. At the end of treatment, animals are photographed and then euthanized. The transplanted human tissue along with the surrounding mouse skin is surgically removed and fixed in 10% formalin and samples obtained for microscopy. Epidermal thickness is measured. Tissue sections are stained with an antibody to the proliferation-associated antigen Ki-67 and with an anti-human CD3.sup.+ monoclonal antibody to detect human T lymphocytes in the transplanted tissue. Sections are also probed with antibodies to c-myc and beta-catenin. A positive response to treatment is reflected by a reduction in the average epiderma thickness of the psoriatic skin transplants. A positive response is also associated with reduced expression of Ki-67 in keratinocytes.
Example 36: Psoriasis Mouse Model II Using the Imidquimod model of skin inflammation (Fits et al, Journal of Immunology, 2009, 182: 5836-5845), 10-12 week old BALB/c, I117c+/+ or 1117c-/-, or I117re+/+ or I117re-/- mice were administered 50 mg Aldara cream (5% Imidquimod in Graceway, 3M) in the shaved back and right ear daily for 5 days. Clinical scoring and ear thickness measurements were performed daily. Scoring was based upon the manifestation of psoriatic symptoms, such as erythema, scaling and thickness: 0, No disease. 1, Very mild erythema with very mild thickening and scaling involving a small area. 2, Mild erythema with mild thickening and scaling involving a small area. 3, Moderate erythema with moderate thickening and scaling (irregular and patchy) involving a small area (<25%). 4, Severe erythema with marked thickening and scaling (irregular and patchy) involving a moderate area (25-50%). 5, Severe erythema with marked thickening and scaling (irregular and patchy) involving a large area (>50%). Ear and back tissue were harvested on day 5 for histological evaluation. Efficacy of compounds is compared in the imiquimod (IMQ) mouse model of psoriasis. Balb/c mice (10 males/group) received daily topical IMQ (5% cream) on shaved back and right ear for 5 days as described above. Animals received oral dose of a representative compound or DMF (45 or 90 mg-eq MMF/kg twice daily) or vehicle from Day -5 to Day +5. Erythema score is the primary outcome measure. The Erythema score values of the compounds tested at an oral dose of 90 mg-eq MMF/kg BID for 10 days in male Balb/C mice are set forth in Table 3, below. The data shows that the compounds of the disclosure are equipotent to DMF.
Example 37: Irritable Bowel Disease Mouse Model I
Effectiveness in treatment of inflammatory bowel disease may be evaluated as described by Jurjus et al., J Pharmaocol Toxicol Methods 2004, 50, 81-92; Villegas et al., Int'l Immunopharmacol 2003, 3, 1731-1741 ; and Murakami et al., Biochemical Pharmacol 2003, 66, 1253-1261. Briefly, female ICR mice are divided into treatment groups which are given either water (control), 5% DSS in tap water is given at the beginning of the experiment to induce colitis, or various concentrations of test compound. After administering test compound for 1 week, 5% DSS in tap water is also administered to the groups receiving test compound for 1 week. At the end of the experiment, all mice are sacrificed and the large intestine is removed. Colonic mucosa samples are obtained and homogenized. Proinflammatory mediators (e.g., IL-lalpha, IL-lbeta, TNFalpha, PGE2, and PGF2alpha.) and protein concentrations are quantified. Each excised large intestine is histologically examined and the damage to the colon scored.
Example 38: Chronic Obstructive Pulmonary Disease Mouse Model
The cigarette smoke model of Martorana et al., Am J Respir Crit Care Med 2005, 172,
848-835; and Cavarra et al., Am J Respir Crit Care Med 2001, 164, 886-890 can be used for assessing efficacy in treating emphysema. Briefly, six-week old C57B 1/6J male mice are exposed either to room air or to the smoke of five cigarettes for 20 minutes. For the acute study, mice are divided into three groups of 40 animals each. These groups are then divided into four subgroups of 10 mice each as follows: (1) no treatment/air-exposed; (2) no treatment/smoke-exposed; (3) a first dose of test compound plus smoke- exposed; and (4) a second dose of test compound. In the first group, trolox equivalent antioxidant capacity is assessed at the end of the exposure in bronchoalveolar lavage fluid. In the second group, cytokines and chemokines are determined in bronchoalveolar lavage fluid using a commercial cytokine panel at 4 hours; and in the third group bronchoalveolar lavage fluid cell count is assessed at 24 hours.
In a chronic study, the mice are exposed to either room air or to the smoke of three cigarettes/day, for 5 days/week, for 7 months. Five groups of animals are used: (1) no treatment/air- exposed; (2) a first dose of a test compound plus air-exposed; (3) no treatment/smoke-exposed; (4) a second dose of the test compound plus smoke-exposed; and (5) the first dose of the test compound plus smoke exposed. Seven months after chronic exposure to room air or cigarette smoke, 5 to 12 animals from each group are sacrificed and the lungs fixed intratracheally with formalin. Lung volume is measured by water displacement. Lungs are stained. Assessment of emphysema includes mean linear intercept and internal surface area. The volume density of macrophages, marked immunohistochemically with anti-mouse Mac-3 monoclonal antibodies is determined by point counting. A mouse is considered to have goblet cell metaplasia when at least one or more midsize bronchi/lung showed a positive periodic acid-Schiff staining for the determination of desmosine, fresh lungs are homogenized, processed, and analyzed by high-pressure liquid chromatography.
Example 39: Asthma Mouse Model
A single inhaled allergen challenge can induce an acute increase in airway responsiveness in some individuals and animal models. However, repeated allergen inhalations have demonstrated more pronounced, consistent, and prolonged increases in airway responsiveness. This mouse model of long- term repeated inhalations of allergen has been used to study the long term effect of allergic diseases in the lung, and to delineate the cells, mechanisms, molecules, and mediators involved in the induction of airway hyperresponsiveness of lung in humans.
Crystalline OVA is obtained from Pierce Chem. Co. (Rockford, 111.) aluminum potassium sulfate (alum) from Sigma Chem. Co. (St. Louis, Mo.), pyrogen-free distilled water from Baxter, Healthcare Corporation (Deerfield, 111.), 0.9% sodium chloride (normal saline) from Lymphomed (Deerfield, 111.) and Trappsol.TM. HPB-L100 (aqueous hydroxypropylbeta cyclodextrin; 45 wt/vol % aqueous solution) from Cyclodextrin Technologies Development, Inc. (Gainesville, Fla.). The OVA (500 ug/ml in normal saline) is mixed with equal volumes of 10% (wt/vol) alum in distilled water. The mixture (pH 6.5 using 10 N NaOH) after incubation for 60 minutes at room temperature is centrifuged at 750 g for 5 minutes; the pellet resuspended to the original volume in distilled water and used within one hour. The selective 5-lipoxtgenase inhibitor, Zileuton (N-[l-benzo[b]thien-2-ylethyl]-N-hydroxyurea; J. Pharmacol Exp Ther. 1991; 256: 929-937) is dissolved in Trappsol.TM. Histatek, Inc. (Seattle, Wash.) to provide the mast cell degranulation inhibitor, f-Met-Leu-Phe-Phe ("HK-X").
Female BALB/c Once (6-8 wk of age) receive an i.p. injection of 0.2 ml (100 ug) of OVA with alum on the different protocols of Standard (J. Exp Med. 1996; 184: 1483-1494). Mice are anesthetized with 0.2 ml i.p. of ketamine (0.44 mg/ml)/xylazine (6.3 mg/ml) in normal saline before receiving an intranasal (i.n.) dose of 100 ug OVA in 0.05 ml normal saline and an i.n. dose of 50 ug OVA in 0.05 ml normal saline separately on different days. Two control groups are used: the first group receives normal saline with alum i.p. and normal saline without alum i.n. ; and the second group receives OVA with alum i.p., OVA without alum i.n., and normal saline, alone.
The trachea and left lung (the right lung may be used for bronchoalveolar lavage ("BAL") as described below) are obtained and fixed in 10% neutral formaldehyde solution at room temperature for about 15 h. After being embedded in paraffin, the tissues are cut into 5-um sections and processed with the different staining or immunolabling further. Discombe's eosinophil staining is used for counting the cell numbers with the counterstain of methylene blue. The eosinophil number per unit airway area (2,200 urn2) is determined by morphometry (J. Pathol. 1992; 166: 395-404; Am Rev Respir Dis. 1993; 147:448- 456). Fibrosis is identified with the Masson's trichrome staining. Airway mucus iss identified by the following staining method: methylene blue, hematoxylin and eosin, mucicarmine, alcian blue, and alcian blue/periodic acid-Schiff (PAS) reaction (Troyer, H., "Carbohydrates" in Principles and Techniques of Histochemistry, Little, Brown and Company, Boston, Mass., 1980: 89-121; Sheehan, D. C, et al., "Carbohydrates" in Theory and Practice of Histotechnology, Battle Press, Columbus, Ohio, 1980: 159-
179) Mucin is stained with mucicarmine solution; metanil yellow counterstain is employed. Acidic mucin and sulfated mucosubstances are stained with alcian blue, pH 2.5; nuclear fast red counterstain is used. Neutral and acidic mucosubstances are identified by alcian blue, pH 2.5, and PAS reaction. The degree of mucus plugging of the airways (0.5-0.8 mm in diameter) is also assessed by morphometry. The percent occlusion of airway diameter by mucus iss classified on a semiquantitative scale from 0 to 4+. The histologic and morphometric analyses may be performed by individuals blinded to the protocol design.
On day 28, 24 hours after the last i.n. administration of either normal saline or OVA, pulmonary mechanics to intravenous infusion of methacholine may be determined in mice in vivo by a plethysmographic method as previously described (10, 1958; 192: 364-368; J. Appl. Physiol. 1988; 64: 2318-2323; J. Exp. Med. 1996; 184: 1483-1494).
After tying off the left lung at the mainstem bronchus, the right lung may be lavaged three times with 0.4 ml of normal saline. Bronchoalveolar lavage (BAL) fluid cells from a 0.05-ml aliquot of the pooled sample are counted using a hemocytometer and the remaining fluid centrifuged at 4°C. for 10 minutes at 200 g. The supernatant may be stored at 70.degree. C. until eicosanoid analysis is performed. After resuspension of the cell pellet in normal saline containing 10% bovine serum albumin ("BSA"), BAL cell smears are made on glass slides. To stain eosinophils, dried slides are stained with Discombe's diluting fluid (0.05% aqueous eosin and 5% acetone (vol/vol) in distilled water; J. Exp. Med. 1970; 131 : 1271-1287) for 5-8 minutes, rinsed with water for 0.5 minutes, and counterstained with 0.07% methylene blue for 2 minutes.
While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

Claims

1. A co
or a pharmaceutically acceptable salt thereof,
wherein:
m is 0 or 1 ;
n is 0 or 1 ;
p is from 0 to 3;
q is from 0 to 3;
Het is:
a five or six membered heteroaryl selected from: pyrrolyl;
pyrrazolyl;
imidazolyl;
oxazolyl;
thiazolyl;
isoxazolyl;
isothiazolyl;
triazolyl;
oxadiazolyl;
thiadiazolyl;
tetrazolyl;
thiophenyl;
furanyl;
pyridinyl;
pyrimidinyl;
pyridazinyl; or pyrazinyl; or a five membered heterocyclyl selected from:
pyrrolidinyl;
oxazolidinyl;
dioxolanyl;or
imidazolidinyl;
A is:
Ci_6alkylene; or
each of which may be unsubstituted or substituted once or twice with Ra;
W is: -CRbRc-; -0-; -S-; -S02-; or -NRd-;
one of X1, X2, X3 and X4 is N and the others are CRe; or two of X1, X2, X3 and X4 are N and the others are CRe; or three of X1, X2, X3 and X4 are N and the other is CRe; or each of X1, X2, X3 and X4 is CRe;
R1, R2, R3, R4, R5, R6, R7 and R8 each independently is: hydro gen; or Ci_6aikyl which may be unsubstituted or substituted one or more times with halo;
or R3 and R4 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or R5 and R6 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or R7 and R8 together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of R3 and R4 together with one of R5 and R6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of R5 and R6 together with one of R7 and R8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRd- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
each R9 is independently:
Ci-6alkyl;
halo;
Ci_6alkoxy; or
cyano;
wherein the C^aUcyl moieties may be unsubstituted or substituted one or more times with halo; each R10 is independently:
Ci-6alkyl;
oxo;
hydroxy
halo;
cyano;
halo-Ci_6alkyl;
hydroxy-C i _6alkyl ;
Ci_6alkoxy-Ci_6alkyl; or
cyano-Ci_6alkyl.
Ra is:
Ci_6alkoxy;
Ci.6alkoxy-Ci.6alkyl;
hydroxy-C i _6alkyl ;
C3.6cycloalkyl;
C3.6cycloalkyl-Ci_6alkyl;
C3.6cycloalkyloxy;
Cs^cycloalkyl-C!^alkoxy;
heterocyclyl;
heterocylyl-Ci_6alkoxy;
wherein the heterocyclyl moieties are each independently selected from oxetanyl,
tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, and wherein the heterocycyl moieties and C3.6cycloalkyl moieties each may be unsubstituted or substituted one or more times with Rf;
Rb, Rc, and Rd each independent is:
hydrogen; Ci_6aikyl; or
halo-Ci_6alkyl;
or Rb and Rc together with the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of Rb and Rc together with one of R7 and R8 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
or one of Rb and Rc together with one of R5 and R6 and the atoms to which they are attached may form a three, four, five, six or seven membered saturated or partially saturated ring that may optionally include one or two heteroatoms selected from -0-, -NRa- or -S-, and which may be unsubstituted or substituted one or more times with Rf;
each Re is independently:
hydrogen;
Ci-6alkyl;
halo;
Ci_6aikoxy; or
cyano;
wherein the Ci_6aikyl moieties may be unsubstituted or substituted one or more times with halo; and
R is: Ci_6alkyl; halo; oxo; hydroxy; or
The compound of claim 1, wherein n is 0.
The compound of claims 1 or 2, wherein R1, R2, R4, R5, R6, R7 and R8 are hydrogen.
The compound of any of claims lto 3, wherein W is -CRbRc- and Rb and Rc are hydi 5. The compound of any of claims lto 4, wherein X1, X2, X3 and X4 are CRe.
6. The compound of any of claims lto 5, wherein p is 0.
7. The compound of any of claims lto 6, wherein q is 0 or 1.
8. The compound of any of claims 1-7, wherein p is 0.
9. The compound of any of claims 1-8, wherein Het is a five or six membered heteroaryl selected from:
pyrrolyl;
pyrrazolyl;
imidazolyl;
oxazolyl;
thiazolyl;
isoxazolyl;
isothiazolyl;
triazolyl;
oxadiazolyl;
thiadiazolyl;
tetrazolyl;
thiophenyl;
furanyl;
pyridinyl;
pyrimidinyl;
pyridazinyl; or
pyrazinyl;
10. The compound of any of claims 1-9, wherein A is Ci_6aikylene which may be unsubstituted or substituted with Ra.
11. The compound of any of claims 1-10, wherein A is: -CH2-; -CHCH3-; -C(CH3)2-; or -CHRa-
12. The compound of any of claims 1-11, wherein R3 is Ci_6aikyl.
13. The compound of any of claims 1-12, wherein R10 is: Ci_6aikyl; hydroxy; oxo; or hydroxy-Ci.
6' alkyl.
14. The compound of any of claims lto 13, wherein Ra is: Ci_6aikoxy; heterocylyl-Ci_6alkyl; or heterocylyl-Ci_6aikoxy; wherein the heterocyclyl moieties are each independently selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl and piperidinyl, and wherein the heterocycyl moieties each may be unsubstituted or substituted one or more times with Rf.
15. The compou
wherein s is one or two, and Re is halo.
16. The compou
The compou
18. The compound of any of claims 1 to 16, wherein the compound is selected from
[5-[[2,5-difluoro-4-[[(3S,6R)-3-methyl-l, l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]methyl]-l,3,4- oxadiazol-2-yl]methanol;
5-[[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]methyl]-3H- l ,3,4-oxadiazol-2-one; 5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3H- l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3H- l,3,4-oxadiazol-2-one;
5-[(lR) -[2,5-difluoro-4-[[(3S,6R)-3-methyl J-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-2- (oxetan-3-yl)ethyl]-3H-l,3,4-oxadiazol-2-one;
5-[(R)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-(oxetan-3- yloxy)methyl]-3H-l,3,4-oxadiazol-2-one;
5-[(S)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-(oxetan-3- yloxy)methyl] -3H- 1 ,3 ,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4-[[(3S,6S)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-l-methyl- ethyl]-3H-l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-l-methyl- ethyl]-3H-l,3,4-oxadiazol-2-one;
5-[(R) 2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]- tetrahydropyran-4-yloxy-methyl]-3H-l,3,4-oxadiazol-2-one;
3-[[2,5-difluoro-4-[[(3S,6S)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]methyl]-l,4- dihydro- 1 ,2,4-triazol-5-one;
3-[[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]methyl]-l,4- dihydro-l,2,4-triazol-5-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-l,2- dihydropyrazol-3 -one ;
3-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl4J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-2H- isoxazol-5-one;
3-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]4,4- dihydro- 1 ,2,4-triazol-5-one;
3-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-4- methyl4H4,2,4-triazol-5-one;
5-[(lS)4-[2,5-difluoro-4-[[(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]propyl]- 3H4,3,4-oxadiazol-2-one;
5-[(lR)4-[2,5-difluoro-4-[[(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]propyl]- 3H4,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-2- methyl-4H- 1 ,2,4-triazol-3 -one; 5-[l-[2,5-difluoro-4 [(3S,6R)-3-metoyl ,l-dioxo
methyl-4H- 1 ,2,4-triazol-3 -one;
3-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-U-dio^^
methyl- lH-l,2,4-triazol-5-one;
5-[(R)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]- isopropoxy-methyl]-3H-l,3,4-oxadiazol-2-one;
5-[(S)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-lJ-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-isopropoxy- methyl]-3H-l,3,4-oxadiazol-2-one;
5-[(R)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-lJ-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-methoxy- methyl]-3H-l,3,4-oxadiazol-2-one;
5-[(S)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-lJ-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-methoxy- methyl]-3H-l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]isoxazol-3-one;
3-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-lJ-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-lH- imidazol-2-one;
1- [l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]imidazolidine-2,4-dione;
5-[(lS)-l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-3- methoxy-propyl]-3H-l,3,4-oxadiazol-2-one;
5-[(lR)-l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-3- methoxy-propyl]-3H-l,3,4-oxadiazol-2-one;
2- [5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-2- oxo- 1 , 3 ,4-oxadiazol-3 -yl ] acetonitrile ;
5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-lJ-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-3-(2- hydroxyethyl)- 1 ,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-3H- oxazol-2-one;
5-[(lS)-l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-3- hydroxy-propyl]-3H-l,3,4-oxadiazol-2-one;
5-[(lR)-l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-3- hydroxy-propyl]-3H-l,3,4-oxadiazol-2-one;
5-[(R)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-ethoxy- methyl]-3H-l,3,4-oxadiazol-2-one; 5-[(S)-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l ,l-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]-ethoxy- methyl]-3H-l,3,4-oxadiazol-2-one;
2-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-4H- l,2,4-triazol-3-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3- (2,2,2-trifluoroethyl)-l,3,4-oxadiazol-2-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3-eto^^ l,3,4-oxadiazol-2-one;
2 5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl 4-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-2- oxo- 1 , 3 ,4-oxadiazol-3 -yl ] acetamide ;
5- [ 1 - [2,5-difluoro-4 [(3 S,6R)-3-methyl4 J -dioxo-^
methoxyethyl)4 ,3 ,4-oxadiazol-2-one;
1- [l-[2,5-difluoro-4-[[(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]imidazolidin-2-one;
2-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]4H- pyrazol-3-one;
5-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]-3- methyl4,3,4-oxadiazol-2-one;
2- [l-[2,5-difluoro-4-[[(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]isoxazol-5-one;
(3S,6R)-2-[[2,5-difluoro-4-[l-(3-methoxyisoxazol-5-yl)ethyl]phenyl]methyl]-3-methyl-6-phenyl- thiazinane 1 -dioxide;
54142,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-2- methyl-isoxazol-3-one;
4-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl4 -dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethylidene]- 1 , 3 -dioxolan-2-one ;
24142,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]4H- pyrazol-5-one;
54142,5-difluoro-4 [(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-3- methyl-oxazol-2-one;
5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]oxazolidin-2-one;
5-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl44-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]ethyl]oxazolidin-2-one; N-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-l,l-dioxo-6-phenyl-m^^
pyrazole-4-carboxaniide;
l-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyi dimethyl-imidazol-4-one;formic acid;
2-[l-[2,5-difluoro-4 [(3S,6R)-3-methyl4J-dioxo-6-phenyl hiazinan-2-yl]methyl]phenyl]ethyl]4 l,2,4-triazol-5-one;
(3S,6R)-2-[[2,5-difluoro-4-[l-(3-methoxy4,2,4-triazol4-yl)ethyl]phenyl]methyl]-3-methyl-6-phenyl- thiazinane 1 -dioxide;
4-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-14-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-3H- oxazol-2-one;
4-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-14-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-3H- oxazol-2-one;
l-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-14-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-2- methyl- l,2,4-triazol-3-one;
(3S)-l-[l-[2,5-difluoro-4-[[(3S,6R)-3-methyl-14-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethyl]-3- hydroxy-pyrrolidin-2-one;
and pharmaceutically acceptable salts thereof.
A composition comprising:
(a) a pharmaceutically acceptable carrier; and
(b) a compound of any of claims 1 to 18.
20. A method for treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, septic arthritis, spondyloarthropathies, gouty arthritis, juvenile arthritis, chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), psoriasis, biliary colic, renal colic, diarrhea-dominant IBS, muscular sclerosis, Sjogren's disease, lupus, and pulmonary fibrosis, the method comprising administering to a subject in need thereof an effective amount of a compound of any of claims 1-18. 21. A compound according to any one of claims 1 to 18 for use as therapeutically active
substance.
22. The use of a compound according to any one of claims 1 to 18 treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, septic arthritis, spondyloarthropathies, gouty arthritis, juvenile arthritis, chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), psoriasis, biliary colic, renal colic, diarrhea-dominant IBS, muscular sclerosis, Sjogren's disease, lupus, and pulmonary fibrosis.
23. A compound according to any one of claims 1 to 18 for treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, septic arthritis,
spondyloarthropathies, gouty arthritis, juvenile arthritis, chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), psoriasis, biliary colic, renal colic, diarrhea-dominant IBS, muscular sclerosis, Sjogren's disease, lupus, and pulmonary fibrosis.
24. The use of a compound according to any one of claims 1 to 18 for the preparation of a medicament for treating a disease selected from rheumatoid arthritis, osteoarthritis, psoriatic arthritis, septic arthritis, spondyloarthropathies, gouty arthritis, juvenile arthritis, chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), psoriasis, biliary colic, renal colic, diarrhea-dominant IBS, muscular sclerosis, Sjogren's disease, lupus, and pulmonary fibrosis.
25. The invention as hereinbefore described.
EP15819803.6A 2014-12-17 2015-12-16 HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS Withdrawn EP3233849A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093263P 2014-12-17 2014-12-17
US201562190119P 2015-07-08 2015-07-08
PCT/EP2015/079912 WO2016096936A1 (en) 2014-12-17 2015-12-16 HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS

Publications (1)

Publication Number Publication Date
EP3233849A1 true EP3233849A1 (en) 2017-10-25

Family

ID=55068972

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15819803.6A Withdrawn EP3233849A1 (en) 2014-12-17 2015-12-16 HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS

Country Status (4)

Country Link
EP (1) EP3233849A1 (en)
JP (1) JP2017537966A (en)
CN (1) CN107108600A (en)
WO (1) WO2016096936A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3319962B1 (en) 2015-07-08 2020-05-13 H. Hoffnabb-La Roche Ag Aryl sultam derivatives as rorc modulators
WO2017005668A1 (en) * 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag ARYL SULTAM DERIVATIVES AS RORc MODULATORS
WO2017102796A1 (en) * 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS
CN106748816A (en) * 2016-11-30 2017-05-31 河南师范大学 A kind of synthetic method of the amino butanol of Du Lutewei key intermediates (R) 3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092348A1 (en) * 2012-07-11 2015-04-15 Hoffmann La Roche ARIL-SULTAMO DERIVATIVES AS RORc MODULATORS
US20150197529A1 (en) * 2014-01-10 2015-07-16 Genentech, Inc. ARYL SULTAM DERIVATIVES AS RORc MODULATORS

Also Published As

Publication number Publication date
JP2017537966A (en) 2017-12-21
CN107108600A (en) 2017-08-29
WO2016096936A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
EP2872504B1 (en) ARYL SULTAM DERIVATIVES AS RORc MODULATORS
EP3092238B1 (en) Aryl sultam derivatives as rorc modulators
EP3092239B1 (en) Aryl sultam derivatives as rorc modulators
JP2016510781A (en) Arylsulfamide and sulfamic acid derivatives as RORc modulators
WO2016096936A1 (en) HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS
EP3010919B1 (en) Aryl sultam derivatives as ror-c modulators
EP3044224A1 (en) KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS
EP3319962B1 (en) Aryl sultam derivatives as rorc modulators
WO2017005668A1 (en) ARYL SULTAM DERIVATIVES AS RORc MODULATORS
WO2017102796A1 (en) HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS
JP2017502070A (en) Heteroaryl sultam derivatives as RORc modulators
EP3292117B1 (en) Pyridazine derivatives as rorc modulators
EP3292111A1 (en) PYRIDAZINE DERIVATIVES AS RORc MODULATORS
EP3292108A1 (en) PYRIDAZINE DERIVATIVES AS RORc MODULATORS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180220